Bone mass in patients with rheumatoid arthritis by Laan, R.F.J.M.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/114141
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
BONE MASS 
IN PATIENTS WITH 
RHEUMATOID ARTHRITIS 
Roland FJ.M. Laan 

Bone mass in patients with rheumatoid arthritis 

Bone mass in patients with rheumatoid arthritis 
Een wetenschappelijke proeve op het gebied van de 
Medische Wetenschappen, 
in het bijzonder de geneeskunde 
Proefschrift 
ter verkrijging van de graad van doctor 
aan de Katholieke Universiteit Nijmegen 
volgens besluit van het College van Decanen 
in het openbaar te verdedigen 
op donderdag 19 november 1992 des namiddags te 1.30 uur precies 
door 
Rolandus Franciscus Johannes Maria Laan 
geboren 15 september 1958 te Ubbergen 
Nijmegen. 1992 
Drukkerij Benda bv 
Promotor: prof.dr. L.B.A. van de Putte 
Co-promotores: dr. P.L.C.M. van Riel 
dr.ir. L.J.Th.O. van Erning 
The studies described in this thesis were performed in the Department of Internal 
Medicine, Division of Rheumatology (Head: prof.dr. L.B.A. van de Putte) of the 
University Hospital Nijmegen, the Netherlands. 
The investigations described in this thesis were financially supported by the 
Programme for the Stimulation of Health Research ('SGO') and the Dutch League 
against Rheumatism ('Het Nationaal Reumafonds'). 
Financial support by Procter & Gamble Pharmaceuticals n.v. for the printing of 
this thesis is gratefully acknowledged. 
Ter nagedachtenis aan H.B. Benraad, die mijn eerste opleider in de inwendige 
geneeskunde was, en die zijn enthousiasme voor onderzoek op het gebied van 
osteoporose op mij heeft overgedragen. 
Manuscriptcommisic: 
Prof.dr. A.G.H. Smals, intcrnist-endocrinoloog. Katholieke Universiteit Nijmegen 
Prof.dr. J. Dequcker, reumatoloog. Katholieke Universiteit Leuven 
Prof.dr. A.L.M. Verbeek, epidemioloog. Katholieke Universiteit Nijmegen 
Contents 
I General introduction 1 
II Bone metabolism in patients with rheumatoid arthritis: a 11 
review 
III Bone mass in patients with rheumatoid arthritis: a review 25 
IV Single versus dual energy computed tomography for spinal 45 
densitometry in patients with rheumatoid arthritis 
V Bone mineral density in patients with recent onset rheumatoid 55 
arthritis: influence of disease activity and functional capacity 
VI Initial effects of low-dose prednisone on lumbar bone mineral 71 
density and bone metabolism in patients with rheumatoid 
arthritis 
VII Long-term effects of low-dose prednisone therapy on lumbar 97 
bone mineral density in patients with rheumatoid arthritis 
VIII Differential effects of glucocorticoids on vertebral cortical and 111 
peripheral cortical bone 
IX Summary and conclusions 125 
Samenvatting 133 
Dankwoord 139 
Curriculum vitae 141 

Chapter I 
General introduction 

General introduction 
Rheumatoid arthritis (RA) is a chronic inflammatory disease of unknown origin 
characterized by articular, juxta-articular and extra-articular manifestations. The 
most dominant feature is a symmetric polyarthritis, often affecting the small joints 
in hands and forefeet. Juxta-articular demineralization of bone is considered an 
early phenomenon of the disease, and is included in the criteria presently used to 
classify RA (1). The pathogenesis of this peri-articular loss of bone is not comple-
tely understood. Locally produced mediators of inflammation may affect bone 
metabolism, and cause juxta-articular bone loss in patients with RA (2). Articular 
immobility may also be important (3). 
Extra-articular manifestations are common in patients with RA, and a classifica-
tion into different groups has been suggested (4). The first group contains disor-
ders that are an integral part of the rheumatoid disease (such as subcutaneous 
nodules, serosilis and vasculitis). The second group includes features (such as 
anemia), that are directly related to the activity of the chronic inflammatory 
disease, but that are not specific for RA. The third group contains the associated 
disorders (such as the sicca syndrome), that may manifest themselves in otherwise 
healthy individuals, but whose incidence is increased in patients with RA. Compli-
cations of the RA, which constitute the fourth class of extra-articular manifesta-
tions, arc more common with longer disease duration and do not directly relate to 
disease activity. Side effects of anti-rheumatic drugs may also contribute to extra-
articular mani-festations in patients with RA. 
Osteoporosis of the axial and appendicular skeleton is frequently found in patients 
with RA, and generalized bone loss has been suggested as one of the extra-
articular manifestations of the disease. The studies described in this thesis have 
evaluated possible determinants of bone mass and bone loss in patients with RA. 
In this introductory chapter some general topics, that are closely related to this 
subject, will be briefly discussed. 
Osteoporosis: quantity and quality of bone 
Both the quantity and the quality of bone are involved in osteoporosis, and at a 
recent international consensus development conference, osteoporosis was defined 
as "a disease characterized by low bone mass, microarchitectural deterioration of 
bone tissue leading to enhanced bone fragility and a consequent increase in 
fracture risk" (5). 
Bone mass 
Low bone mass has been shown to increase fracture risk in several longitudinal 
studies. In general a decrease in bone mass with one standard deviation is associa-
ted with an approximately twofold increase in future fracture risk (6,7). 
Bone mass increases until peak bone mass is reached in the fourth decade. There-
after, women lose about 35% of their cortical bone and about 50% of their 
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trabecular bone, whereas men lose about two thirds of these amounts. In women 
the rate of bone loss is increased in the first years after menopause (8). The rate 
of bone loss also varies between different parts of the skeleton. Bone is lost 
fastest in trabecular bone and slowest in appendicular cortical bone. Cortical bone 
in the anterior rim of the vertebral body is lost at an intermediate rate (9). 
Low bone mass may thus be the consequence of "normal" age-related bone loss, 
and this phenomenon explains the increase in fracture incidence with age. Bone 
mass will be lower, and fracture risk further elevated, if peak bone mass is low, 
or if increased bone loss occurs thereafter. Several factors have been suggested to 
influence bone mass and consequently fracture risk. Apart from age, sex, and 
menopausal state these include race, geographic factors, some factors related to 
reproductive history, height and weight, dietary factors, physical activity, use of 
alcohol and smoking of cigarettes (10). Traditionally, osteoporosis is classified as 
secondary when bone loss is thought to be caused by a medical condition, a 
surgical procedure or the use of drugs. It has been suggested that these factors 
contribute to osteoporosis in about 20% of women and about 40% of men 
presenting with vertebral or hip fractures. Especially common may be early 
oophorectomy (in women), hypogonadism (in men), subtotal gastrectomy, 
hyperthyroidism, hemiplegia, chronic obstructive lung disease and the use of 
glucocorticoids and anticonvulsant drugs (11). 
Bone quality 
It is generally accepted that qualitative aspects relating to the architecture of bone 
tissue will partly determine bone strength (12). The existence of vertebral 
fractures may indicate impaired bone quality and decreased bone strength, and the 
presence of vertebral fractures has been shown to influence future fracture risk 
independently from bone mass. Women with one vertebral fracture have a 
threefold higher risk (han women with the same age and equal bone mass but no 
vertebral fractures. Going from one to two fractures is associated with an additio-
nal threefold increase in future fracture risk. The age-related increase in fracture 
risk seems to be mostly accounted for by bone mass and existing vertebral fractu-
res (13). 
Bone remodelling 
Volumes of bone tissue are continuously removed and replaced, by the actions of 
bone cells. This process is often referred to with the term "bone remodelling", and 
is responsible for changes in bone mass and bone quality. 
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The cells of bone (14) 
Osteoclasts and osteoblasts are highly specialized cells primarily responsible for 
bone resorption and formation. In addition, osteocytes, bone lining cells, mast 
cells, monocytes and macrophages, and lymphoid cells may modify the remodel-
ling process. 
Osteoclasts are large multinucleated cells, that are responsible for bone resorption, 
by secretion of hydrogen ions, carbonic anhydrase, and lysosomal enzymes, 
including cathcpsin B. They probably originate from mononuclear/phagocyte 
precursor cells. 
Osteoblasts are derived from the stromal cell system and their primary function is 
the production and subsequent mineralization of bone matrix. They synthesize 
collagen type I, and several non-collagenous proteins, including osteocalcin. Os-
teoblasts also play an important role in the regulation of bone remodelling. The 
effects of many different factors on osteoclasts are mediated through osteoblasts, 
and osteoblasts may produce different factors involved in the regulation of bone 
remodelling. 
Inactive osteoblasts may transform into flattened lining cells on bone surfaces, or 
into osteocytes that become incarcerated in the mineralized matrix. Osteocytes and 
lining cells form a network through multiple cellular processes, by which they can 
communicate with each other. Osteocytes may respond to mechanical stimuli and 
it has been suggested that subsequent changes in ion transports may influence 
bone remodelling (15). Bone lining cells probably play an important role in the 
initiation of bone resorption (12). 
Mast cells secrete a variety of factors, including heparin, which have been shown 
to stimulate bone resorption by osteoclasts. Their numbers are increased in various 
diseases, including rheumatoid arthritis, but their role in bone remodelling and in 
the pathogenesis of osteoporosis is speculative (16). 
Monocytes, macrophages and lymphocytes produce a variety of local factors 
which can affect bone remodelling. 
Steges of bone remodelling (12) 
Bone remodelling occurs cyclical on approximately 20% of trabecular and about 
5% of cortical bone surface. Osteoclasts first erode a cavity on a bone surface. 
Osteoblasts subsequently replace approximately the amount of bone that has been 
lost. This balance between resorption and formation at a defined site of bone 
remodelling is generally referred to as "coupling". The cells responsible for these 
events are called the bone remodelling unit. Five successive stages may be 
recognized in the lifecycle of a bone remodelling unit: quiescence, activation, 
resorption, reversal, and formation. 
In the quiescence stage bone surfaces are not actively involved in bone resorption 
or formation, and they are covered by the bone lining cells. 
The sequence of events in bone remodelling is started in the activation phase, 
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which is thought to be initiated by local events at the bone surface. Lining cells 
are believed to be of prime importance in the recruitment of osteoclasts and their 
ultimate attachment to the bone surface. 
The subsequent resorption stage takes between one and three weeks, in which 
period a resorption cavity of characteristic shape and dimensions is eroded. 
After completion of resorption, about one to two weeks pass before formation is 
started. This period may be crucial for the coupling of bone resorption and 
formation, but the exact events responsible for this phenomenon are not known. 
During the formation period osteoblasts deposit osteoid in the resorption cavity, 
which begins to mineralize after about ten days. It takes approximately three 
months before formation is completed. Thereafter, the bone surface returns to the 
quiescence stage. 
Regulation of bone remodelling (14,17) 
Bone remodelling is probably regulated by combined actions of systemic and local 
factors. 
Systemic factors 
Parathyroid hormone interacts with specific receptors on osteoblasts, which then 
produce soluble factors that stimulate osteoclastic bone resorption. At high 
concentrations parathyroid hormone also inhibits bone formation, but at low 
concentrations the hormone may actually stimulate osteoblasts. 
Vitamin D, and especially the active metabolite 1,25-dihyclroxy-vitamin D, plays 
an important role in mineralization of osteoid and in enhancing bone resorption. 
Bone resorption is stimulated by a parathyroid hormone like mechanism that 
involves osteoblasts, and which results in an increase in activity and the number 
of osteoclasts. The hormone probably also stimulates the capacity of lymphocytes 
to produce lymphokines with bone resorption stimulating properties. 
Calcitonin inhibits the activity of osteoclasts, probably by a direct mechanism 
without intervention of osteoblasts. They may also influence the actions of 
lymphocytes, monocytes and macrophages. 
Sex hormones are probably not important regulators of normal bone remodelling, 
although a deficiency of estrogen in women and androgens in men may result in 
osteoporosis by as yet unknown mechanisms. Other hormones that may influence 
bone metabolism include growth hormone, thyroid hormone, insulin, and gluco-
corticoids. 
Local factors 
Many types of local factors appear to influence bone remodelling. They include 
growth factors, prostaglandins, several cytokines, and mechanical and electrical 
stimuli. Most knowledge about the actions of these factors is derived from in vitro 
experiments. These data should be cautiously interpreted, and their significance 
for in vivo physiology and pathophysiology has as yet not been established. 
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Growth factors derived from non-skeletal tissues, like epidemial growth factor, 
transforming growth factors α and ß, fibroblast growth factor, platelet-derived 
growth factor, and somatomedins, may influence bone remodelling. Most stimula-
te bone resorption, some stimulate bone cell proliferation, and a few seem to 
decrease bone formation. In contrast, platelet-derived growth factor may stimulate 
osteoblast activity. 
Growth factors may also be produced locally. They may be products of the bone 
cells themselves (probably osteoblasts) or of specialized macrophages residing 
near remodelling sites. Bone specific growth factors include bone-derived growth 
factor I and II, and human skeletal growth factor. Their principal action seems to 
be stimulation of bone formation. 
Prostaglandins of several subtypes are produced by bone cells, and their produc-
tion is stimulated by a variety of agents including parathyroid hormone, growth 
factors and cytokines. They are potent stimulators of bone resorption, and may 
also stimulate osteoblast activity. 
Several cytokines, that may be locally produced by lymphocytes and monocy-
tes/macrophages in the bone marrow or by bone cells themselves, are known to 
affect bone metabolism. Interleukin-1 α and β, and tumor necrosis factor a and β 
increase osteoclast activity. They can also interact synergistically with other 
stimulators of bone resorption. In contrast, interferon-γ inhibits bone resorption. 
Glucocorticoids and osteoporosis 
Patients with RA are frequently treated with glucocorticoids. In the initial period 
after their introduction in 1949, moderate to high doses were used. The side 
effects, including osteoporosis, soon became apparent. As a consequence the use 
of these agents was discouraged. More recently the use of low-dose glucocorti­
coids (< 10 mg/day prednisone or equivalent) has been advocated, especially in 
patients with active disease who are family breadwinners, or as bridge therapy, 
adjunct to disease modifying antirheumatic drugs, while awaiting improvement of 
disease activity (18). However, data documenting the efficacy of low-dose gluco­
corticoids are scarce, and side-effects may occur even when low doses are used. 
The question whether low-dose glucocorticoids contribute to the development of 
osteoporosis is controversial (19). 
Pathogenesis of glucocorticoid-induced osteoporosis 
The pathogenesis of glucocorticoid-induced osteoporosis has been recently 
reviewed (20-23). The available data are summarized shortly. 
Direct effects on bone cells 
Glucocorticoids have been shown to decrease the number and function of osteo­
blasts by a direct mechanism. They may also increase osteoclast activity directly, 
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but the results of in vitro and animal studies have been contradictory, partly as a 
consequence of interspecies differences. The discrepancies in the literature may 
also be related to differences in dose. In general, higher doses have been associa­
ted with a decrease, and lower, although supraphysiological, doses with an 
increase in bone resorption. 
Indirect effects on bone metabolism 
Glucocorticoids decrease intestinal calcium absorption, probably by a vitamin D 
independent mechanism, and may also increase renal calcium excretion. In 
response to these changes secondary hyperparalhyroidism may develop, and in 
consequence bone resorption will be stimulated. In addition, it has also been 
suggested that glucocorticoids may directly stimulate the parathyroid glands. 
Glucocorticoids decrease the production of sex hormones by suppression of 
gonadotrophic and adrenocorticotrophic hormones. They may also act directly on 
the gonadal level. The effects on sex hormone concentrations may contribute to 
the development of osteoporosis. 
Glucocorticoids may alter the sensitivity of bone cells to parathyroid hormone and 
active vitamin D metabolites. They have also been shown to influence the 
production of several local factors that regulate bone remodelling. Finally, they 
may cause myopathy, which may contribute to the development of osteoporosis 
by decreasing the mechanical stimuli necessary for adequate bone remodelling. 
In conclusion, glucocorticoids have multiple direct and indirect effects on bone 
cells, that result in an imbalance between bone formation and resorption, which 
may ultimately cause symptomatic osteoporosis. 
Aim and contents of this thesis 
The main purpose of this thesis is to evaluate possible determinants of bone mass 
and bone loss in patients with RA. The studies have focussed on the influence of 
the activity of the chronic inflammatory process, of functional impairment, and of 
low-dose (< 10 mg/day) prednisone therapy. 
The literature on bone metabolism and bone mass in patients with RA is reviewed 
in chapters II and HI respectively. 
Bone mass may be measured by quantitative computed tomography (QCT), using 
either a single or dual energy technique. Measurements with single energy are 
subject to a considerable error due to varying amounts of fat in the vertebral 
body. This may limit the use of single energy QCT in patients with diseases that 
affect vertebral fat content. The results of a study comparing single and dual 
energy QCT in patients with RA are presented in chapter Г . 
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At the rheumatology department of the University Hospital Nijmegen, the Nether­
lands, patients with recent onset RA are followed prospectively since 1985. The 
influence of disease duration, disease activity and functional capacity on lumbar 
and femoral bone mass was evaluated in these patients. The results are presented 
in chapter V. 
The effects of low-dose glucocorticoid therapy on bone mass have been studied in 
several ways. It has been suggested that the negative effects of glucocorticoids 
occur mainly in the first months of therapy (24), and the results of a randomized, 
placebo controlled study of the initial, short term effect of low-dose prednisone on 
bone metabolism and bone mineral density are presented in chapter VI. A cross-
sectional survey evaluating the influence of long-term low-dose glucocorticoid 
treatment on bone mineral density is described in chapter VII. The pattern of 
glucocorticoid associated bone loss has also been studied in more detail, and the 
results are presented in chapter ІП. 
Finally, a summary of the results and the conclusions is offered in chapter IX. 
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Bone metabolism in patients with rheumatoid arthritis: a 
review 

Bone metabolism in RA: a review 
It has often been suggested that a disorder of bone metabolism may be responsi-
ble for the development of generalized osteoporosis in patients with rheumatoid 
arthritis (RA). In this review of bone metabolism in RA we will first briefly 
indicate the methods available for evaluating bone metabolism. Some topics 
especially important for the study of bone metabolism in RA will be mentioned. 
Thereafter, it will be discussed how RA may influence bone remodelling. Finally, 
the available data on bone metabolism in RA will be examined. 
Methods available for evaluating bone metabolism. 
Bone histomorphometry 
Direct assessment of trabecular bone volume is possible by histomorphometric 
analysis of iliac crest (or other bone) biopsies. In a population of patients with 
diverging conditions, iliac crest trabecular bone volume correlates moderately well 
with trabecular mineral density in the spine as assessed by quantitative computed 
tomography. However, in patients with RA no correlation between these two 
parameters was observed (1). Static as well as dynamic (after double labelling 
with tetracycline) parameters of bone formation and bone resorption can also be 
assessed. These methods are subject to a considerable variability: the coefficients 
of variation for the various parameters range from 10 to 25% (2,3). 
Diphosphonate uptake studies 
The skeletal retention of diphosphonates mainly reflects osteoblastic activity. 
Quantitative approaches include bone to soft tissue uptake ratios, and the measure-
ment of 24 hour whole body retention. Both methods have been employed in the 
study of metabolic bone diseases (4). 
Biochemical markers of bone metabolism 
Both the rate of bone formation and of resorption may be assessed with various 
methods, which are mentioned shortly below. A more extensive discussion of 
these methods has been published (5,6). 
Bone formation 
Markers of bone formation currently available include alkaline phosphatase, 
osteocalcin, and procollagen I propeptide. 
Total serum alkaline phosphatase reflects the approximately equal contribution of 
iso-enzymes from bone and liver. Available assays for bone specific alkaline 
phosphatase have only slightly improved the usefulnes of this parameter. In 
patients with RA (hepatic) alkaline phosphatase may be related to disease activity, 
and react as an acute phase protein (7). 
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Osteocalcin is one of the non-collagenous proteins produced by osteoblasts, and 
its concentration in serum has been shown to reflect osteoblastic activity as 
assessed by histomorphometric techniques. Serum osteocalcin is probably not 
influenced directly by osteoclast activity, and fragments released into the circulati-
on during bone resorption are not recognized by most assays. Since a circadian 
rhythm has been described, repeated measurements of osteocalcin should be done 
at the same time of day (8). Serum osteocalcin may be a sensitive index of the 
inhibitory effect of glucocorticoids on osteoblasts (9). However, the relevance of 
depressed osteocalcin levels during glucocorticoid therapy with respect to the 
development of osteoporosis has been questioned (10). 
Type I collagen is the most important protein synthesized by osteoblasts. Amino-
terminal and carboxyterminal peptides are cleaved from the procollagen-I molecu-
le during synthesis and deposition in the bone matrix. These propeptides can be 
measured in scrum, and they may reflect bone formation. 
Bone resorption 
Markers of bone resorption include, among others, the urinary excretion of hy-
droxyproline and the urinary excretion of collagen pyridinium crosslinks. 
Traditionally bone resorption has been assessed by either the 24-hour urinary 
excretion of hydroxyproline in patients on a low collagen diet, or by the fasting 2-
hour urinary hydroxyprolinc/creatinin ratio. Hydroxyproline is produced during the 
breakdown of collagen, about half of which is of skeletal origin. Only about 10% 
of all hydroxyproline produced is ultimately excreted in the urine. Several studies 
have compared hydroxyproline excretion with data on bone resorption derived 
from bone biopsies in the same persons. Generally only poor to moderate 
correlations between the 2 parameters have been observed. 
Part of the urinary hydroxyproline is derived from the Clq fraction of the comple-
ment system. In patients with active RA serum Clq levels are elevated, which 
may also be reflected in urinary hydroxyproline excretion (11,12). 
Deoxypyridinoline excretion in the urine may be a more specific, and possibly 
also more sensitive, marker of bone resorption (13). 
The urinary calcium/creatinin ratio 
The ratio between urinary calcium and Creatinin after a 12 hour fast is thought to 
represent the difference between bone formation and bone resorption. High values 
may indicate an increased net resorption (14). However, in the presence of an 
abnormal gastrointestinal calcium absorption or an increase in urinary calcium 
excretion, the results are difficult to interpret. 
RA and bone metabolism 
Several pathogenetic mechanisms may be responsible for the development of 
generalized osteoporosis in patients with RA. Treatment with glucocorticoids, 
reduced mobility, and direct influences of the disease itself have been suggested 
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as possibly important factors in the literature (15-18). 
Bone remodelling is regulated by a complex interaction between systemic and 
local factors(*), and the chronic inflammatory process in RA may affect bone 
cells in several ways (18,19). 
Mast cells 
In patients with RA, mast cells accumulate locally in the synovium of inflamed 
joints. They produce several substances that may increase bone resorption, 
including heparin and prostaglandins (19,20). Many data suggest a role for mast 
cells in promoting juxta-articular bone loss. Their importance in the pathogenesis 
of generalized osteoporosis in patients with RA remains to be determined. How-
ever, mast cells have been implicated in the development of osteoporosis in some 
other conditions. Generalized osteoporosis is one of the manifestations of systemic 
mastocytosis (21). Increased skeletal mast cells have also been reported in 
primary osteoporosis (22,23). 
Cytokines 
Different cytokines have been implicated in the pathophysiology of RA (24). For 
example, serum levels of interleukin-1 and tumor necrosis factor are elevated in 
patients with active RA (25,26). Some of the extra-articular manifestations of RA, 
such as fever, the synthesis of acute phase proteins and anemia, may be explained 
by the actions of these substances (27). Several cytokines, including interleukin-1 
and tumor necrosis factor, are potent stimulators of bone resorption (28). Interleu-
kin-1 has been suggested to be involved in the pathogenesis of primary osteoporo-
sis (29). Cytokines may therefore be important in the development of generalized 
osteoporosis in patients with RA. However, at the present time this hypothesis has 
not been proven. Cytokines have also been implicated in the pathogenesis of 
juxta-articular osteopenia (15-17). Systemic regulators of bone remodelling may 
interact with cytokines in promoting bone loss, and levels of parathyroid hormone 
and 1,25 dihydroxyvitamin D have been shown to be correlated with future 
trabecular bone loss at the distal radius in patients with RA (30). 
Bone biopsies in RA 
Bone histomorphometric data are scarce in patients with RA. In an early report, 
an increased number of bone resorption spaces together with signs of reduced 
bone formation were described in the rib biopsies of 7 non-glucocorticoid treated 
patients with RA (31). Mellish et al (32) studied iliac crest biopsies in 48 patients 
(*) See also chapter I of this thesis for a brief discussion of bone remodelling 
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with RA, who were not treated with glucocorticoids. They found a decrease in 
trabecular bone volume, especially in patients with aged less than 50 years. This 
decrease in bone mass was associated with a decrease in the thickness of trabecu-
lar plates. The number of trabecular plates was not affected. In a later report the 
same group reported that mean wall thickness (an index of bone formation) was 
decreased in these patients (33). A decrease in trabecular bone volume and of 
cortical width in iliac crest biopsies was also reported by Rico et al in 25 patients 
with RA (34). Finally, iliac crest biopsies were also examined in 17 patients with 
recent onset RA. Again, trabecular bone volume was decreased. In these patients 
the number of resorption cavities was increased, while the surface percentage 
covered with osteoid was unchanged (35). 
Some studies have focussed on a possible association between osteomalacia and 
RA. Ng et al (36) studied iliac crest biopsies and biochemical parameters in 45 
patients with RA. Seventeen patients received glucocorticoids. The findings did 
not support an increased prevalence of osteomalacia in RA. However, a decrease 
in trabecular bone volume was shown, especially in female patients on glucocorti-
coids. Van Soesbergen et al (37) studied iliac crest bone biopsies in 17 patients 
with RA. No overt osteomalacia was diagnosed in any patient. The mineralisation 
rate and the thickness of the osteoid seam were normal in all patients. However, 
some biochemical parameters suggested vitamin D deficiency, and secondary 
hyperparathyroidism. These changes were accompanied by signs of high bone 
turnover in the biopsies, and by a decrease in trabecular bone volume. The 
authors conclude that minor degrees of vitamin D deficiency and concomitant 
secondary hyperparathyroidism may contribute to bone loss in patients with RA. 
Skeletal uptake of diphosphonates in RA 
Several studies have shown that the skeletal uptake of """Technetium methylene 
diphosphonate is increased in patients with RA (38-41). The 24 hour whole body 
retention of these compounds may be related to disease activity (41). These 
findings suggest that bone turnover may be increased in patients with (active) RA. 
Biochemical parameters of bone metabolism in RA 
Alkaline phosphatase 
Many studies have reported increased levels of alkaline phosphatase in patients 
with (mostly active) RA (35,37,42-49). As mentioned above these data are 
difficult to interprete because alkaline phosphatase may also be derived from 
extra-skeletal sources. 
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Osteocalcin 
A more specific indicator of osteoblast activity is serum osteocalcin, which has 
also been increased in several studies involving patients with active RA (34,44-
47). However, other studies have not confirmed this finding. Eggelmeijer et al 
(49) found no significant difference in osteocalcin levels between patients with 
either active or inactive disease, and osteocalcin concetralion did not correlate 
with parameters of disease activity. Normal levels of osteocalcin in RA have been 
reported by Weisman et al (50), and Pietschmann et al (51). Marhoffer et al (48) 
found normal osteocalcin levels in active RA patients with a disease onset before 
the age of 65 years. It should be noted, however, that 28 out of 55 patients used 
low-dose glucocorticoids. This may have influenced the results of their study, 
since osteocalcin levels are affected by glucocorticoid treatment, as will be 
discussed below. A subgroup of 17 patients with a disease onset after the age of 
65 did have elevated osteocalcin levels despite the fact that 6 of them were 
treated with glucocorticoids. Sambrook et al (52) reported a trend for patients with 
recent onset RA to have decreased levels of osteocalcin and of "Strontium 
accretion rates, another parameter of bone formation. However, these differences 
were not statistically significant. The levels of osteocalcin did not correlate with 
disease activity, but a positive correlation was found with total body potassium, a 
parameter of muscle mass. In a more recent paper an association between rates of 
radial and spinal bone loss on the one hand and biochemical parameters of bone 
formation and resorption on the other was reported for these patients (30). 
Ekenstam et al (53) found decreased levels of osteocalcin in patients with active 
RA on NSAIDs alone. Osteocalcin levels did not correlate with disease activity. 
During treatment with second line antirheumatic drugs osteocalcin levels increased 
significantly. All patients in this study were hospitalized. If this implies bed rest 
and reduced physical activity, this may perhaps explain the decreased osteocalcin 
levels. Reduced levels of osteocalcin were also found by Als et al (42) in patients 
treated with D-penicillamine or gold salts. No data on disease activity are 
available from this report. Kroger el al (54) found decreased osteocalcin levels in 
patients with recent onset RA. 
Procollagen I propeptide 
At the present time only limited data are available on this new maileer of bone 
fonnation in patients with RA. Pitt el al (35) found normal levels in patients with 
recent onset RA who had signs of increased bone resorption, which may indicate 
a relative decrease in bone fonnation. Kroger et al (55) found decreased levels of 
this peptide in patients with RA, especially in those with recent onset disease. 
Urinary hydroxyproline excretion 
In the majority of studies active RA has been associated with an increased urinary 
hydroxyproline excretion (34,35,37,43,44,49,52). However, Als et al (42) found 
normal urinary hydroxyproline/creatinin ratios in RA patients with unspecified 
disease activity, treated with either D-penicillamine or gold salts. Magare et al 
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were unable to demonstrate a difference in hydroxyproline excretion between RA 
patients with active and inactive disease (45). The same group also found no 
difference in this parameter between patients with active RA and patients with 
active psoriatic arthritis (47). 
Urinary excretion of deoxypyridinoline 
In patients with RA, the excretion of deoxypyridinoline was significantly increa-
sed in one study (56). In another report, involving a smaller number of patients, 
the increase was not statistically significant (57). 
The urinary calcium/creatinin ratio 
Some authors have found normal values for the urinary calcium/creatinin ratio in 
patients with RA (43,52). However, Eggelmeijer et al found significantly higher 
values in RA patients with active versus inactive disease (49). 
Influence of glucocorticoids on parameters of bone metabolism 
Glucocorticoids may cause osteoporosis by decreasing osteoblastic activity, and 
increasing bone resorption (58-60).(**) 
In longitudinal studies glucocorticoids cause a decrease in alkaline phosphatase 
(61,62) and osteocalcin levels (61-63). This has also been shown for the relatively 
low doses of inhalation steroids (63,64). In patients with RA the results of 
published reports have been contradictory. Most authors (46,53,62,65,66) have 
demonstrated decreased serum osteocalcin levels in RA patients on glucocorti-
coids. However, others could not confirm this (42,54). Kroger et al (55) found no 
decrease in procollagen I propeptide in patients on glucocorticoids. 
Glucocorticoids have been shown to increase urinary hydroxyproline (42,63,67-69) 
and calcium (63,64,67-70) excretion. Again, some investigators have not been 
able to confirm these findings (62,71). In a cross-sectional study involving 
patients with RA, glucocorticoids have also been suggested to increase the urinary 
excretion of deoxypyridinoline (56). Bijlsma et al (72) showed a significant 
transient increase in the urinary calcium/creatinin ratio, and a decrease in the 
urinary hydroxyproline/creatinin ratio during methylprcdnisolone pulse therapy in 
patients with active RA. 
Some of the effects of glucocorticoids on bone metabolism may be less pro-
nounced with deflazacort, a new oxazoline derivative of prednisone (67-70). 
(**) see also chapter I of this thesis 
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Concluding remarks 
Many studies have evaluated bone metabolism in patients with RA. Most data 
support an increase in bone turnover in patients with active disease. In general, 
parameters of bone resorption are increased. Markers of bone formation may be 
increased, nonnal, or decreased in these patients. Differences in age at onset of 
RA, duration of disease, seventy of the inflammatory process, and the degree of 
functional impairment and reduced mobility may perhaps explain the discrepancies 
in the literature. Adequately controlled studies are needed to clarify these issues. 
Glucocorticoids may decrease bone formation, and increase bone resorption. 
However, the effects of low-dose glucocorticoid treatment on bone metabolism in 
patients with RA are controversial. Most previous studies have had a cross-
sectional design. Some prospective studies have been published, but the decision 
to start glucocorticoids was left to the treating physician, which may have 
introduced a selection bias. This problem can be solved only in randomized, 
controlled studies. 
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Bone mass ¡η RA: a review 
Low bone mass is a frequent abnormality in patients with rheumatoid arthritis 
(RA) and may relate to the disease in different ways. Firstly, localized, juxta-
articular bone loss is a common phenomenon, and may be directly related to joint 
inflammation. Secondly, generalized bone loss has been suggested as an extra­
articular manifestation of RA, and several factors including disease-activity and 
reduced mobility, have been implicated in its pathogenesis. Finally, patients with 
RA are treated with a variety of agents that may affect bone mass, including 
glucocorticoids. However, whether low dose glucocorticoid therapy contributes to 
generalized osteoporosis in patients with RA is a matter of debate. Some have 
suggested that positive influences on disease-activity and mobility may outweigh 
their deleterious effects on bone (1-7). 
In this review we will focus on the association between generalized osteoporosis 
and RA, and on the effects of low dose glucocortcoid treatment on bone mass in 
these patients, including data that have been presented at recent scientific mee­
tings. Abnormalities in bone metabolism and calcium regulating hormones, or 
strategies for the management of osteoporosis in patients with RA, are not 
included. These topics have been reviewed recently elsewhere (1-3,5,6). 
Before discussing currently available data, we would like to mention some special 
problems related to bone mass measurements and to the design of studies dealing 
with bone mass in patients with RA. 
Special problems in methodology 
Bone mass measurements 
Low bone mass is an essential feature of osteoporosis (8), and over the past two 
decades new non-invasive methods for its measurement have been developed. 
Those that have been used in patients with RA include neutron activation analysis 
(NA), single photon absorptiometry (SPA), dual photon absorptiometry (DPA), 
dual energy X-ray absorptiometry (DXA), and quantitative computed tomography 
(QCT). The characteristics of these methods have been extensively reviewed 
elsewhere, and are summarized in table 1 (9-12). 
The appropriateness of peripheral bone mass measurements by SPA in the distal 
radius of patients with RA has been debated. It is generally accepted that the 
correlation between bone mass measurements at appendicular and axial sites is 
poor to moderate at best, both in normal persons and in patients with osteopenic 
bone diseases (13,14). In addition it has been suggested that in patients with RA, 
measurements in the distal forearm might also be affected by the inflammatory 
process in the adjacent wrist, and thereby reflect juxta-articular instead of 
generalized osteoporosis (1,6). Existing data do not support this view, however, 
since measurements in the distal radius are not affected by the degree of radiolo­
gical wrist destruction (15-17). 
Measurements of total body bone mass should also be interpreted cautiously since 
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juxta-articular and generalized bone loss cannot, of course, be separated with 
these methods. 
Table 1 : Characteristics of methods for measurement of bone mass, adepted from several 
sources (9-12). 
Method* 
Site 
Precision t 
Accuracy % 
Radiation dose (mrem) 
NA 
total body 
integral 
2-5% 
5-10% 
2000-5000 
SPA 
radius 
integral 
1-2% 
5% 
5-10 
DPA 
spine 
hip 
total body 
integral 
2 ^ % 
5-10% 
5 
DXA 
spine 
hip 
total body 
integral 
1-2% 
4-8% 
1-3 
QCT 
spine 
trabecular 
cortical 
2-5% 
5-20% 
100400 
* NA = neutron activation analysis, SPA = single photon absorptiometry, 
DPA = dual photon absorptiometry, DXA = dual energy X-ray absorptiometry, 
QCT = quantitative computed tomography 
t Precision is defined as the coefficient of variation for repeated measurements. 
$ Accuracy is defined as the coefficient of variation between the result of the measurement 
involved and that of a reference method (for example measurement of ashed weight). 
Low bone mass, as measured by different techniques at different sites, was shown 
to be associated with an increased risk of fractures in many studies. In general a 
decrease in bone mass of one standard deviation is associated with an increase in 
future fracture risk of 50 to 100 percent (12,18). Other factors, probably related to 
bone quality, may also partly determine fracture risk. In a recent prospective study 
for example, reduced bone mass and existing vertebral fractures were strong 
independent predictors of future vertebral fractures (19). In patients with RA, or 
with glucocorticoid-induced osteoporosis the relation between bone mass and 
fracture risk has not been studied extensively. Some reports have suggested 
however that in these conditions bone loss is associated mainly with trabecular 
thinning and that bone microarchitecture - and thus perhaps also bone strenght -
may be relatively preserved (20,21). 
Study designs 
Most studies of bone mass in RA published sofar have had cross sectional 
designs. Mean bone mass in rheumatoid patients without glucocorticoid treatment 
is compared with mean bone mass in a normal control group, or with mean bone 
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mass in patients with RA receiving long term glucocorticoid treatment, or with 
both. Bone mass is measured only once, and information about possible determi-
nants, such as disease duration, disease activity, functional capacity and glucocor-
ticoid treatment, is collected at the same time. 
When interpreting these studies one has to take into account the broad range of 
bone mass in normal subjects. In consequence it is difficult to be certain that 
differences found between groups are caused by either the disease or its treatment. 
To minimize the risk of misinterpretation one should at least be informed about 
the distribution of known risk factors for osteoporosis. Bone mass decreases with 
age, is lower in women than in men, and varies also with race, genetic back-
ground, menopausal state, body build, dietary factors, the level of physical 
activity, alcohol consumption, and cigarette smoking. Bone mass may also be 
affected by some medical conditions such as insulin dependent diabetes mellitus, 
hyperthyroidism, hyperparathyroidism and Cushing's syndrome (22). 
Another problem in cross sectional studies is that the severity of the disease varies 
during the course of the RA. If a diminished bone mass is found only in those 
patients who, at the moment of measurement, have a low level of physical 
activity, it is tempting to conclude that that may be the most important factor in 
the pathogenesis of osteoporosis in these patients. One can, however, not exclude 
the possibility that the past disease activity caused both the osteoporosis and the 
functional disability, although the measured disease activity at the moment of 
study may be the same in patients with and without severe functional impairment. 
Prospective studies, which have been scarce until now, offer the possibility of 
baseline and follow up bone mass measurements, and of regular evaluations of 
possibly important determinants, such as disease activity and functional capacity. 
It has been suggested that deleterious effects on bone arc present predominantly 
early in the course of the disease or of glucocorticoid treatment (23-25). If bone 
mass measurements are properly timed, prospective follow-up studies allow for 
the further evaluation of these hypotheses. 
An important issue is whether low dose prednisone therapy causes osteoporosis in 
patients with RA. Study of this problem is seriously hampered by the possibility 
of selection-bias in non-randomized studies. Glucocorticoid treatment is started 
mostly because the patient has a severe, active disease with concomitant functio-
nal disability. Decreases in bone mass observed after the start of such treatment 
may well be the consequence of the condition of the patient, and not of glucocor-
ticoid therapy. This problem can only be solved if the decision to start glucocor-
ticoid treatment is left to chance in a randomized trial. 
Bone mass in patients with RA 
Studies of bone mass in patients with RA focus on bone loss as extra-articular 
manifestation of RA, or on the effects of corticosteroid treatment. Many published 
reports have addressed both issues at the same time. For this review we have 
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Table 2: Bone mass in non-glucocorticoid treated patients with rheumatoid arthritis: cross-sectional studies 
Ref 
(nr) 
Number 
(women лпеп) 
Age 
(years) 
Patient Characteristics 
Duration RA Functional 
(years) Capacity 
(FC)* 
method 
t 
site 
Bone Mass 
results (percentage of normal) 
mean 95% CI 
26 34:21 49 2 9 1.7 SPA radius, proximal 93 
radius, distal 90 
88 to 98 
85 to 95 
27 34.29 women: 52.4 women: 8.2 women: 1 99 
men. 51.7 men: 8.5 men. 2.14 
NA total body women: 94 
men 95 
90 to 98 
91 to 99 
15 33.28 515 7.7 not available SPA radius, proximal 
radius, distal 
95 6 
92.9 
92.0 to 99.2 
88.3 to 97.5 
23 76-29 
28 36:0 
53.0 
59.2 
FC I: 7.6 
FC II· 10.2 
FC ІІІЛ : 12.3 
6.2 
I. n=37 
II: n=50 
ІІІЛ : n=18 
II: n=22 
III: n=14 
SPA 
SPA 
DPA 
radius, distal FC I· 92 88 to 96 
FC II. 86 82 to 90 
FC ІІІЛ : 79 74 to 84 
radius, proximal 84.4 
radius, distal 87.2 
spine 109.4 
78.3 to 90.5 
81.6 to 92.8 
102.0 to 116.8 
Table 2 (continued) 
Ref Number 
(nr) (womenmen) 
Age 
(years) 
55.8 
62 
51.7 
56.0 
Patient Characteristics 
Duration RA 
(years) 
11.8 
8 
4 
10.4 
Functional 
Capacity 
I: n=15 
II. n=22 
HI: n=3 
not available 
I:n=ll 
II. n=62 
III. n=15 
not available 
method 
DPA 
SPA 
QCT 
SPA 
site 
spine 
femoral neck 
radius, distal 
spine 
radius, distal 
Bone Mass 
results (percentage of normal) 
mean 
pre: 95.0 
post: 91.9 
pre: pre 
post:89.8 
women: 88 
men: 84 
89.4 
pre: 111.1 
95% CI 
90.3 to 99.3 
86.9 to 96.9 
83.8 to 101.4 
84.2 to 95.4 
82 to 96 
78 to 90 
84.8 to 94.0 
99.5 to 122.7 
29 
32 
40:0 
30 41:9 
31 51:37 
16 44:27 
30:14 women: 56.7 12.3 
men: 54 2 10.4 
(HAQ): 0.53 
(HAQ): 0.32 
QCT spine, trabecular 
spine, cortical 
post: 97.8 
men: 97.1 
women: 99.2 
men: 111.9 
women: 106.9 
men: 109.7 
88.3 to 107.3 
90.4 to 103.8 
87.8 to 110.6 
92 9 to 130.8 
98.3 to 115.4 
97.3 to 122.1 
* Functional capacity is evaluated with the Steinbrocker classification (Qass I-1V), or with a health assessment questionnaire (range 0-3). 
t SPA = single photon absorptiometry, NA = neutron activation analysis, DPA = dual photon absorptiometry, QCT = quantitative computed tomography 
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Table 3: Bone mass in glucocorticoid treated patients with rheumatoid arthritis: cross-secbonal studies 
Re f NombcT 
(nf) 
Pabea Chancterutic? 
men) Age Durition Funcuoiul Glococorticoids t 
(years) RA Capgcity — — — — — 
(уст) (PC)· ¿ox dunt 
metbad 
* 
NA 
SPA 
SPA 
DPA 
SPA 
DPA 
DPA 
SPA 
ЯІС 
toulbody 
ndius, prounul 
ndius disiai 
ndius, distal 
toulbody 
radius, projumal 
radius, distal 
фше 
spme 
femixïl iKck 
radius, distal 
Bots Mass 
Rsulls (% of Donnai) 
mean 
w 85 
m. 90 
897 
843 
pre 70 
post 90 
ni.73 
ρ« 78 
post 77 
m. 77 
881 
915 
95 9 
pre 949 
pos 885 
pre 886 
posf814 
pre 111 1 
post 817 
m.85 3 
9 5 * α 
80 to 90 
83 to 97 
8«1 to 933 
7 9 9 ι ο β 8 7 
60 to 80 
80 to 100 
59 to 87 
70 to 86 
71 to 83 
71 to 83 
TIA to 98 8 
844 to 98 6 
85 9 to 105 9 
81 6 to 1073 
84 3 to 917 
71 0 to 106.2 
77j4to874 
92 Ito 1301 
72 6 to 90 8 
769 to937 
preausooe mfloence # 
mean 
-9 
-5 
•59 
-8 6 
-23 
•10 
-14 
20 
-1 
-18 
•3 7 
•43 
-135 
-01 
-3/4 
-4.0 
•ΊΑ 
0 
-161 
11Л 
95% α 
-15 to -3 
•13ΙΟ+3 
-llOto-ОЛ 
•149 to 2 3 
-38 to-8 
-6 to+26 
-32 to M 
31 to 9 
-15 to+13 
-28 to-8 
-8.4 to +15 8 
-45 10+13 1 
-25/4 to -1 6 
-13.4 to+13 2 
9 9 to +3 1 
-157 to+77 
-149 to+01 
-21Λ to +21 0 
-29 1 to -3 1 
-223 to -1 3 
women. 56 I 
men. 53 6 
pre 462 
post 67 6 
men 567 
28 28 0 59 2 
29 44-0 56.2 
16 44 27 565 
123 
57 
104 
15 1 
14 5 
15 6 
117 
2.00 
139 
not 
available 
2.6 
2.4 
63 
61 
7 6 
8 3 
7 9 
6 6 
2.7 
8/4 
56 
10 2 
Π t e l l 
Ш n-16 
IV.n-1 
I n-7 
Π IK27 
Ш о>10 
DOt 
available 
8 9 
8 0 
pre 4 2 
post 4 3 
men 5 0 
47 
7 5 
4 0 
5/4 
52 
Table 3 (continued) 
Rtf 
32 
32a 
Number 
(women 
meo) 
16 14 
15 
Ag« 
(уем») 
«omen. 61 2 
men 68 6 
56J 
PatKin Characterutics 
Duration 
RA 
(yean) 
18.8 
104 
10 6 
Functional 
Capacity 
(FC)· 
HAQ 108 
HAQ OJO 
DO! 
available 
GlucocCTticoids t 
doae 
6Я 
71 
66 
duration 
79 
4 2 
25 
method 
t 
QCT 
DPA 
site 
apine trabecular 
зрте, corneal 
spine 
Гепмпі neck 
trochanteric 
Uard s aiea 
Bone Mass 
results (% of nornial) 
mean 
»•65 0 
m. 1014 
» 75J 
m. 103 6 
96J 
»48 
901 
917 
95% α 
5 5 6 t o 7 4 4 
84 1 to 1187 
68 7 to 82 2 
83 Oto 124 1 
85 6 t o l 0 7 J 
83 1 to 106 6 
73 6 to 109 7 
74 7 to 105 6 
prednisone influence ft 
man 
-312 
-105 
-37 2 
-61 
-07 
+0 9 
•5 6 
+1 9 
95% α 
503 10.12.1 
349to-»139 
53 6to-20.8 
28910 4167 
19410 »180 
13 8 to+15 6 
14 8 10 426 0 
14 1 to+18 0 
* Funaional capacity is evaluated with the Steinbrocker classification (Qass I-IV), or with a health assessment questionnaire (HAQ, range 0-3). 
Higher classes or scores indicate more functional impairment 
t The mean dose represents miligrams prednisone equivalents / day The mean duration of therapy is given in years 
t SPA = single photon absorptiometry, NA = neutron activation analysis, DPA = dual photon absorptiometry, QCT = quantitative computed tomography 
# Represents the difference between glucocorticoid treated and untreated patients, expressed as percentage from bone mass in untreated patients 
Chapter III 
attempted to separate them as much as possible. In the next paragraph we will 
discuss more extensively some factors that have been suggested as determinants 
of bone loss in patients with RA. 
Results of studies have often been contradictory. Discrepancies may in part be due 
to differences in methods for bone mass measurement, and to different study 
designs, as was discussed above. 
Cross sectional studies 
Tables 2 and 3 summarize the results of cross sectional studies of bone mass in 
RA for patients without and with glucocorticoid treatment respectively (15-17,27-
32). Confidence intervals reported in the tables have been calculated from tables 
or graphs. Reports not allowing calculation of 95 percent confidence intervals are 
not included in the tables, but are discussed below. 
Sambrook et al studied lumbar and femoral bone mass by DPA in 12 glucocorti-
coid treated and 15 untreated male patients with RA. The mean daily prednisone 
dose was 10.3 mg in those patients. The study also included 20 normal male 
controls. Bone mass was significantly decreased in the RA patients versus normal 
controls. The prednisone treated patients had a significantly lower bone mass than 
those without glucocorticoid treatment (33). O'Malley et al studied axial bone 
mass in 75 patients with RA by DPA and DXA. An unspecified number of their 
patients was treated with glucocorticoids. Details about dosage and duration of 
prednisone therapy were not given. Bone mass was measured in the lumbar spine 
and the femur. Mean bone mass was significantly lower than in healthy controls, 
and varied between 74.0 and 95.2 percent of normal in the different regions. No 
differences were found between the glucocorticoid treated and untreated patients 
(34). 
At recent scientific meetings further cross sectional studies were presented, that 
had evaluated axial bone mass by DXA. Eggelmeijcr et al measured lumbar bone 
mass in 45 non-steroid treated, ambulant patients with RA. Mean bone mass was 
101.1 percent of normal (35). Hall et all found a small decrease in mean bone 
mass in the lumbar spine and femoral neck (96.9 and 94.7 percent of normal 
respectively), when they compared 137 postmenopausal, non-steroid treated RA 
patients with 739 controls. This difference disappeared however after further 
increasing the number of persons in the study. Bone mass was also measured in 
45 postmenopausal glucocorticoid treated RA patients. Prednisone was given in a 
mean daily dose of 6.4 mg, and the mean cumulative dose was 1.6 grams. The 
prednisone treated patient had a significantly lower bone mass than those not 
treated, the difference being 6.5% in the lumbar spine and 8.3% in the femoral 
neck (36). 
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Longitudinal studies 
Few longitudinal studies have been published sofar. Sam brook et al compared 17 
female non-glucocorticoid treated patients with recent onset RA, with 19 age and 
sex matched controls. They measured bone mass at the distal and proximal radius 
with QCT, and at the lumbar spine with DPA. In patients with RA bone loss was 
increased over 1-2 years at the distal radius only (37). The same investigators also 
measured changes in bone mass in the lumbar spine and the femoral neck with 
DPA in 15 glucocorticoid treated and IS non-glucocorticoid treated female 
patients with longstanding RA. The patients treated with glucocorticoids were 
already receiving prednisone before they entered the study, and the mean daily 
dose was 6.6 mg. A controlgroup of 15 normal women, matched for age, was also 
included in this study. Baseline bone mass was significantly decreased in both the 
prednisone treated and untreated patients, but between these two groups no 
differences were found. Over a 2 year period rales of bone loss in patients with 
RA were normal, and no difference was seen between the prednisone treated and 
untreated patients (38). Reid et al measured changes in total body bone mass with 
NA over an 18 month period in 30 glucocorticoid treated and 34 untreated 
patients with RA. At the start of the study the mean duration of prednisone 
therapy was 4.7 years, and the mean daily dose was 5.7 mg. Nineteen patients 
with primary generalized osteoarthrosis served as a control group. Baseline bone 
mass was significantly decreased in the non-glucocorticoid treated patients with 
RA, and even more in those treated with prednisone. Rates of bone loss were 
increased in the rheumatoid patients without glucocorticoid treatment, but normal 
in the patients treated with prednisone (24). 
Cough et al, who evaluated bone mass with DXA, recently reported significant 
bone loss over a one year period occurring in patients with early RA. Of 52 
patients 13 lost bone at the lumbar spine and 15 at the femoral neck (39). We 
have ourselves reported the preliminary data of a randomized controlled trial, in 
which 40 patients with active RA who started treatment with intramuscular gold 
salts were randomly assigned to either low dose prednisone or placebo. The 
prednisone treated patients showed a significant reduction in trabecular lumbar 
bone mass after a period of only 20 weeks, while bone mass remained unchanged 
in patients on placebo (40). Laoussadi et al reported the results of a randomized 
controlled trial that compared the effects of 1 gram methylprednisolone intra-
venously once every 2 months, with the effects of 16 mg methylprednisolone 
orally each day. The patients receiving oral treatment showed a significant 
decrease in lumbar bone mass of about 10 percent after 2 months of treatment, 
with no further losses in the next 4 months. In patients on intravenous pulse 
therapy bone mass did not change (41). 
35 
Chapter III 
Determinants of bone mass in patients with RA 
Some studies have attempted to identify determinants of bone mass in patients 
with RA, mostly by calculating correlation coefficients between bone mass and a 
single suspected determinant. As bone mass in patients with RA will probably be 
influenced by more than one factor at the same time, such simple analyses are of 
limited value only. Other studies have used multivariate techniques that allow the 
simultaneous evaluation of several possible determinants (17,33,39,42,43). 
Risk factors for RA-related bone loss 
Generalized osteoporosis may be an extra-articular manifestation of RA, and some 
disease related factors have been suggested as possible risk factors for increased 
bone loss. These include disease duration, reduced mobility and disease activity. 
Some have also suggested that the risk of RA-related bone loss is associated with 
age and menopausal state. 
Age and menopausal state 
In some studies bone mass corrected for age was smaller in postmenopausal than 
in premenopausal patients with RA, though the differences have not always been 
statistically significant (16,17,29). These observations seem to indicate that 
deleterious effects of RA on bone mass may be somewhat accentuated postmeno-
pausally. In contrast Compston et al have suggested that RA related bone loss 
occurs mainly in younger patients with RA (31). 
Duration of disease 
If disease related mechanisms are responsible for bone loss in patients with RA, 
one might expect bone mass to be correlated with disease duration. In patients 
with longstanding RA such correlations have however not been shown in most 
studies (16,27,31,34). Als et al stratified 105 non-glucocorticoid treated patients 
with RA in 3 subgroups according to the duration of disease: 0-3, 4-8, and more 
than 8 years. Their data indicated that RA related mechanisms for bone loss may 
be more important in the first years of the disease (23). Further support for this 
hypothesis came from a recent study in our department. With multivariate 
techniques we demonstrated (hat bone mass in the lumbar spine and the femoral 
neck is related to disease duration in RA patients with disease durations varying 
between 3 months and 5 years (43). 
Reduced mobility 
The level of weightbcaring activity may be an important determinant of bone 
mass. Extreme inactivity causes rapid loss of considerable amounts of bone, and 
most exercise intervention programmes have shown either a reduction in bone loss 
or an increase in bone mass (22,44,45). 
Sambrook el al showed that the level of physical activity as measured with the 
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Framingham activity index, is correlated with axial bone mass in patients with 
rheumatoid arthritis. In a multiple linear regression analysis in female patients this 
association persisted for the femoral neck, but not the lumbar spine. Parameters of 
disease activity were however not included among the variables considered in the 
analysis (33). 
Functional capacity, evaluated with either the Steinbrocker classification or more 
recently with health assessment questionnnaires, has also been considered as a 
possible determinant of bone mass in patients with RA. Als et al stratified 105 
non-glucocorticoid treated patients with RA in 3 subgroups according to their 
functional class: Ι, Π, and Ill/TV. The lowest bone mass was found in the patients 
with the greatest functional impairment. It should be noted that the 3 subgroups 
also showed significant differences in disease duration (23). Using multiple linear 
regression analysis we recently showed that femoral bone mass is negatively 
associated with functional impairment in patients with early RA (43). In a 
prospective study Cough et al, who also used multivariate techniques, showed that 
patients with more functional impairment were more at risk for femoral bone loss 
(39). 
Disease activity 
Several cytokines have been implicated as pathogenetic factors in patients with 
active RA (46). Some of these are also known to influence bone cells. Interleukin-
1 and tumor necrosis factor are among the strongest stimulators of osteoclasts, 
and interleukin-1 has been suggested as a pathogenetic factor in patients with 
primary osteoporosis and high bone turnover (47,48). 
The evidence linking disease activity to bone loss in patients with RA is as yet 
limited. Sambrook showed a significant correlation between serum levels of C-
reactive protein and the rate of lumbar bone loss in patients with recent onset RA 
(37). With multivariate tecniqucs we have shown an association between bone 
mass in the femoral neck and the erythrocyte sedimentation rate also in patients 
with early RA. Some other parameters of disease activity were not related to bone 
mass (43). Cough et all showed that recent onset RA patients with higher serum 
C-reactive protein levels were more at risk for lumbar bone loss (39). 
influence of anti-rheumatic therapy on bone mass 
Patients with RA are treated with a variety of medications, some of which may 
affect bone mass. 
Non-steroidal anti-inflammatory drugs inhibit bone formation and resorption in in 
vitro-experiments and in laboratory animals (49,50). In patients with primary 
osteoarthrosis of the hip it has been suggested that these drugs may be associated 
with acetabular bone destruction (51). No studies are available to suggest their 
involvement in the pathogenesis of generalized bone loss in patients with RA. 
Disease modifying antirheumatic drugs (DMARDs) may also affect bone metabo­
lism. In vitro, gold salts inhibit osteoclastic bone resorption (52). It has been 
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documented that some DMARDs may reverse metacarpal bone loss in patients 
with active RA (53). 
Risk factors for glucocorticoid-induced bone loss 
The effects of glucocorticoids on bone, and the pathogenesis of prednisone 
induced osteoporosis have been reviewed extensively. In short, glucocorticoids 
have both direct and indirect effects on bone. They inhibit bone formation and 
increase bone resorption, and cause osteoporosis in patients with various primary 
diseases (54-57). The effect of low dose glucocorticoid treatment on bone mass in 
patients with RA is controversial, as was discussed before. 
Not all patients treated with glucocorticoids will loose bone at an increased rate, 
which may partly explain the reported discrepancies. Dykman et al have shown 
that about 40 percent of patients treated with prednisone have elevated ratios of 
diaphyseal to metapyseal bone mass in the forearm (42). This finding has been 
suggested as a specific marker of glucocorticoid-induced osteopenia (58). The 
factors that determine the individual susceptibility to the effects of glucocorticoids 
on bone have not been fully defined. 
Age, sex, and menopausal state 
Deleterious effects of low dose prednisone therapy have been documented in both 
female (15-17,27,32,36), and male (15-17,33) patients with RA. Premenopausal 
patients with RA have been found to be at increased risk in one study (17), while 
in two other studies postmenopausal patients were more likely to be affected by 
low dose glucocorticoid therapy (15,16). Age over 50 has also been suggested to 
be a risk factor for glucocorticoid-induced bone loss in male patients with RA 
(15). 
Dykman et al studied the diaphyseal to metaphyseal bone mass ratio in the 
forearm in 161 patients with diverse rheumatic diseases on long-term glucocorti-
coid therapy (42). By multivariate techniques they were unable to show that sex, 
age or menopausal state influenced the prevalence of increased ratios, although 
fractures were more common in postmenopausal women and in patients aged 50 
or over. 
Characteristics of treatment 
The patients in the study of Dykman et al were treated with a daily prednisone 
dose ranging from 1 to 80 mg, for 1 month to 25 years. The cumulative dose 
ranged from 0.2 to 118.5 grams. By multivariate techniques they showed a 
significant influence of cumulative, but not daily, dose on the prevalence of both 
an increased diaphyseal to metaphyseal bone mass ratio and fractures (42). No 
such associations have been found in most studies of low dose prednisone treated 
patients with RA, in whom cumulative doses were much smaller (17,27,28,33,34). 
The risk of glucocorticoid-induced bone loss is probably similar in patients on 
daily and on alternate day therapy (42,59). 
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Bone sparing glucocorticoids 
Deflazacort, a new oxazoline derivative of prednisone, may have less influence on 
bone than prednisone in dosages with a similar anti-inflammatory action (54,61). 
Fractures In patients with RA 
Bone mass is an important factor in the pathogenesis of fractures. If bone loss 
occurs in patients with RA an increased risk of fractures may be expected. 
Fracture incidence has been shown to be moderately increased in patients with 
RA. The relative risk for fracture in RA is about 1.5 to 2.5 (62,63). The risk is 
increased especially for pelvic and hip fractures (62). A diagnosis of osteoporosis 
prior to the development of RA, and prednisone therapy in a dose of more than 5 
mg/day, may be associated with an additional increase in fracture risk (64). 
Current use of corticosteroids did not significantly influence fracture risk in 2 
other studies (62,63). Impaired mobility and a low body mass index have also 
been stressed as important predisposing factors for fractures (62,63). 
Concluding remarks 
In this review we have summarized the most recent literature on the association 
between decreased bone mass and RA. Some data have as yet only been publis-
hed in abstracts, and full length reports should be awaited before drawing definite 
conclusions. 
The available data seem to indicate thai generalized osteoprosis may indeed be an 
extra-articular manifestation of RA, occurring in a subset of patients. The disease 
is probably associated with a small decrease in mean bone mass, which has not 
been statistically significant in all studies, and with a moderate increase in fracture 
risk. Recent studies suggest that bone mass may be affected by disease dependent 
factors, such as functional impairment and the activity of the inflammatory 
process itself, especially early in the course of RA. Long-term follow-up studies 
are needed to better understand changes in bone mass in patients with longstan-
ding RA, but the present data suggest impaired mobility as an important determi-
nant of both bone loss and fractures throughout the course of the disease. 
The influence of prednisone therapy on bone mass has been evaluated in patients 
with RA. Some cross sectional studies have shown significant negative associati-
ons between bone mass and low dose prednisone therapy, whereas other studies 
did not show significant differences. As the 95% confidence intervals for the 
difference between prednisone treated and untreated patients are mostly rather 
broad, deleterious effects of prednisone therapy are not excluded in the negative 
studies. In longitudinal studies no increased bone loss has been demonstrated in 
patients who had received glucocorticoid treatment for several years, but signifi-
cant bone loss has recently been shown early in the course of treatment, even 
when low doses are used. Further prospective studies arc urgently needed to better 
understand the long-term effects of low dose glucocorticoids on bone mass. They 
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may also help to characterize better the factors that determine the individual 
susceptibility to glucocorticoid-induced osteoporosis in patients with RA. 
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Single versus dual energy OCT in RA 
Summary 
Lumbar bone mineral density was measured by both single- and dual-energy 
quantatitive computed tomography in 109 patients with rheumatoid arthritis. The 
results were corrected for the age-related increase in vertebral fat content by 
converting them to percentages of expected densities, using sex and energy-level 
specific regression equations obtained in a normal reference population. The 
percentages of expected density are apppronmately 10% lower in the single- than 
in the dual-energy mode, both in the patients with and without prednisone 
therapy. This difference is statistically highly significant, and is positively correla-
ted with the duration of the disease and with the degree of radiological joint 
destruction. The data suggest that the vertebral fat content may be increased in 
patients with rheumatoid arthritis, as a consequence of disease dependent 
mechanisms. 
Introduction 
Quantitative Computed Tomography (QCT) is one of the methods available for 
spinal densitometry, and can be performed in a single-energy or a dual-energy 
mode (SEQCT and DEQCT). The results of SEQCT are influenced by the 
presence of varying amounts of fatty yellow bone marrow within the vertebrae. 
Correction for this fat associated error, as offered by DEQCT, is particularly 
important if densitometry is performed in patients with disorders that might be 
associated with changes in bone marrow composition (1). In the literature, 
changes in marrow composition, independent of changes in age or bone density, 
have been described for example in patients with Gaucher Disease, or with 
anorexia nervosa, and after irradiation (2,3,4). 
Both SEQCT and DEQCT have been used to evaluate bone mineral density 
(BMD) in patients with rheumatoid arthritis (RA) (5,6). The possibility of changes 
in marrow composition has however not been explored in patients with this 
disease. If such changes exist, the relationship between SEQCT and DEQCT 
measurements would be different in patients with RA and in normal controls. We 
report here SEQCT and DEQCT data that were obtained simultaneously in the 
same patients, and which suggest that the vertebral fat content may be increased 
in patients with RA. 
Patients and methods 
Patient selection 
The study was performed in 109 patients with rheumatoid arthritis. They were 
initially selected for two different studies: a cross-sectional survey and a control-
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led clinical trial, designed to evaluate the influence of low-dose prednisone 
therapy on bone mineral density, on the long term and short term respectively. 
The results on these issues are reported elsewhere (6,7). 
To select patients for the cross-sectional survey the records of all classical or 
definite RA patients attending the outpatient clinic of a university rheumatology 
department during a four month period were reviewed. Patients on long-term (> 6 
months) low-dose (< 10 mg/day) prednisone therapy (n=30), and patients who had 
never been treated with systemic corticosteroids, but who had been treated with at 
least 2 different disease modifying anti rheumatic drugs (DMARD) (n=44) were 
selected for this study. 
For the controlled clinical trial patients with active, classical or definite RA, who 
were started on intramuscular gold salts were selected (n=35). Only base line bone 
mineral density measurements are used in the present report. At that time no 
patients were treated with corticosteroids. 
Normal controls were not included in the study; instead, we used normal reference 
data published in the literature (8). To check, however, for systematic errors in 
the analytical technique, 18 patients with primary osleo arthrosis (OA) were also 
measured. These patients all had long-standing primary arthrosis of either hip or 
knee, and were selected from a waiting list for joint replacement. AU OA patients 
had a primary degenerative disorder with no symptoms of inflammatory disease. 
Bone densitometry 
All measurements were done with a Siemens Somatom DR3, according to 
methods described before (8,9). This apparatus allows rapid kilovolt switching. 
The voltage is switched between 85 and 125 kilovolt (kV) from pulse to pulse. 
The absorption data are thus obtained at two kV peak values in a single scan. 
Patients are positioned with the lumbar spine over a calibration phantom, consis-
ting of two stable plastics: a water-equivalent and a bone-equivalent standard 
containing 200 mg hydroxy apatite/ml. Scans arc made through the midvertcbral 
level with a slice thickness of 8 mm. While Kalender et al measured L, - Lj, we 
used lumbar vertebrae Lj - L4. 
Three images are reconstructed for each scan: at 125 kV, at 85 kV, and a dual-
energy calcium density image after processing by material decomposition techni-
ques. Regions of interest (ROI) are automatically defined for the trabecular part 
and the cortical rim of the vertebral body separately. The algorithm automatically 
traces the cortical ridge line, and locates a ROI center point. The inner and outer 
cortical contour are chosen at 60% between cortical ridge line and trabecular 
values. The contour for trabecular bone is fixed at 90% of the distance between 
the ROI center point and the inner cortical contour. A more extensive description 
of this ROI definition procedure has been published (10). 
The SEQCT data presented in this study refer to the measurements with 85 kV. 
The DEQCT data are, of course, derived from the calcium density image. 
The patients with RA were measured over an approximately 3-year period. The 
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patients with OA were measured not as a single cohort, but randomly interspersed 
with the other patients in the first year of the measurements. 
The results are expressed as percentages of expected densities. For this purpose 
we used energy-level specific linear regression equations, derived from a populati-
on that has been measured on the same type apparatus according to the same 
analytical techniques as described above, in Germany, Belgium and France. This 
reference population consists of 135 males and 139 females, who were scheduled 
for a CT examination mainly for trauma or neurological disorders, and in whom 
no conditions were present that could affect bone mass. The exclusion criteria 
included amongst others spinal and hip fractures, inactivity, steroid use, and bone 
marrow disorders including anemia. The normal reference data obtained show 
reasonable agreement with normal data obtained in other countries with different 
apparatus and measurement protocols (8). 
Clinical parameters 
In the RA patients the severity of the disease was assessed by the following 
parameters. 
The radiological destruction of hands and wrists was evaluated independently by 2 
investigators using the Larsen method (11). In case of disagreement consensus 
was reached after re-evaluation of the radiographs. A total of 20 joints was 
examined in each patient ( range from 0 to 100 ; a zero score indicates no 
radiological destruction ). 
The functional capacity of each patient was evaluated by the Dutch equivalent of 
the Stanford Health Assesment Questionaire (HAQ), which has been validated for 
RA patients in our department ( range from 0.00 to 3.00 ; a zero score indicates 
no functional impairment ) (12). 
Statistical analysis 
Differences in percentages of expected densities of identical ROIs in the same 
patient, between the single and dual energy modes, were analyzed with a two 
sided paired t-test. The use of paired instead of unpaired t-tests is justified 
because SEQCT and DEQCT measurements, obtained in identical regions of 
interest, are compared in the same patient Differences in proportions of patients 
with a negative and a positive difference between SEQCT and DEQCT are tested 
with the two tailed Fisher's exact test for 2x2 tables. 
Pearson correlation coefficients are calculated as indicated in the text. 
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Results 
The clinical data on the participating patients are summarized in Table 1. 
Table 1: Clinical data: mean (median, range) 
Number 
Age (yr) 
Duration RA (yr) 
Larsen score 
Functional capacity 
Rheumatoid Arthritis 
Females 
73 
56.0 
(58.0, 26.1 - 86.9) 
10.9 
(9.5, 0.3 - 54.0) 
32.8 
(27.5, 0 - 87) 
0.74 
(0.65, 0.00 - 2.08) 
Males 
36 
60.6 
(61.0, 32.6 - 87.3) 
8.8 
(78, 0.6 - 27.9) 
26.2 
(26, 2 - 76) 
0.53 
(0.36,0.00- 1.74) 
Osteo Arthrosis 
18 
63.2 
(61.5,43.9-73.6) 
not applicable 
not applicable 
not applicable 
The bone densitometry results are summarized in Table 2. In the patients with OA 
the percentages of expected density are, as expected, quite similar in single- and 
in dual-energy modes. In the patients with RA however the SEQCT measurements 
are significantly lower than the DEQCT values, both for the trabecular and the 
cortical ROI. The difference between SEQCT and DEQCT in patients with RA is 
highly significant ( p<0.0001 by paired t-test ), suggesting a consistent difference 
in the same direction in all patients. The difference between SEQCT and DEQCT 
was negative in 95 (87%) and positive in 14 (13%) patients with RA. In patients 
with OA the difference was negative in 8 (44%) and positive in 10 (56%) 
patients. This difference in proportion of patients with positive and negative 
differences between patients with RA and OA is also statistically significant. 
(two-tailed Fisher's exact test, p=0.0003) 
The difference between SEQCT and DEQCT is similar in patients with and 
without low-dose prednisone therapy (data not shown). 
The difference between the percentages of expected BMD as measured by 
SEQCT and by DEQCT, respectively, is significantly correlated with the duration 
of RA (г=0.38, p=0.0001), and with the Larsen score (r=0.27, p=0.01), but not 
with age or functional capacity at the moment of the BMD measurement. 
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Table 2: Bone mineral density by single and dual energy computed tomography, in a trabecular and a cortical region of interest (ROI) 
Trabecular ROI 
Rheumatoid arthritis, females 
Rheumatoid arthritis, males 
Osteoarthrosis 
Cortical ROI 
Rheumatoid arthritis, females 
Rheumatoid arthritis, males 
Osteoarthrosis 
η 
73 
36 
18 
73 
36 
18 
Single 
mean 
85.4 
99.0 
102.9 
92.4 
99.2 
112.8 
energy 
(85 kV) 
(SD) 
(33.0) 
(28.3) 
(21.5) 
(22.1) 
(22.2) 
(16.4) 
Dual 
(85, 
mean 
94.6 
110.2 
104.1 
101.0 
105.7 
113.6 
energy 
125 kV) 
(SD) 
(33.2) 
(30.4) 
(21.5) 
(26.1) 
(26.5) 
(16.4) 
Difference 
single - dual energy 
mean 
-9.2 
-11.1 
-1.2 
-8.7 
-6.5 
-0.8 
95% Π limits 
-11.1,-7.2 
-15.0 , -7.3 
- 6.0 . +3.6 
- 9.9 , -7.4 
- 8.5 , -4.4 
- 3.6 , +2.0 
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Discussion 
Our results indicate that the relation between SEQCT and DEQCT is different in 
patients with RA than in a normal reference population reported in the literature. 
Several hypotheses could be put forward to explain this phenomenon. 
At first one may argue that the differences between SEQCT and DEQCT in our 
RA patients could be either apparatus or procedure related. Although we used the 
same type of equipment that was used for the normal reference population, 
apparatus related artefacts can never be completely ruled out. Our protocol differs 
from the one used in the normal reference population only in the fact that we 
measured lumbar vertebra L3 and L4 instead of LI to L3. Since no differences 
between SEQCT and DEQCT were seen in the patients with О A, we do not 
believe that either type of error could be very important. 
An alternative hypothesis would be that RA patients develop a different vertebral 
soft tissue composition from normal controls during the course of their disease. In 
SEQCT the measured CT number represents the combined x-ray attenuation of all 
materials present in a defined volume element. DEQCT allows for the selective 
measurement of the density of material with a high atomic number (=calcium). 
The differences between SEQCT and DEQCT percentages of expected density in 
RA patients must therefore be due to differences in the composition of the non-
mineralized tissue components. 
Our results could be explained if more red bone marrow is replaced by fat in the 
RA patients than in the normal reference population reported in the literature. We 
have to emphasize, however, that this hypothesis should be tested by directly 
estimating the vertebral fat content in patients with RA, by either computed 
tomography or nuclear magnetic resonance imaging. To the best of our knowledge 
such data are not available at the moment. 
One may argue that our explanation is less probable for the cortical than for the 
trabecular ROI. The cortical ROI definition is based, however, on adaptive 
trcsholding and the resulting cortical width depends in part on the trabecular 
values adjacent to the cortical bone. A lower trabecular level results in a lower 
cortical value simply because the width will be increased. This effect will be even 
more pronounced if the subcortical fat content is increased. 
The significant positive correlations between the duration of disease and the 
severity of the RA as judged by the Larsen score on the one hand and the 
difference between SEQCT and DEQCT percentages of expected densities on the 
other, further support the hypothesis that a disease dependent mechanism is 
responsible for the observed phenomenon. It can not be excluded, however, that it 
might be caused by the therapies presribed to these patients rather than by the 
disease itself. The fact that similar results were obtained in patients with and 
without prednisone treatment seems to rule out the possibility that corticosteroid 
therapy is responsible for the observed differences between SEQCT and DEQCT 
measurements. This would be in accordance with the data of Mayo-Smith et al, 
who found no differences in vertebral fat content between patients with Gushing 
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disease and normal controls (3). 
Sofar one study has been published on SEQCT data in patients with non steroid 
treated RA (5). The main finding of this study was an approximately 10% reducti-
on in trabecular BMD compared to normal controls. Our data show that in 
patients with RA bone mineral density is underestimated in comparison to normal 
controls, even when the age dependent increase in vertebral fat content is correc-
ted for. The present study suggests that the reduction in trabecular BMD reported 
by Compston et al may in fact have been due to an increased vertebral fat 
content. 
We suggest that, certainly for research puiposes, DEQCT instead of SEQCT 
should be used for accurate bone mineral densitometry in patients with RA. 
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Disease activity and functional capacity as determinants of BMD 
Summary 
Generalized osteoporosis is frequently descnbed m patients with rheumatoid 
arthritis (RA) The aim of the present study was to evalúale disease related 
determinants of bone mineral density (BMD) in RA Patients weie selected f ι от a 
group of 147 patients with recent onset RA Disease activity and functional 
capacity were studied prospectively in this cohoit Aitivity of the disease was 
assessed once every three months by various parameters, and fune lumai сарае ity 
was measured with a health assessment questionnait e (HAQ) once every six 
months Ninetyseven patients consented to paitnipate in the piesent study BMD 
was assessed with dual energy X-ray absorptiometry ¡n the lumbar spine, in a 
combined region of interest m the hips, and in Waid's 4 tangle Multiple linear 
regression procedures were used to analyse the data Dm anon of RA was 
negatively associated with BMD at all 3 sites of measwement The mean eryth-
rocyte sedimentation rate in the 6 months befoie BMD measuiement was negati-
vely associated with BMD in the hip and m Waid's tiiangle Othei païameteis of 
disease activity were not related to BMD The mean HAQ in the 18 months befoie 
BMD measurement was negatively assotiated with BMD in the coml)ined hip 
region only BMD tended to be decreased when patients nere (ompaied with a 
normal reference group, espec tally in the fenwt al ι egions of inlet est 
We conclude that BMD may be affected m patients with tec ent onset RA by 
disease dependent mechanisms I η the literalute, sevetal factois have been 
suggested as determinants of BMD in RA The ι esults of the pi esent stiuly show 
that disease duration, disease activity and functional impaument may, indepen­
dently from each other, contribute to bone loss, especially m the pioximal femur 
Introduction 
The pathogenesis of axial osteopenia in patients wiih rheumatoid arthritis (RA) is 
poorly understood. As in patients without RA, age, sex, height, weight, panty, 
duration of postmenopause, drinking and smoking history, and some dietary 
habits, may affect bone mineral density (BMD) (1). In addition several factors 
specifically related to RA could also be important. Most frequently, the duration 
of the disease, the degree of functional impairment, and the severity of the 
inflammatory process, have been suggested as potential risk factors for osteoporo­
sis in patients with RA. 
Most previous studies have had a cross-sectional design. A negative association 
between duration of RA and BMD was found in some of these studies (2,3), but 
has not been confirmed by others (4-8) The degree of functional impairment has 
been suggested as an important risk factor for fracture by some authors (9,10), 
however, not by all of them (11) A negative association between the latter factor 
and BMD has been described (2,7). and denied (4,6,8). Disease activity has also 
been suggested as possible risk factor for osteopenia in patients with rheumatoid 
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arthritis (3,4). Recently other investigators found no such association (12). 
Since many, often interdependent, factors may contribute to the development of 
osteoporosis in patients with RA, the influence of one specific factor is difficult to 
evaluate, and the effect of potentially confounding factors on the results should be 
corrected for. Sofar, no study included all suggested disease related risk factors in 
an analysis suitable for the evaluation of the influence of multiple factors on 
BMD. Furthermore, these studies have only assessed potential risk factors such as 
degree of functional impairment and activity of RA at the lime when BMD was 
measured. It may be expected however, that their effects will only become 
apparent after a sufficiently long period of time. Therefore these data should be 
interpreted with restraint. 
In our department, disease activity and functional capacity arc studied prospective-
ly in all patients with recent onset RA. These data were used to study the 
influence of RA related factors on axial BMD. 
Patients and methods 
Patients 
Since 1985 all patients who presented themselves at the rheumatology outpatient 
clinic of the University Hospital Nijmegen with recent onset RA, were asked to 
participate in a long-term prospective follow up study. All patients included in 
this study had classical or definite RA (13), had symptoms for less than one year, 
and had not been treated with disease modifying antirheumatic drugs prior to 
inclusion in the study. 
At the start of the present investigation, 147 patients participated in the long-term 
prospective follow up. All patients were asked to participate in the present study. 
Prospective clinical measures 
Disease activity and functional capacity were prospectively assessed in all partici-
pating patients by specially trained research nurses. Measures of disease activity 
were assessed at least once every three months. For the present study only three 
monthly assessments were used. Functional capacity was assessed once every six 
months. 
Measures of disease activity included the number of tender joints, the number of 
swollen joints, Ritchie articular index (14), duration of morning stiffness (minu-
tes), severity of pain (100 mm visual analogue scale: 0 indicating no and 100 
indicating maximal pain), degree of general health (100 mm visual analogue scale: 
0 indicating best and 100 indicating worst possible), left and right hand grip 
strength with a vigorimeter (mm Hg), erythrocyte sedimentation rate (ESR) 
according to Westergren (mm in 1st hour), haemoglobin (g/1), thrombocyte count 
(109/1), total protein, albumin, al-globulin, a2-globulin, ß-globulin and γ-globulin 
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(all g/1), С reactive protein (g/1), and IgM rheumatoid factor (lU/ml). 
Functional capacity was assessed by a Dutch equivalent of the Stanford health 
assessment questionnaire (HAQ) (range from 0.00 to 3.00; a zero score indicates 
no disability), that was validated for patients with RA in our department (15). 
At each visit the use of any medication, including glucocorticoids, was noted. 
Other clinical measures 
At the time of bone mineral densitometry additional information was collected on 
some clinical variables. Height and weight were determined and a body mass 
index (BMI), expressed in kg/m2, was calculated in all patients. In female patients 
the menopausal state, the duration of poslmenopause (years) and the number of 
children were also noted. 
Bone Mineral Densitometry 
BMD was measured once by dual energy X-ray absorptiometry (DXA) with a 
Hologic QDR 1000 (Hologic Inc. Wallham, MA, USA) at the lumbar spine (Ll-
L4), and at the left and right hip. The results of both hips were averaged. In some 
patients BMD could not be assessed in one or both hips because of hip replace­
ment. BMD in the hips was assessed in a combined region including the femoral 
neck, the trochanteric and intertrochanteric region, and also separately in Ward's 
triangle, a region with a greater proportion of trabecular bone that may be 
specially important for femoral bone strength (16). The DXA results are expressed 
in g/cm2, and in Z-scores (number of standard deviations above or below normal 
mean after comparison with age- and sex-matched normal control values, based 
on measurements in a North American population, as supplied by the manufactu­
rer). In vivo reproducibility was evaluated in 60 women (mean age 51.4 years). 
The coefficient of variation was 1.0% for the lumbar spine, 1.7% for the combi­
ned region in the hip, and 2.4% for Ward's triangle. 
Analytical and statistical methods 
The duration of RA was defined as the duration of follow-up plus the duration of 
symptoms before entry in the prospective study, and was expressed in months. 
Disease activity was evaluated prospectively by different parameters as stated 
before. In previous reports on the prospective follow up study, the Ritchie 
articular index, the number of swollen joints, the ESR, and the degree of general 
health were found to best reflect different aspects of disease activity. A combined 
disease activity score (DAS), consisting of those parameters, was also constructed 
(17,18). In the present study we limited the analysis to the DAS and its four 
constituents. We first inspected plots between BMD and each of the disease 
activity reflecting variables. Initially, only those assessments done at approxima­
tely the same time as densitometry were used. We then repeatedly extended 
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backwards the observation period with 3 months intervals, now plotting the mean 
value of the DAS and each of (he four constituting parameters against BMD, and 
the observation period with the best linear association between disease activity 
and BMD was selected. 
A similar procedure was done for defining functional capacity. We plotted the 
HAQ scores against BMD, and used 6 in stead of 3 months intervals for the 
backwards extension of the observation period. 
The influence of duration of RA, disease activity and functional capacity on BMD 
was then evaluated by multiple linear regression analysis. The results obtained 
with DXA in the lumbar spine, the combined region in the hip, and in Ward's 
triangle were used as dependent variables. The independendent variables included 
age (years), gender (0=male, l=fcmale), body mass index (kg/nr), duration of RA 
(months), and disease activity and functional capacity as defined according to the 
above described procedures. In a subgroup of female patients the duration of 
postmenopause (years) and parity (number of children) were also included among 
the independent variables. The regression analysis was carried out both with and 
without model selection techniques. Model selection was done by stepwise 
regression. In this analysis variables were added one by one to the model if they 
contributed lo BMD with a p-value < 0.15. After adding a variable, all variables 
already included in the model were rc-evalualcd and deleted if they did not 
contribute to BMD with a p-value < 0.15 anymore. Wc also checked whether the 
finally selected models explained best the variation in BMD by calculating R2 
(adjusted for number of variables) for all possible models. 
The relationship between BMD on (he one hand, and the various independent 
variables mentioned above al ihe other, is described in three regression equations 
for each skeletal region separately. The proportion of variance of BMD explained 
by the regression equation is indicated by R2, which has also been calculated after 
correction for the number of variables in the equation (R*,^ ,,,«,))). The influence on 
BMD of the independent variables selected for the model is described in further 
detail by providing the parameter estimate, its 95% confidence interval, and the 
probability for testing the null hypothesis thai ihe parameier eslimale is nol 
significantly different from zero. To facilitate the comparison between indepen-
dent variables measured in different units, standardized parameter estimates have 
also been calculated. 
Differences in parameter eslimales between subgroups of patients were evaluated 
with the t-test. 
All statistical analyses were done with Ihe SAS/STAT® software package (19). 
Results 
At the time of the present study 147 patients with recent onset RA participated in 
Ihe prospective follow-up for al least three months. A total of 97 patients agreed 
to bone mineral densitometry. Detailed clinical data on the participating patients 
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are given in Table 1. In those patients on prednisone therapy the daily dose never 
exceded 10 mg/day. The median duration of glucocorticoid therapy was 1.4 years 
(range from 0.2 lo 2.7 years). 
BMD data are summarized in Tables 2 an 3. Lumbar BMD was measured in all 
97 patients. In 6 patients no measurements could be performed in the hips because 
of bilateral joint replacement. Z-scores tended to be negative in our patients, 
indicating a decrease in mean BMD compared with the data of a normal age- and 
sex-matched reference population supplied by the manufacturer. The mean Z-score 
was positive only for female patients in the lumbar spine. The proportion of 
patients with a low BMD (Table 3) was consistently higher than would be 
expected. 
Table 1 : Clinical data; mean (median, range) 
Number 
Age 
(years) 
Number postmenopausal 
Du ral ion postnienopause 
(years) 
Panty 
(number of children) 
Body Mass Index 
(kg/m2) 
Duration of RA 
(months) 
Mean ESR 
Oast 6 months, mm in 1st hour) 
Mean functional capacity 
Oast 18 months, HAQ, score 
Number using prednisone 
0-3) 
Female 
58 
55.2 
(57.5. 27 - 78) 
41 
13.8 
(12, 1 -32) 
2.1 
( 2 . 0 - 9 ) 
24.5 
(24.0, 17.6 - 34.8) 
30.2 
(30.5, 5 - 65) 
25.1 
(22. 1 -76) 
0.49 
(0.28. 0 - 2.44) 
17 
Male 
39 
56.9 
(57, 30 - 80) 
not applicable 
not applicable 
not applicable 
25.5 
(24.9. 20 9 - 30.0) 
30.1 
(32, 3 - 53) 
19.6 
(15 .2 -54) 
0.38 
(0.25. 0 - 1.72) 
5 
In the plots between BMD and the parameters reflecting disease activity, no 
association was seen for any of the observation periods between BMD and Ritchie 
articular index, number of swollen joints, degree of general health, or the combi-
ned DAS. A negative linear association was suggested between ESR and BMD 
for simultaneous measurements. When extending the observation period back-
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wards, the association between ESR and BMD improved and was judged optimal 
for a period of six months preceding bone mineral densitometry. Gradual worse­
ning of the observed association resulted from further extending backwards the 
observation period. For the purpose of the present study disease activity was then 
defined as the mean ESR in the six months before bone mineral densitometry 
(mean ESRJ. 
Table 2: Bone mineral density (BMD) Mean ± Standard Deviation (95% confidence interval) 
Female Male 
Lumbar Spine n=58 ii=19 
BMD (g/cm2) 0952 ± 0 172 0951 ± 0 147 
(0 907 to 0 997) (0 906 to 1 000) 
Z-score +013± 1 48 0 67 ± 1 41 
(-0 06 io+0 72) ( 1 1 3 io-0 22) 
Hip n=52 n=39 
BMD (g/cm2) 0 821 ± 0 142 0 906 ± 0 124 
(0781 lo 0 860) (0 866 lo 0 946) 
Z-score 0 27 ± 1 09 0 33 ± 0 83 
(-0 57 lo+0 04) (-0 59 to 0 06) 
Ward's mangle n=52 n=39 
BMD(g/cm2) 0527 ± 0 165 0535 ± 0 118 
(0 481 lo 0 573) (0 497 to 0 573) 
Ζ score -0 55 ± 1 17 -0 73 ± 0 82 
(-0 87 lo-0 22) (-0 99 to-0 47) 
Table 3: Proportion of patients with low bone mineral density 
Z-score Proportion (%) with BMD < Z-score (95% CI) 
(expected proportion *) 
Lumbar spine Hip Ward's mangle 
-10(15 9%) 32 0(22 7 lo 41 2) 24 2 (15 4 lo 33 0) 39 6 (29 5 to 49 6) 
- 1 6 4 5 ( 5 0 % ) 1 5 5 ( 8 3 l o 2 2 7 ) 1 1 0 ( 4 6 l o l 7 4 ) 1 3 2 ( 6 2 l o 2 0 1 ) 
- 2 0 ( 2 3 % ) 9 3 (35 to 150) 4 4 (02 to 86) 6 6 (15 to 11 7) 
* Expected proportion with BMD й Z-score in the population (assuming normal distribution) 
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Table 3: Influence of various factors on bone mineral density in different skeletal regions (stepwise multiple linear regression) 
variable 
Gender 
Age 
(years) 
Body Mass Index 
(kg/ml) 
Duration RA 
(months) 
Mean ESR 
(6 months) 
Mean HAQ 
(18 months) 
Prednisone 
factor 
t 
102 
103 
102 
10' 
103 
10 = 
1 
Lumbar Spine 
estimate standardized 
(95% CI) estimate 
(P value) 
not selected 
-2.94 
(-5.30 to -0.57) 
[0.01] 
+ 1.05 
(+0.15 to+1.95) 
(0.02) 
-1.87 
(-4.07 to +0.33) 
[0.09] 
not selected 
not selected 
not selected 
-0.25 
+0.23 
-0.17 
Hip 
estimate 
(95% CI) 
[P value) 
-6.10 
(-11.1 to-1.13) 
[0.02] 
-2.92 
(-4.80 to-1.05) 
[0.003] 
+ 1.43 
(+0.72 to +2.15) 
[0.0001] 
-2.15 
(-3.81 to -0.49) 
[0.011 
-1.62 
(-3.27 to +0.03) 
(0.05) 
-5.73 
(-10.7 to -0.76) 
[0.02] 
standardized 
estimate 
-0.21 
-0.28 
+0.35 
-0.22 
-0.18 
-0.21 
not selected 
Ward's Triangl 
estimate 
(95% CI) 
[P value] 
le 
standardized 
estimate 
not selected 
-4.62 
(-6.46 to -2.78) 
[0.0001] 
+0.66 
(-0.03to+1.35) 
10.06] 
-2.81 
(-4.45 to-1.16) 
[0.001] 
-2.46 
(-4.07 to -0.85) 
[0.003] 
-3.73 
(-8.57to+1.12) 
[0.13] 
not selected 
-0.43 
+0.16 
-0.28 
-0.26 
-0.13 
2 t factor whereby slated parameter estimate must be multiplied 
Chapter V 
In the plots between BMD and HAQ scores a linear association was suggested for 
simultaneous assessments. The association was judged optimal for an observation 
period of eighteen months before densitometry. For the purpose of the present 
study functional capacity was then defined as the mean HAQ score in the eighteen 
months preceding BMD measurement (mean HAQ,8). 
Multiple stepwise linear regression analysis was done first using the data of all 
patients together, and the following models were reached. (See also Table 4 for 
detailed information on parameter eslimatcs.) 
BMD l u m b a r s p r c = 0.911 - ( ΐσ 3 χ 2.94 χ age) 
+ (10 2 x 1.05 xBMI) 
- (103 χ 1.87 χ duration RA) 
R2 = 0 . 1 1 . ^ , ^ ^ = 0.10,/· = 0.004 
BMDhip = 0.886 - (ΙΟ2 χ 6.10 χ a) [a=0 if male, a=l if female] 
- ( 1 0 3 x 2.92 χ age) 
+ (10 2 x 1.43 xBMI) 
- (103 χ 2.15 χ duration RA) 
- (ΙΟ3 χ 1.62 χ mean ESR«) 
- ( 1 0 2 x 5.73 χ mean H A Q J 
R2 = 0.42, R2(adjU5Icd) = 0.37, Ρ = 0.0001 
BMDw-d.™*,- 0.779 - ( ΐ σ 3 χ 4.62 χ age) 
+ (ΙΟ2 χ 0.66 χ BMI) 
(ΙΟ3 χ 2.81 χ duration RA) 
б) - ( ΐσ 3 χ 2.46 χ mean ESR6) 
- ( Ι Ο 2 χ 3.73 χ mean HAQI8) 
R2 = 0.47, R2(adjuwd) = 0.42, Ρ = 0.0001 
When Z-scores were used as the dependent variable, similar results were reached 
with respect to the influence of duration of RA, mean ESR6 and mean HAQI8. 
In an attempt to exclude patients with false increases in lumbar BMD due to 
severe degenerative spine changes, we checked the images produced by the 
Hologic bone densitometer for the presence of osteophytes. Patients who had less 
than 2 vertebrae with marked osteophytes were analysed separately. The mean Z-
score in the lumbar spine was -0.19 (95% confidence interval from -0.59 to 
+0.23) in the remaining 41 female patients and -1.05 (95% confidence interval 
from -1.45 to -0.65) in the remaining 31 male patients. With the stepwise 
regression analysis the following model was reached: 
B M D L . ^ , „ « = 1.027 - (103 χ 4.36 χ age) 
+ (10 2x0.84 χ BM1) 
- (103 χ 2.80 χ duration RA) 
R2 = 0.28, R2(ad)USIcd) = 0.25, Ρ = 0.0001 
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The 95% confidence interval for the parameter estimates were -6.68 to -2.05 for 
age (Λ=0.0003), ^.89 to -0.71 for duration of RA {P=0M9), and -0.07 to +1.76 
for BMI (Р=0.(П). 
Further analysis showed that the models resulting from the stepwise regression 
analysis were also those wilh the highest R2, after adjustment for the number of 
variables included. 
Multiple linear regression analysis was done also in subgroups of premenopausal 
and postmenopausal women, and in male patients. The parameter estimates for 
disease duration, ESR6 , HAQ,8, and BMI were almost identical and not signifi­
cantly different between these three subgroups. Prednisone therapy influenced 
BMD in the combined region of the hip only in postmenopausal females (estima­
ted influence of prednisone therapy -0.088, 95% confidence interval (CI) from 
-0.167 to -0.008, Ρ = 0.03). The age related decrease in BMD was significantly 
greater in postmenopausal females than in premenopausal women or in male 
patients, both in the lumbar spine and in the hip areas (P < 0.01 for all skeletal 
regions). 
In postmenopausal patients a separate analysis was done including duration of 
postmenopause and parity among the independent variables. Age and duration of 
postmenopause were highly correlalcd. Duration of postmenopause in stead of age 
was included in the model for the lumbar spine and for the combined region in 
the hip. Age was selected for the model for Ward's triangle, and duration of 
postmenopause was not included. Parity was included only in (he model for 
lumbar BMD (parameter estimate +0.022, 95% CI from - 0.003 to +0.048. 
Ρ = 0.09). The inclusion of duration of postmenopause and parity among the 
independent variables in the analysis did not significantly change the estimales for 
duration of RA, mean ESR6, mean HAQ18, use of prednisone and BMI. 
Discussion 
The present study was designed to evaluate the influence of certain disease 
characteristics on axial bone mass in RA. For this purpose we used prospectively 
assessed measures of functional impairment and of activity of the inflammatory 
process, and we measured BMD in the lumbar spine and in the hips, in patients 
wilh recent onset RA. 
A negative association between duration of RA and BMD was found in three 
skeletal regions. This has been described before by some, but not all previous 
investigators (2-8). Our data suggest that RA dcpendenl mechanisms cause a 
gradual decrease in bone mass within the first five years of (he disease in the 
axial skeleton. 
The degree of physical activity is generally recognized as a dclerminant of BMD. 
Extreme inactivity causes rapid bone loss, while athletes have a higher BMD than 
sedentary subjects. Exercise intervenlion programs have shown reduced bone loss 
or increased bone mass (20,21). In patients with RA impaired funclional capacity 
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and reduced physical activity have been associated with a decrease in bone mass 
and an increase in fracture risk in some cross-sectional studies (2,7,9,10). None of 
these studies contained prospective data on functional capacity or disease activity. 
Our data show that the degree of functional impairment, expressed by the mean 
value of the HAQ score in the last 18 months is related to BMD in the hip areas, 
even after correction for differences in ESR. 
The level of activity of the inflammatory proces has also been suggested as a 
determinant of BMD in patients with RA, in some cross-sectional studies (3,4). 
Our data show that some but not all measures of disease activity may be related 
to BMD. The mean ESR in the last six months was negatively associated with 
BMD in the hip areas. This association was no longer present when the observati-
on penod was extended over six months before densitometry, suggesting (hat only 
recent disease activity is important for BMD. Other measures of disease activity, 
including the Ritchie articular index, the number of swollen joints and the degree 
of general health, were not related to BMD. The data suggest that Ihc acute phase 
response may be associated with a release of factors that influence bone metabo-
lism. Probable candidates are cytokines like interlcukin-1 and tumor necrosis 
factor, which are probably involved in the pathogenesis of RA (22). These factors 
are known to influence bone metabolism (23), and interleukin-1 has been sugge-
sted as a pathogenetic factor in patients with high bone tum-ovcr osteoporosis 
(24) 
The proportion of variance of lumbar BMD explained by the regression equation 
is rather low, and sex, mean ESR and mean HAQ were not related to spinal BMD 
in our patients. We suspect that this may be due to measurement errors in some 
of our patients. False increases in lumbar BMD may result from vertebral 
fractures, from aortic calcifications, or from degenerative spinal changes. Since no 
spine radiographs were obtained, these explanations cannot be properly evaluated. 
However, chaecking the BMD of individual vertebrae did not suggest the presence 
of lumbar vertebral fractures in our patients. We also attempted to correct for the 
influence of possible degenerative spinal changes by checking the images produ-
ced by the densitometer for marked osteophytes Stepwise regression analysis in 
the resulting subgroup showed an approximately twofold improvement of R2 for 
the lumabr spine. However, sex, mean ESR and mean HAQ still had no effect on 
spinal BMD. We conclude that our lumbar data should be cautiously interpreted. 
The regression analysis was perlormed in both sexes combined. No significant 
differences were observed in the estimated influence of duration of RA, degree of 
functional impairment, or level of disease activity, between the sexes or between 
pre- and postmenopausal women. The number of patients in each subgroup 
however is small, and differences cannot actually be excluded. In postmenopausal 
patients multiparity exerted a protective effect on BMD in the spine, as was 
previously described by Sambrook el al (7). 
No effect of prednisone on BMD could be demonstrated, except in postmenopau-
sal patients. Data on the influence of low dose glucocorticoids on bone mass in 
patients with RA are controversial (25) The present study was not designed to 
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evaluate the possible contribution of this drug to the development of osteoporosis, 
and the number of patients using prednisone in the study is loo small to allow 
conclusions on this topic. 
The data presented in this paper support the hypothesis that BMD may be affected 
by RA related mechanisms. This may lead to a decreased BMD in patients with 
RA versus normal controls. However, we cannot definitely confirm this hypothe­
sis, since our study did not include normal controls. Instead, Z-scorcs were 
calculated after comparison with reference values supplied by the manufacturer. 
For this data set measurements were done in 950 (spine) and 1500 (hip) North 
American persons. Reference data accumulated in France, Belgium and Australia 
correlate closely to North American values, within ± 2% over the whole B M D 
range for spinal measurements (26). Furthermore, 60 healthy women, who 
participated in a trial aimed at the prevention of postmenopausal bone loss, were 
measured in our hospital. Baseline measurements in these patients confirm the 
valididty of the Hologic normal data for Dutch women aged between 40 and 60. 
Mean Z-scores in our study were negative with the exception of the Z-scorc for 
the lumbar spine in female patients. After exclusion of patients with suspected 
severe degenerative spinal changes, Z-scores were also negative in this subgroup. 
The proportion of patients with a low bone mass was consistently higher in our 
patients then expected. Taken together our data suggest that BMD may be 
decreased in a subset of RA patients of recent onset, with active disease and 
functional disabilities. 
Although clinical parameters were collected prospectively in our study, BMD was 
measured only once. Sambrook et al (27) have previously studied a small number 
of patients with recent onset RA prospectively. Over a period of one to two years 
increased bone loss was demonstrated at the distal radius, but not at the proximal 
radius or lumbar spine. The rate of lumbar bone loss was, however, positively 
correlated to the serum concentrations of С reactive protein. A preliminary report 
of a prospective study of BMD in recent onset RA, involving a greater number of 
patients, has been recently published by Gough et al (26), and our results are in 
accordance with their findings: patients with active disease were at increased risk 
for spinal bone loss, while patients with greater functional impairment had a 
higher risk for femoral bone loss. 
Previous reports on bone mass in patients with RA have shown contradictory 
results (25). In the present study the separate influence of disease duration, 
disease activity, and functional impairment on BMD was evaluated. We conclude 
that BMD may be affected by RA dependent mechanisms, and that functional 
impairment and disease activity may both be determinants of bone loss in patients 
with recent onset RA. 
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arthritis 
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Short-term effects of low-dose prednisone 
Summary 
Published data on the effects of low-dose (< 10 mglday prednisone) glucocor-
ticoids on bone mass in patients with rheumatoid arthritis are controversial, but 
no randomized controlled studies have been reported so far 
We performed a double blind, placebo controlled, randomized study in 40 patients 
with active rheumatoid arthritis In the first 20 weeks, prednisone treated patients 
were given an initial dose of 10 mglday, and a cumulative dose of 1050 mg After 
discontinuation of trial medication, patients were followed for an additional 24 
weeks Activity of the rheumatoid arthritis and functional capacity were assessed 
at regular intervals Lumbar bone mineral density was measuied with quantitative 
computed tomography m a trabecular and a coitical region of interest at base-
line, and öfter 20 and 44 weeks Mai kers of bone metabolism were also measured 
in the initial 20 weeks of the study 
Treatment with prednisone resulted ¡n a rapid and marked decrease m activity of 
RA and in an improvement of functional capacity Trabecular bone nvneral 
density decreased significantly ¡n the prednisone treated patients between baseline 
and week 20 (mean change -82%, 95% confidence interval -12 7% to -3 7%) No 
change was found m the placebo tieated patients, and the difference between the 
two treatment groups was significant (P=0 003) Parallel to the decrease in 
trabecular bone mineral density, biochemical maikers of bone foi motion decrea-
sed, and parameters of bone resorption increased in the prednisone treated 
patients After discontinuation of prednisone a significant increase was found in 
trabecular bone mineral density between neeks 20 and 44 (mean change 5 1%, 
95% confidence interval 0 4% to 9 8%) No significant change was seen after 
withdrawal of placebo The dijfeience between the two gioups was almost 
statistically significant (P=0 06) In both treatment groups, cortical bone mineral 
density did not change significantly, m either penod 
The data indicate that glucocorticoids cause marked vertebral trabecular bone 
loss in the initial months of therapy m patients with rheumatoid arthritis, despite 
improvements in disease activity and functional capacity Aftei discontinuation of 
treatment, this bone loss may be reversible, when duration of theiapy is limited to 
a short period of time 
Introduction 
Published data on the effects of low-dose (< 10 mg/day prednisone) glucocorti-
coids on bone in patients with rheumatoid arthritis (RA) are controversial, and it 
has been suggested that favourable effects of glucocorticoids on the inflammatory 
process and on physical activity, may outweigh the negative effects of these drugs 
on bone, in patients with active RA. Previous cross-sectional studies have had 
contradictory results. Some investigators showed a considerable, glucocorticoid 
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associated bone loss (1-6), while others failed to observe significant differences 
between patients with and without low-dose glucocorticoid treatment (7,8). 
Longitudinal studies have been carried out in patients who had been on glucocor-
ticoid treatment for some time, and no increased rates of bone loss could be 
demonstrated (9,10). 
Several explanations may be offered for the discrepancies in the literature. Firstly, 
non-randomized studies may be subjected to selection bias, since the RA itself, 
and its concomitant reduced mobility may also adversely affect bone mass 
(11,12). Secondly, it has been documented that negative influences of glucocorti-
coids may be most pronounced in the first months of therapy (13), and studies 
evaluating bone loss in the chronic phase of treatment may thus underestimate the 
effects of these drugs on bone. So far, randomized controlled studies of the initial 
effects of low-dose glucocorticoids on bone have not been reported. 
Glucocorticoids are frequently used in the management of patients with RA. The 
question whether this therapy increases the risk of osteoporosis, is of considerable 
interest. The additional morbidity associated with osteoporotic fractures, may be 
quite dramatic in these patients, who are often already disabled by their primary 
disease. 
We report the results of the first randomized, placebo controlled study of the 
initial effects of low-dose prednisone on bone mineral density and bone metabo-
lism in patients with active RA. 
Patients and methods 
Patients 
Patients were selected from a single university outpatient clinic, from April 1988 
to April 1991. All patients with classical or definite RA (16) who started intra-
muscular gold salts were considered for participation in the trial. The decision to 
start intramuscular gold therapy was left to the rhcumatologist in charge of the 
patients. In general, parenteral gold salts were started in patients with active RA 
who failed treatment with at least one of the other disease modifying anti-
rheumatic drug (DMARD). These included hydroxychloroquine, sulfasalazine, D-
pcnicillamine, azathioprine, and methotrexate. 
Patients were admitted to the trial only if they fulfilled at least three of five 
criteria: five or more joints that were tender or painful during motion; three or 
more swollen joints; an erythrocyte sedimentation rate above 28 mm/h; morning 
stiffness for at least 60 minutes; and a hemoglobin level below normal limits. 
Patients with other diseases or medication, including calcium supplements, that 
might affect bone mass were excluded from the study. Female patients who were 
postmenopausal for less than three years, or who had irregular menstrual cycles, 
were also excluded from the study. 
Informed consent was obtained from all patients. The study was approved by the 
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local Ethics Committee. 
Study design and medication 
All patients were treated with intramuscular aurothioglucose (Auromyose®; 20% 
oily suspension, Noury Pharma, Oss, the Netherlands) according to a standard 
regimen. All patients started with a test dose of 10 mg prior to the trial. They 
then continued with a dose of 50 mg weekly, for 20 weeks. Modification of this 
schedule was possible in case of side-effects. Aurothioglucose could then be either 
discontinued or its dose reduced. Patients were monitored for side effects weekly 
for the first 8 weeks of treatment, and once every 2 weeks thereafter. 
The trial was a double-blind, placebo controlled study over 20 weeks. Patients 
were followed for an additional 24 weeks after this period. All patients were 
randomly assigned to either prednisone or placebo treatment. No stratification or 
block randomization was used. 
Prednisone was given in a dose of 10 mg once daily for 12 weeks. Thereafter the 
dose was gradually reduced: 7.5 mg/day in weeks 13 and 14, 5.0 mg/day in weeks 
15 and 16, 2.5 mg/day in weeks 17 and 18, and 0 mg/day in weeks 19 and 20. 
This resulted in a cumulative dose after 20 weeks of 1050 mg, and a mean daily 
dose of 7.5 mg. 
All patients were seen between 1.00 and 4.00 p.m. for clinical assessments by one 
observer, and for measurements of bone mineral density, bone metabolism and 
calcium regulating hormones, according to the methods described below. 
Assessments of rheumatoid arthritis 
Disease activity was measured by a composite index, consisting of the erythrocyte 
sedimentation rate (ESR) (mm in first hour), the Ritchie articular index, the 
number of swollen joints, and a visual analogue scale (VAS) for general health 
(range 0-100 mm; a zero score indicating excellent health), which has been 
constructed and validated in our department.(17,18) Assessments were done at 
baseline, after 1, 2, and 4 weeks, and thereafter at intervals of 4 weeks. 
Functional capacity was assessed at baseline and after 12, 20 and 44 weeks, by a 
Dutch equivalent of the Stanford health asscsment questionnaire (HAQ) (range 
0.00-3.00; a zero score indicating no functional impairment), which has been 
validated for patients with RA.(19) 
Assessments of bone mineral density 
Bone mineral density (BMD) was measured in the lumbar spine by quantitative 
computed tomography (QCT) with a Siemens Somatón DR3. The details of this 
method have been published before.(20-22) 
In short, patients are positioned with the lumbar spine over a calibration phantom, 
consisting of two stable plastics: a water-equivalent and a bone-equivalent 
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standard containing 200 mg hydroxyapatite/ml. Scans arc made through the 
midvertebral level of lumbar vertebrae L2 - L4, with a slice thickness of 8 mm. 
Regions of interest (ROI) are automatically defined for the trabecular bone and 
the anterior cortical rim of the vertebral body separately. BMD is then calculated 
by comparison of the absorption in the ROI and the calibration phantom. BMD is 
expressed in mg hydroxyapatite/ml. 
Measurements were made at 125 and 85 kilovolt (kV), and three images were 
reconstructed from each scan: at 125 kV, at 85 kV, and a calcium equivalent 
density image after processing by material decomposition techniques. Dual energy 
QCT (DEQCT) results were calculated from the calcium density image. 
The coefficient of variation (CV) for in vivo measurements, during the period of 
the trial, was calculated with the results obtained in the placebo treated patients, 
assuming that all variation in BMD between baseline and week 20 was due to 
(random) precision errors. The CV was 6.1% for the trabecular and 5.2% for the 
cortical bone. 
To exclude the possibility that new vertebral fractures caused changes in BMD, 
lateral spine radiographs were obtained in all patients at baseline and after 44 
weeks, and evaluated by an experienced radiologist. 
Biochemical assessments 
Blood samples were drawn at baseline and after 4, 8, 12, and 20 weeks. Plasma 
calcium (mmol/1), albumin (g/1), creatinine (pmol/l) and total alkaline phosphatase 
(IU/1) were determined automatically on a Hitachi 717 (Boehringcr Mannheim) 
according to standard hospital procedures. Plasma calcium was corrected for the 
albumin concentration [corrected calcium=measured calcium + 0.02 χ (40 -
albumin) mmol/1]. 
Blood samples for measurements of osteocalcin, parathyroid hormone, calcitonin 
and 1,25 dihydroxyvitamin D were placed in ice and centrifugatcd immediately 
after collection. Thereafter, samples were kept at minus 20° С All measurements 
were done in duplicate, and performed batchwise. Scrum osteocalcin was measu­
red by radioimmunoassay (OSTK-PR, CIS bio international, France, inlra-assay 
CV 3.0%-8.5%, and inter-assay CV 5.5%-8.5%). Plasma intact parathyroid 
hormone was measured by a two-site immunoradiomctric assay (Allégro assay, 
Nichols Institute Diagnostics, USA, inlra-assay CV 1.8%-3.4%, inter-assay CV 
5.6%-6.1%). Plasma calcitonin was measured by radioimmunoassay (Amersham 
International pic, United Kingdom, inlra-assay CV 4.8%-9.0%, inter-assay CV 
7.4%-9.3%). 1,25-dihydroxyvitamin D was determined using a radioreceptorassay 
according to Reinhardt et al (23). However, we used paperchromatography instead 
of Silica/C-18 cartridge extraction (intra-assay CV 14.7%, inter-assay CV 19%). 
At baseline and after 4, 8, 12, and 20 weeks 2 hour urine samples were collected 
after a 12 hour fast for measurement of the calcium/creatinine and hydroxyproli-
ne/creatinine ratios. Urinary creatinine was automatically measured with a Cobas 
Rio (La Roche). Urinary calcium was automatically measured on a Hitachi 717 
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(Boehringer Mannheim). Total urinary hydroxyproline was measured using a 
commercially available kit (Hypronosticonkit, Organon Teknika, The Nether­
lands). 
Statistical analysis 
Because patients were randomly assigned to the 2 treatment groups, there was 
only a 5% chance of statistically significant differences occurring in baseline 
variables. The validity of the treatment group allocation was investigated with 
Student's t-test or Fisher's exact test as indicated in table 1. 
Areas-under-lhe-curve (AUC) were calculated for disease activity and functional 
capacity, and differences between placebo and prednisone treated patients were 
analyzed with Student's t-test. 
For BMD and parameters of bone metabolism, paired and unpaired Student's t-
tests were used to analyze within-group changes, and differences in timed changes 
between treatment groups, respectively. The results are expressed as means and 
ninetyfive percent confidence intervals (95% CI). All analyses were performed 
according to intention to treat principles. 
Percentages change in BMD were calculated between baseline and week 20 and 
between week 20 and 44. The influence of possibly confounding variables was 
corrected for by an ANOVA procedure, as indicated in the text. 
Changes in parameters of bone metabolism were analyzed between baseline and 
week 12. To utilize all available data at each 4 weekly interval, a relative AUC 
[relative AUC = AUC/(baseline value χ duration of follow-up)] was calculated. 
The percentage change in parameters of bone metabolism between weeks 12 and 
20 was analyzed separately. 
To evaluate possible mechanisms of observed changes in bone mineral density, a 
structural model was constructed and analyzed by path-analysis techniques, using 
multiple linear regression (ordinary least squares) methods. 
Results 
During the recruitment period 55 patients started aurothioglucose treatment. Three 
patients were inadvertently not reported by their treating physician. Nine patients 
refused cooperation for various reasons. One patient did not fulfil the required 
criteria for active disease. Two patients were excluded because of irregular 
menstrual cycles, indicating perimenopause. The remaining 40 patients were 
randomized and started treatment according to the protocol. 
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Table 1 Patient characteristics, mean ± standard deviation (median, range) 
Number 
Age 
years 
Sex 
female male 
Menopause 
pre postmenopausal 
age al menopause 
duration postmenopause 
yeare 
Duration RA 
months 
Rheumatoid factor 
positive negative 
Height 
centimeters 
Weight 
kilograms 
Scrum Creatinine 
pmoiyi 
Prednisone 
20 
53 3 ± 12 5 
(57.29 71) 
146 
59 
497 ± 3 4 
(50 45 55) 
9 0 ± 4 2 
(9 1-15) 
63 1 ± 107 8 
(21 5 7 468) 
164 
1 6 6 5 ± 9 0 
(165 0, 154 0 185 0) 
7 1 0 ± 9 0 
(70 8. 55 5 93 0) 
81 0 ± 17 9 
(79 5,49 116) 
Placebo 
20 
562 ± 14 1 
(56, 35 78) 
14 6 
8 6 
49 0 ± 5 7 
(51,41 55) 
20 0 ± 9 1 
(21.6 31) 
49 2 ±51 6 
(29 5, 3 192) 
17 3 
166 1 ± 9 2 
(163 3 154 0 185 0) 
72 1 ± 15 0 
(74 5.415 96 0) 
83 0 ± 20 2 
(81 5, 57-128) 
P* 
0 5 0 t 
1 0 0 t 
044 t 
079 φ 
003 t 
0 6 0 * 
1 0 0 t 
0 89 t 
077 % 
074 t 
* significance of the difference between the prednisone and placebo treated patients 
t probability by Fisher exact test 
% probability by Student's t lest 
Participating patients were well matched for most variables (table 1). An imbalan­
ce was present for the ratio of pre- to postmenopausal women, and for duration of 
postmenopause. Prior treatments with the various DMARDs were also equally 
distributed between the 2 groups (data not shown) 
The course of treatment in all 40 patients is illustrated in figure 1. One patient in 
the placebo group with progressive disease refused further treatment with the trial 
medication after 4 weeks She was then treated with prednisone 10 mg/day. 
Assessments were earned out according to the protocol, and this patient remained 
included in the placebo group in all analyses. One other patient in the placebo 
group dcveloppcd an acute and irreversible pancylopenia, probably related to 
aurolhioglucose. She died as a consequence of massive pulmonary hemorrhage. 
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Figure 1 : Course of treatment ' in patients randomized for participation in the study. 
Time (weeks) 
Group I (n=20) 
Aurolhioglucose and Prednisone ' 
Stop Au 
side effects (4) 
Patients on 
Au: 16 
MTX 1 
n o D M A R D 3 
Stop Au 
side effects (3) 
inefficacy (5) 
0 Group И (n=20) 
Placebo and Aurolhioglucose 
switch lo 
prednisone (1) 
Au related falal bone marrow suppression 
(1) 
Available for 
analysis (ITT1) 
in prednisone 
group 
n=20 
20 
Available for 
analysis ( П Т ) 
in placebo 
group 
n=19 
no data available (2) 
Au: 6. MTX. 7, 
Sulí 2, 
no DMARD 3 
Prednisone 
no 12 
yes 6 
44 
Stop Au 
side effects (4) 
Palienls on 
Au 15 
no DMARD 4 
Slop Au 
side effects (0) 
inefficacy (2) 
no dala available (1) 
Prednisone 
no 16 
yes 2 
Au 12. Suif. 1 
Min A 
no DMARD· 1 
* Au=Aurolhioglucose; MTX=Methotrexale, Suir=Sulfasalazine. DMARD=diseasc modifying 
antirheumatic drug 
t Daily dose: week 0-12· 100 mg, week 13-14· 7 5 mg, week 15-16. 5 0 mg, week 17-18. 2 5 mg, 
week 19-20 0 mg 
\ ITT intention to treat analysis 
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Intra-articular injections with glucocorticoids were avoided as much as possible, 
but were considered necessary once in 1 prednisone, and 6 times in 4 placebo 
treated patients. During (he second period of the trial 6 patients who were 
originally randomized to Ihe prednisone group, and who had all discontinued the 
trial medication according to the protocol, again started to use prednisone. At the 
time of analysis no data about the period from week 20 to 44 were available from 
2 patients in the prednisone and 1 in the placebo group. 
Disease activity and functional capacity 
At baseline, no significant differences were present in parameters of disease 
activity and functional capacity between the 2 groups.(table 2) 
The course of the DAS, of the ESR. and of the HAQ during the trial is illustrated 
in figure 2. All constituents of the DAS show a similar course. The ESR is 
presented separately because it may be more closely related to changes in bone 
metabolism than other parameters of disease activity (13). 
The DAS and ESR both showed a marked and rapid decrease in the prednisone 
treated patients. 
For the DAS the AUC is significantly lower in prednisone than in placebo treated 
patients between 0 and 12 weeks (p<0.0001), and between 0 and 20 weeks 
(p=0.004). No significant differences were present in the AUC for the DAS 
between 12 and 20 weeks, between 20 and 44 weeks, and between 0 and 44 
weeks. A similar pattern was found for the ESR. The AUC for the ESR was 
significantly lower in prednisone treated patients between 0 and 12 weeks 
(p=0.0002), and between 0 and 20 weeks (p=0.003), but no significant differences 
were found between 12 and 20 weeks, between 20 and 44 weeks and between 0 
and 44 weeks. Changes in HAQ were less marked. The AUC for this parameter 
was significantly higher in the prednisone group between week 0 and 44 only 
(p=0.03). No significant differences were present in any other of the periods men-
tioned above. 
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Table 2: Baseline parameters of disease activity and functional capacity; mean ± standard 
deviation (median, range) 
Number 
Erylhrocyte sedimentation rale 
mm in first hour 
Ritchie articular index 
Number of swollen joints 
General health 
visual analogue scale, 0-100 mm 
Disease activity score 
composite score t 
Functional capacity 
health assessment questionnaire. 
range 0-1 
Prednisone 
20 
43 1 ± 27 9 
(33 5,7-110) 
1 7 4 ± 4 7 
(18,8-24) 
1 8 0 1 6 0 
(18.6-28) 
49 3 1 15 S 
(48 5. Π 76) 
4 92 ± 0 58 
(4 87.3 97-6 18) 
0 86 ± 0 47 
(0 69.0 15 196) 
Placebo 
20 
54 5 ± 23 7 
(44 5, 25-95) 
170 ± 7 6 
(16. 5 32) 
1 8 6 ± 7 6 
(16 5.9-32) 
52 0 ± 22 1 
(54. 4-95) 
5 03 ± 0 88 
(4 97.3 84 6 95) 
0 67 ± 0 42 
(0 58.0 03-1 40) 
P* 
0 17 
0 86 
0 78 
0 65 
0 64 
019 
* significance of the difference between the prednisone and placebo treated patients, by Student's I-
test 
t references 17,18 
Lumbar bone mineral density 
At baseline no significant differences in lumbar BMD were present between the 
prednisone and placebo groups. The mean (SD) trabecular BMD was 110.7 (45.3) 
mg/ml in the prednisone group versus 111.3 (27.8) mg/ml in the placebo group. 
The mean (SD) cortical BMD was 272.3 (58.5) mg/ml in the prednisone group 
versus 276.4 (55.4) mg/ml in the placebo group. 
Percentages change in BMD (Δ-BMD) are presented in table 3. In the first 20 
weeks, a significant decrease was found only in trabecular BMD within the 
prednisone group. The difference in Δ-BMD in the initial 20 weeks, between the 
prednisone and placebo group, is highly significant for the trabecular (p=0.003), 
but not cortical (p=0.82) bone. To correct for the imbalance in menopausal 
characteristics between the 2 treatment groups, an ANOVA was carried out. For 
this purpose patients were classified as male, premenopausal, postmenopausal for 
< 7 years, or postmenopausal for > 7 years. No significant effects of this clas­
sification on trabecular Δ-BMD in ihe first 20 weeks could be demonstrated, but 
prednisone treatment remained significantly associated with trabecular bone loss in 
this period (p=0.01). 
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Figure 2. Course of disease activity score (upper panel), erythrocyte sedimentation rate 
(mm/hr, middle panel), and functional capacity (HAQ, lower panel) in patients treated with 
prednisone ( ) and placebo ( ); represented are the mean and the 95% confidence 
interval. 
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Table 3: Percentage change in lumbar bone mineral density (BMD) by dual energy computed tomography 
Change 0-20 weeks 
trabecular BMD 
cortical BMD 
Change 20-44 weeks * 
trabecular BMD 
cortical BMD 
Change 20-44 weeks t 
trabecular BMD 
cortical BMD 
η 
20 
20 
12 
12 
6 
6 
Prednisone 
mean 
-8.2 
-2.1 
+ 5.1 
+ 0.4 
-8.1 
-5.9 
95% CI limits 
-12.7 to -3.7 
-5.4 to+1.2 
+ 0.4 to +9.8 
- 3.7 to +4.5 
not calculated 
not calculated 
η 
19 
19 
16 
16 
2 
2 
mean 
+ 1.3 
- 1.6 
- 1.3 
- 1.3 
-7.3 
-6.4 
Placebo 
95% CI limits 
-3.1 lo+5.7 
-5.3 to + 1.6 
- 6.1 to + 3.5 
- 5.1 to + 2.5 
not calculated 
not calculated 
Difference 
prednisone - placebo 
mean 
-9.5 
-0.5 
+ 6.4 
+ 1.7 
95% CI limits 
-15.6 to-3.0 
- 5.3 to + 4.3 
- 0.2 to +13.0 
- 3.7 to + 7.1 
not calculated 
not calculated 
* patients who used prednisone in this period were excluded from the analysis. 
t only patients who used prednisone in this penod were included m the analysis. 
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As indicated before, glucocorticoid treatment was re-started, after discontinuation 
of trial-medication, in 6 patients originally randomized to prednisone therapy. In 
the remaining 12 patients, a significant increase in trabecular BMD between week 
20 and 44 was seen. The difference in trabecular Δ-BMD between the prednisone 
and placebo group was almost statistically significant in this period (p=0.06). The 
small number of patients using prednisone between weeks 20 and 44 precluded 
statistical analysis in this subgroup. 
No vertebral fractures were diagnosed on lateral spine radiographs, at baseline or 
after 44 weeks. 
Bone metabolism and calcium regulating hormones 
At baseline, no significant differences were present between the 2 treatment 
groups in parameters of bone metabolism or in levels of calcium regulating 
hormones (table 4). The course of these variables during the initial 20 weeks of 
the study is illustrated in figures 3 and 4. 
The relative AUCs, showing the degree of change in these parameters in the 
initial 12 weeks, are presented in table 5. Serum levels of alkaline phosphatase 
and osteocalcin decreased, and the urinary hydroxy-proline/crcatinine and calci-
um/creatinine ratios increased significantly in the prednisone group. No changes 
were observed in the placebo group, and the differences between the two treat­
ment groups were statistically significant. No consistent changes were observed in 
the corrected calcium concentration, and in the levels of the calcium regulating 
hormones, with the exception of the calcitonin levels that increased significantly 
in both treatment groups. 
The percentages change between weeks 12 and 20 are presented in table 6. Seram 
levels of alkaline phosphatase and osteocalcin increased, and the urinary calci-
um/crealininc ratio decreased significantly during prednisone withdrawal. No 
significant change was found in the urinary hydroxyproline/creatinine ratio. In the 
corresponding period, the placebo treated patients showed no significant change in 
these parameters. Parathyroid hormone concentrations showed a marginally 
statistically significant decrease during prednisone withdrawal. No other changes 
in either treatment group were observed in the corrected calcium concentration or 
the levels of calcium regulating hormones between weeks 12 and 20. 
Mechanisms of change in BMD 
The results show a relation between the change (between weeks 0 and 20) in 
trabecular BMD (Δ-BMD) and treatment (prednisone or placebo). Possible 
mechanisms involved in this effect of treatment on bone mineral density were 
further evaluated, as described below. 
A structural model was constructed issuming that treatment induced Δ-BMD was 
mediated through changes (after 12 weeks of treatment) in bone formation and/or 
bone resorption. In the initial analysis, changes in osteocalcin and in alkaline 
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Table 4: Baseline parameters of bone metabolism: mean ± standard deviation (median, 
range) 
Calcium 
(normal range' 2.20-2 60 mmol/l) 
Albumin 
(normal range' 37-47 gj\) 
Corrected calcium 
(normal range 2.15-2 65 mmol/l) 
Alkaline phoshatase 
(nornial range < 120 U/l) 
Osteocalcin 
(nornial range. 0 4-2 5 nmol/l) 
Parathyroid hormone 
(normal range 10-6 5pmol/l) 
Calcitonin 
(normal range' < 30 pmol/l) 
l,25(OH)2D3 
(normal range: 80-180 pmol/l) 
Unnary hydroxyproline/creatinine ratio 
(normal range. < 22 μηιοΐ/mmol) 
Unnary calcium/creatmine ratio 
(normal range < 0 450 mmol/mmol) 
Prednisone 
2 42 ± 0 08 
(2 42, 2 27-2 58) 
42 9 ± 4 0 
(44, 37-50) 
2 36 ± 0 10 
(2 37,2 15-2 52) 
87 4 ± 29 6 
(81.51-179) 
1 54 1 0 40 
(154,0 89-2 22) 
2 9 ± 0 7 
(2 8, 1 7-4 4) 
5 8 ± 3 5 
(5 5. 17-116) 
107 9 ± 3 8 3 
(99.29-111) 
237 ± 8 2 
(217, 12 2-49 2) 
0 332 ± 0 122 
(0 314,0 142 0 588) 
Placebo 
2.35 ± 0 08 
(2 35,2 18-2 52) 
4 1 0 ± 4 0 
(41,31 49) 
2 33 ± 0 09 
(2 33.2 16 2 48) 
80 8 ± 18 3 
(84. 56-122) 
1 49 ± 0 49 
(143,0 68-2 36) 
3 2 ± 12 
(3 0. 1 7 7 0) 
5 3 ± 4 1 
(4 1. 17-12 9) 
130 8 ± 4 9 6 
(132,40-223) 
314 ± 183 
(29 6. 13 6-98 6) 
0 382 ± 0 174 
(0 394,0 103-0 721) 
P* 
0 008 
014 
0 26 
041 
0 77 
0 48 
0 73 
011 
0 10 
0 29 
* difference between two treatment groups by t test 
phosphatase were used as indicators of changes in bone formation, and changes in 
the fasting urinary hydroxyproline/creatinine and calcium/crcalinmc ratios as 
indicators of changes in bone resorption. It was assumed that only part of the 
changes in bone formation and resorption are reflected in changes in these 
parameters. Therefore, a "direct" path between treatment and Δ-BMD was also 
included in the model. Standardized effect-parameters were calculated for every 
path in the model by linear regression analysis techniques. If indicated, multiple 
regression analysis was used. Changes in alkaline phosphatase and in the fasting 
unnary hydroxyproline/creatinine ratio were not included in the final model, 
because they did not significantly influence Δ-BMD. 
85 
Chapter VI 
Figure 3. Course of alkaline phosphatase (IU/1, upper left panel), osteocalcin (nmol/l, upper 
right panel), lasting urinary hydroxyproline/creatinine ratio (цглоі/ттоі, lower left panel), and 
fasting urinary calcium/creatinine ratio (mmol/mmol, lower right panel), in patients treated 
with prednisone ( ) and placebo ( ) between weeks 0 and 20; represented are the 
mean and the 95% confidence interval. 
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Figure 4. Course of corrected calcium (mmol/l, upper left panel), parathyroid hormone 
(pmol/l, upper right panel), calcitonin (pmol/l, lower left panel), and 1,25 dihydroxyvitamin D 
(pmol/l, tower right panel), in patients treated with prednisone ( ) and placebo ( ) 
between weeks 0 and 20; represented are the mean and the 95% confidence interval. 
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Table 5: Relative area-under-the-curve between week 0 and week 12 
Prednisone Placebo Difference 
(n=20) (n=20) Prednisone - Placebo 
Corrected calcium 
Alkaline phosphatase 
Osteocalcin 
Hydroxyprolme/creatinme 
Calcium/creatinine 
Parathyroid hormone 
Calcitonin 
1.25(OH)2-vitamin D 
mean 
099 
077 
0 82 
1 17 
124 
101 
145 
1 18 
95% CI * 
0 98 to 1 00 
073 to 0 81 
0 78 to 0 86 
1 03 to 1 31 
1 15 to 1 35 
0 90 to 1 12 
1 08 to 1 82 
0 97 to 1 39 
mean 
100 
101 
104 
0 92 
0 95 
100 
1 65 
096 
95% CI * 
099 to 101 
095 to 107 
096 to 1 12 
0.81 to 1 03 
0 77 to 1 13 
0 94 to 1 06 
1 11 to 2 19 
0 82 to 1 10 
mean 
-0 01 
0 24 
0 22 
+ 0 25 
+ 0 29 
+ 0 01 
0 20 
+ 0 22 
95% CI t 
-0 03 to+0 01 
-0 31 to-017 
-0 22 to-013 
+0 08 to +0 42 
+0 08 to +0 50 
-0 Π to +0 13 
-0 84 to +0 44 
-0 02 to +0 46 
* The change from baseline is statistically significant if 1 is not included in the 95 % confidence interval 
t The difference between the prednisone and placebo groups is statistically significant if 0 is not included in the 95% confidence interval 
Table 6: Percentage change in parameters of bone metabolism between week 12 and week 20, during withdrawal of trial medication. 
Corrected calcium 
Alkaline phosphause 
Osteocalcin 
Hydroxyproline/creatinine 
Calcium/creatinine 
Parathyroid hormone 
Calcitonin 
l,25(OH)2-viUmin D 
mean 
+ 1.0 
+33 7 
+30 6 
-6 2 
-13 1 
-13.6 
-6 6 
+3 7 
Prednisone 
(n=20) 
95% CI 
-0.5 to +2 5 
+26 3 to +41 1 
+13 3 to +47 9 
-16.9 to+4 5 
-21 4 to -4 8 
-26 2 to-1 0 
-24 9 to+11 7 
-12 4 to+19 8 
mean 
-0 7 
+0 9 
+12 1 
-08 
+ 103 
53 
+37 2 
+24 6 
Placebo 
(n=19) 
95% CI 
-2 2 to +0.8 
-5 I to+69 
-2 6 to +26.8 
-10 5 to+8 9 
-6 9 to +27 5 
-17 Oto+6 4 
-1 0 to +75.4 
-7 7 to +56 9 
Difference 
Prednisone - Placebo 
mean 
+ 1.7 
+32 8 
+ 185 
-5 4 
-23 4 
-8 3 
^3 8 
-20 9 
95% CI 
-0 4 to +3 8 
+23 5 to+42.1 
-3.5 to +40.5 
-19 4 to+8.6 
-42 1 to -4.7 
-25 0 to +8.4 
-85 2 to -2.4 
-56 Ho+14.3 
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The final model is shown in figure 5. The overall correlation between treatment 
and Δ-BMD is -0.49 (p=0.002). For the different paths indicated in figure 5, the 
standardized effect parameters were: a= -0.33 (p=0.04), b= +0.43 (p=0.009), 
c= +0.39 (p=0.006), d= -0.24 (p=0.10),and e= -0.28 (p=0.05). The effect parame­
ters c, d, and e, were calculated with multiple regression techniques. According to 
this model, treatment had two indirect effects on Δ-BMD, respectively mediated 
through a change in osteocalcin (-0.33 χ +0.39 = -0.13), and a change in the 
urinary calcium/creatinine ratio (+0.42 χ -0.28 = -0.12). The remaining part of the 
correlation between treatment and Δ-BMD (-0.49 - [0.13 + 0.15] = -0.24), repre­
sented in the model as a "direct" effect of treatment on Δ-BMD, was due to 
changes in bone metabolism that were not detected by changes in either the 
osteocalcin concentration or the fasting urinary calcium/creatinine ratio. 
Figure 5. Structural model for the influence of therapy (prednisones, placebo=0) on the 
change in trabecular bone mineral density. 
Change osteocalcin 
Therapy • d • Change trabecular BMD 
\ / 
Change urinary calcium/creatinin 
Discussion 
The effects of low-dose glucocorticoid treatment on bone in patients with RA, are 
controversial. Flaws in study designs may partly explain the discrepancies in the 
literature. Firstly, patients on prednisone will in general have a more severe 
disease than those not treated by glucocorticoids. Since RA patients with more 
active disease and concomitant functional impaimients are at risk for increased 
bone loss (13,14), (his may introduce a selection-bias in non-randomized studies. 
Secondly, it has been suggested that bone loss may be most severe in the first 
months of treatment (15). In consequence, studies that evaluate bone loss some 
lime after the initial period of treatment may underestimate the effects of gluco-
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corticoids on bone. Therefore, the main purpose of our study was to evaluate the 
initial effects of low-dose prednisone therapy on BMD and biochemical markers 
of bone metabolism in patients with active RA, using a randomized controlled 
study design, to avoid selection bias. 
In a period of 20 weeks, the mean trabecular BMD decreased significantly by 8.2 
percent in the patients on prednisone therapy, despite a marked improvement in 
disease activity and functional capacity. In patients on placebo, no trabecular bone 
loss was seen, and the difference between the two treatment groups was statisti-
cally highly significant. No changes were observed in the anterior cortical rim of 
the vertebral body. This observation clearly shows that glucocorticoids may 
decrease spinal trabecular BMD in patients with active RA, even when low doses 
are used. However, this does not imply that all patients on low-dose prednisone 
will develop osteoporosis. The number of patients in the study was too small to 
allow an estimate of the incidence of glucocorticoid-induccd bone loss. Further-
more, the reproducibility of DEQCT was too low to permit a reliable distinction 
between individual patients with and without bone loss. 
The finding of a 8.2 percent decrease in mean BMD after 20 weeks, induced by 
low-dose prednisone, is quite remarkable. Similar magnitudes of bone loss have 
been documented after oophorectomy (24), and during immobilization (25). 
Marked decreases in BMD have also been found in patiens treated with higher 
glucocorticoid doses. Julian et al (26) recently reported a mean decrease of 6.8 
percent in lumbar BMD, as assessed by dual photon absorptiometry, six months 
after renal transplantation in 20 patients treated with a threefold higher cumulative 
prednisone dose. LoCascio et al (15) found a mean decrease in trabecular bone 
volume (iliac crest biopsies) of 34 percent, 5-7 months after the start of predniso-
ne (daily dose: 10-25 mg). Comparison of our results with these previous reports 
seems to indicate that the incidence and degree of the initial, glucocorticoid-
induced, bone loss may not be closely related to glucocorticoid dose. In fact, 
Julian et al (26) observed no correlation between the degree of bone loss and the 
cumulative dose of glucocorticoids. In contrast, an increase in glucocorticoid-
induced osteoporosis with longer durations of therapy and higher cumulative doses 
has been observed in a cross-sectional study involving patients on long-term 
therapy (27). 
The pathogenesis of glucocorticoid-induced bone loss has been recently reviewed. 
In short, available data indicate that glucocorticoids decrease osteoblastic activity 
and may also increase bone resorption (1,2). 
In our patients we observed changes in alkaline phosphatase and osteocalcin levels 
consistent with a glucocorticoid-induced decrease in bone formation. 
Changes in bone resorption were evaluated using the fasting urinary hydroxyproli-
ne/creatinine and calcium/crealinine ratios. These data are more difficult to 
interpret. 
At baseline, the urinary hydroxyproline/creatinine ratio was somewhat higher in 
the prednisone than in the placebo treated patients. However, the difference was 
not statistically significant. Follow-up measurements showed no differences 
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between the 2 treatment groups (figure 3). Nevertheless, changes were observed 
within each treatment group. The urinary hydroxyproline/creatinine ratio tended to 
decrease in the patients treated with gold salts alone, as may be expected since the 
urinary excretion of hydroxyproline is related to disease activity in RA (28). In 
contrast, the urinary hydroxyproline/creatinine ratio increased significantly in the 
prednisone treated patients, despite an improvement in disease activity. Therefore, 
our data seem to suggest a prednisone-induced increase in bone resorption. 
Previous studies of the glucocorticoid effects on bone resorption have shown 
inconsistent results. Some of these discrepancies may be related to differences in 
dose. For instance, Frummel et al (29) found no increase in urinary hydroyproline 
excretion in 10 euthyroid patients with Graves' ophthalmopathy treated initially 
with 60 mg/day prednisone. In animal studies, high glucocorticoid doses are 
mostly associated with a decrease, and lower, although supraphysiological, doses 
with an increase in bone resorption (I). The urinary calcium/creatinine ratio 
showed similar changes as the urinary hydroxyproline/creatinine ratio. However, it 
should be noted that glucocorticoids may increase urinary calcium excretion 
independent from changes in bone metabolism (30). 
The relation between treatment and the initial decrease in trabecular bone mineral 
density was further analyzed with path-analysis techniques, in an attempt to 
evaluate the mechanisms involved in the observed bone loss. The results show 
that changes in bone metabolism associated with a decrease in osteocalcin 
concentration and an increase in urinary calcium excretion, may in part be 
responsible for the observed effect of prednisone trealmenl on trabecular bone 
mineral density. The decrease in osteocalcin probably reflects a decrease in 
osteoblastic activity, and the increase in urinary calcium excretion may reflect a 
net increase in bone resorption. Therefore, the data seem to support the notion 
that glucocorticoid-induced bone loss may be mediated by a decrease in bone 
formation, without concomitant decrease in bone resorption. However, it should 
be noted that only about half of the observed correlation between treatment and 
change in trabecular BMD was explained by the two variables included in the 
model. Therefore, no definite conclusions can be reached with regard to this issue. 
During prednisone withdrawal, biochemical markers of bone formation increased, 
while the urinary hydroxyproline/creatinine ratio tended to decrease. Furthermore, 
after discontinuation of prednisone, a significant increase in trabecular BMD was 
found between weeks 20 and 44. These observations suggest that the deleterious 
effects of short-term glucocorticoid treatment on bone, may be, partly, reversible. 
Data on reversibility of osteopenia associated with long-term glucocorticoid excess 
are scarce. However, reversibility of osteopenia has been suggested after surgical 
cure of endogenous Cushing's syndrome (31). 
Some patients resuming prednisone treatment in the second period of the study 
demonstrated further bone loss. However, these patients were selected for renewed 
glucocorticoid treatment because of progressive disease. Since this may have 
introduced a selection bias, these data should be looked at with restraint. 
No significant differences were found between the two treatment groups in 
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calcium regulating hormones. Previously, secondary hyperparathyroidism has been 
suggested as a pathogenetic mechanism for glucocorticoid-induced osteoporosis 
(1,2). Our data show that marked decreases in BMD may be found without 
significant increases in parathyroid hormone levels. 
All patients in our study, suffered from active RA. It has been suggested, that 
patients with this condition may be at increased risk for axial bone loss (13,14). 
However, no significant changes in BMD were observed in the placebo treated 
patients. One may speculate, that intramuscular gold therapy may protect patients 
with active RA against increased bone loss. Previously, gold salts have been 
shown to reduce bone resorption in in vitro experiments (32). Furthermore, 
treatment with various second-line antirheumatic drugs has been associated with 
increases in serum osteocalcin (33), and with increases in metacarpal bone mass 
(34). In our patients, osteocalcin increased significantly between week 0 and 20 
(mean increase 22.3%, 95% CI 0.4% - 44.2%). Interestingly, we also observed 
significant increases in calcitonin levels in both treatment groups, which may have 
been related to the treatment with intramuscular gold salts. However, studies 
comparing calcitonin levels in patients with and without intramuscular gold 
therapy are required to further evaluate this hypothesis. 
Nonsteroidal anti-inflammatory drugs often cause gaslro-inteslinal side effects, and 
they are increasingly substituted by low-dose glucocorticoids in the management 
of patients with RA (35), and it has been estimated that about 25 percent of RA 
patients, who are treated by rheumatologists, use glucocorticoids (36). The data 
presently reported, indicate that glucocorticoids may cause marked decreases in 
BMD, even when low doses are used. The results also suggest, that this effect is 
reversible when glucocorticoids are discontinued, after a short duration of therapy. 
Further prospective studies are needed to clarify the long-term effects on bone 
mass and fracture risk, but we suggest that the use of low-dose prednisone should 
be limited as much as possible to short periods of lime, until randomized control-
led trials have documented the efficacy and safety of long-term, low-dose 
glucocorticoid therapy in patients with RA. 
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Summary 
The effect of low dose prednisone therapy on spinal bone mass is controversial 
We measured lumbar trabecular and cornial bone mineial density (BMD) m 74 
rheumatoid arthritis (RA) patients by dual energy quantitative computerized 
tomography in a cross-sectional study The presence of veitebial defornvties was 
evaluated on a lateral spine radiograph Patients who had never been treated 
with corticosteroids (n=44) were compared with patients on long-teim low dose 
(< 10 mglday) prednisone therapy (n=30) Aflei conection foi confounding 
variables the lumbar BMD was highly signifuantly tnfluemed by piedmsone 
therapy in postmenopausal patients (estimated mflueme -312% on tiabecular 
BMD and -37 2% on cornial BMD) Veitebial defoi mines wet e also significantly 
more frequent in piedmsone tieated postmenopausal patients No negative effect 
of prednisone treatment could be demolisti cited m male patients In lontiadiition 
to pievious leports we conclude that long-teim piedmsone theiapy may be 
associated with development of spinal osteopoiosis in postmenopausal RA 
patients, even when low doses aie used 
Introduction 
Despite a general concern about prednisone induced osteoporosis corticosteroids 
arc frequently used in medical practice. High dose corticosteroid therapy has long 
been known to cause vertebral bone loss in patients with various primary diseases. 
Whether low dose (< 10 mg/day) prednisone therapy also contributes to the axial 
osteoporosis frequently desenbed in rheumatoid arthritis (RA) patients is a matter 
of debate (1,2). Dual photon absorptiometry (DPA), Dual energy X-ray absorptio-
metry (DXA), and quantitative compulcn/cd tomography (QCT) are the only 
methods now available to evaluate the mineral content of the spine. So far three 
cross-sectional studies (3-5) failed to show a negative effect of low dose predniso-
ne therapy on lumbar bone mass in RA patients. In all three studies bone mass 
was measured with DPA or DXA, methods that evaluate the whole vertebra. QCT 
allows the seperate measurement of the trabecular and cortical part of the verte-
bra, and may be a more sensitive method to study the influence of prednisone. 
Lumbar bone mass of RA patients is influenced by several factors other than 
prednisone therapy. As in persons without RA, age, sex, height, weight, panty, 
duration of postmenopause, drinking and smoking history, and some dietary habits 
may affect bone mass (6). In addition, the duration and the seventy of the disease, 
and the concomiUint reduced physical activity may also constitute important 
factors (7). 
In a cross-sectional study we evaluated the influence of low dose prednisone 
therapy on spinal bone mineral density and on vertebral deformities in patients 
with RA. We used QCT to measure both cortical and trabecular lumbar bone 
mineral content and adjusted for various possibly confounding variables. 
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Patients and methods 
Patient selection 
During a 4 month period the records of all classical or definite RA patients (8) 
attending the outpatient clinic of a university rheumatology department were 
reviewed. 
Patients treated with low dose (< 10 mg/day) prednisone therapy for at least 6 
months were selected for participation in a first group (P group). Patients who had 
never been treated with systemic corticosteroids, but who had been treated with at 
least two different disease modifying anti rheumatic drugs (DMARD) were 
selected for participation in a second group (NP group). Drugs considered as 
DMARDs included hydroxychloroquine, sulphasalazine, D-pcnicillamine, oral and 
intramuscular goldsalts, azathioprinc and methotrexate. AH patients in both groups 
were required to use non steroidal anti inflammatory drugs (NSAID). Patients 
with other conditions or medication that might affect bone mass, were excluded 
from the study. Patients with oral calcium supplements (four in the Ρ group ) 
were not excluded. 
Informed consent was obtained from all participants. The study was approved by 
the local Ethics Committee. 
Clinical evaluation 
Factors not directly related to the disease 
Data recorded on all patients included age, sex, height, and weight. Height and 
weight were combined in the Quetelet index (weight/height2). A dietary history 
was done and the average daily intake of calcium, phosphorus and proteins at the 
time of the study was calculated. Smoking and drinking habits (average daily 
number of cigarettes and average daily number of alcoholic consumptions 
respectively ) were also noted. 
In women menopausal state, age at menopause, the duration of the postmenopause 
and the parity were recorded. 
In patients on prednisone therapy the present daily dose, the duration of therapy, 
and the cumulative dose were noted. 
Disease related factors 
In all patients data were recorded on the duration of the disease. The severity of 
the RA was assessed by the following parameters. 
The radiological destruction of hands and wrists was evaluated independently by 
two observers using the Larsen method (9). In cases of disagreement consensus 
was reached after re-evaluation of the radiographs. A total of 20 joints was 
examined in each patient (range 0-100; a zero score indicates no radiological 
destruction). 
The functional capacity of each patient was evaluated by the Dutch equivalent of 
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the Stanford Health Assessment Questionnaire, which has been validated for RA 
patients in our department (range 0.00-3.00; a zero score indicates no functional 
impairment) (10). 
Bone densitometry 
Dual energy QCT was performed at 125 and 85 kilovolt with a Siemens Somatom 
DR3. The patients were positioned over a reference phantom consisting of a water 
and a bone equivalent plastic. Scans were made through the middle of the third 
and fourth lumbar vertebra. Slice thickness was 8 mm. Collapsed vertebrae were 
excluded from the analysis. 
The region of interest (ROI) was automatically defined. ROIs were generated for 
the ventral cortical and for the central trabecular bone separately. 
The details of the densitometry method have been published before (11,12). 
To correct for the influence of age the results are expressed as percentage of 
expected densities. For this purpose we used linear regression equations derived 
from a normal reference population that has been measured with the same 
protocol on the same type of apparatus in several Western European countries 
(13). 
Vertebral fractures 
Lateral radiographs of the thoracic and lumbar spine were obtained for all 
patients. The images were digitized and measuring points were interactively 
marked. Thereafter the anterior (A), midvcrtebral (M) and posterior (P) height of 
13 vertebrae (T4 - L4) were determined automatically. Some vertebrae had to be 
excluded from the study because of adjacent intervertebral discilis. 
The severity of vertebral deformities was expressed in a vertebral deformity score 
(VDS). For this purpose we used a modification of the method proposed by 
Kleerekoper et ai (14). The criteria for defining vertebral deformities were chosen 
with reference to published normal A/P ratios in both the thoraciv and lumbar 
spine (15). All criteria were defined before the start of the study. 
Crush fractures were considered present if obvious on visual inspection. Wedge 
fractures were defined as an A/P ratio < 0.75 in the thoracic or an A/P ratio 
< 0.85 in the lumbar spine. A mild end plate deformity was defined as a M/P 
ratio < 0.85. A severe end plate deformity was defined as a M/P ratio < 0.75. 
All vertebrae were graded as follows: 0 if normal, 1 for mild end plate deformity, 
2 for severe end plate deformity, 3 for wedge fracture, and 4 for crush fracture. A 
Vertebral Deformity Score (VDS) was calculated for each patient by dividing the 
total score by the number of vertebra included in the analysis. 
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Statistical analysis 
To test for a negative influence of prednisone the differences in the mean values 
between the Ρ and NP groups were analyzed with an one-sided unpaired T-test or 
with a Mann Whitney test when appropriate. Spearman correlation coefficients (r
s
) 
were calculated as indicated. 
To correct for possibly confounding variables in the association of prednisone 
therapy and lumbar bone mass a stepwise multiple linear regression analysis was 
performed. 
All statistical analyses were done with standard personal computer software (16). 
Results 
In the 4-month period 167 patients met the inclusion criteria. A total number of 
42 patients had to be excluded from the study. Reasons for exclusion were renal 
disease (/i=4), gastro-intestinal disease (/i=2), endocrine disease (n=20), malignan­
cy (n=4), vitamin D medication (;i=2), depression (n=3), hypochondria (/i=2), and 
a rheumatoid arthritis so active at the time of the study that participation was 
judged too exhaustive («=5). No patients used estrogens. Of the remaining 125 
patients, 77 gave informed consent. Bone mineral densities could not be obtained 
in 3 patients due to technical problems. 
Clinical data 
Detailed clinical data are given in table 1. In general the prednisone treated 
patients had a longer and more severe disease as indicated by the Larsen score 
and the functional index. 
The other variables did not differ between the two groups, and are stated only for 
all patients together: the mean (± SD) Quetelet index was 25.42 (± 3.35). The 
mean dietary intake of calcium was 960 (± 350) mg/day, of phosphorus 1288 
(± 324) mg/day and of proteins 65.3 (± 14.7) g/day. On average patients smoked 
5.4 cigarettes per day (median 0, range 0-33). The mean daily number of al­
coholic drinks was 0.6 (median 0, range 0-5). 
The female patients had a mean parity of 3.1 (± 2.1). Five women had never been 
pregnant, while 36 had had 2 children or more. 
The mean daily dose of prednisone in the female patients was 6.8 (± 2.6) mg. The 
mean duration of therapy was 7.9 yr (median 5.6, range 1.1 - 31.9). The mean 
cumulative prednisone dose was 22.5 g (median 14.6, range 3.2 - 31.9). 
In the male patients the mean daily prednisone dose was 7.1 (± 2.8) mg. The 
mean duration of therapy was 4.2 yr (median 4.3, range 0.9 - 9.2). The mean 
cumulative prednisone dose in the male patients was 10.1 g (median 11.6, range 
2.0 - 20.3). 
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Table 1 : Clinical data: Mean (Median, Range) 
Total number 
Females 
Premenopausal 
Postmenopausal 
Age (years) 
Years since menopause 
Duration RA (years) 
Larsen score 
Functional index 
Males 
Age (years) 
Duration RA (years) 
Larsen score 
Functional index 
Ρ group 
30 
16 
4 
12 
612 
(62 5, 36 8-86 9) 
153 
(14. 7-38) 
188 
(15 7.5 2-54 0) 
59 5 
(62. 29-87) 
108 
(102.0 22-2 08) 
14 
68 6 
(68 9.57 0 87 3) 
104 
(9 0.1.9 25 2) 
40 6 
(41 5, 10-76) 
0 50 
(0 27.0 04-1 74) 
NP group 
44 
30 
9 
21 
56 7 
(57 7.26 1-79 0) 
14 3 
(15 5,2-29) 
123 
(116.2 0-24 8) 
35 1 
(31.2-78) 
0 53 
(0 38-1 85) 
14 
54 2 
(52 4. 32 6-75 4) 
104 
(112. 1 9-28 0) 
21 4 
(22. 3-49) 
0 32 
(0 11.0-146) 
Bone densitometry 
The data on trabecular and cortical bone mineral density (BMD) arc given in 
tables 2 and 3. 
In postmenopausal patients the difference in both cortical and trabecular BMD be­
tween the Ρ and NP groups is highly significant. The small number of premeno­
pausal women in the Ρ group precludes statistical analysis in this subgroup. 
In the male patienls the difference between the treated and untreated groups is 
small and not statistically significant. 
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Table 2: Trabecular bone mineral density (BMD) 
P group NP group 
All males η=Ι4 n=14 
101.4 ± 2 9 9 111 9 ±32.8 NS 
(84 1-118 7) (92.9-130.8) 
All females n=]6 n=30 
6 5 0 1 1 7 6 992 ±30.4 =00001 
(55 6-74 4) (87.8-1106) 
Postmenopausal n=12 n=21 
61 5 ± 1 8 I 94 2 ± 2 8 7 =00006 
(50 0-73 0) (811-107.2) 
Mean ± SD (95% confidence interval) BMD (% of expected after correction for age) in prednisone 
treated (P group) and untreated (NP group) patients with rheumatoid arthritis. Probability by unpaired 
one-sided t-test 
Table 3: Cortical bone mineral density (BMD) 
P group NP group 
All males 
All females 
Postmenopausal 
n=14 
103 6 ± 35 6 
(83 0-124 1) 
n=]6 
75 5 ± 12.7 
(68 7-82 2) 
ii=12 
70 4 ± 9 8 
(64 2-76 7) 
n=14 
1 0 9 7 ± 2 1 4 
(97.3-122.1) 
n=30 
106.9 ± 2 2 9 
(98.3 115 4) 
.1=21 
106 1 ± 2 4 5 
(94 9-117.3) 
NS 
< 0.0001 
<00001 
Mean ± SD (95% confidence interval) BMD (% of expected after correction for age) in prednisone 
treated (P group) and untreated (NP group) patients with riieunialoid arthritis Probability by unpaired 
one-sided t-test 
To correct for possibly confounding variables the influence of prednisone therapy 
on lumbar bone mass was further evaluated in a stepwise multiple linear regressi­
on analysis on the age corrected BMD in the postmenopausal patients. Prednisone 
therapy was condidercd as a dummy independent variable and all possibly 
confounding variables as other independent variables. These included Quetelet 
index, dietary habits, smoking and drinking habits, disease duration, Larsen score 
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of hands and wrists, functional capacity, duration of postmcnopause and parity. 
The following results were reached. 
trabecular BMD = 131.3% - 31.2% χ a - 15.7% χ b (R2=0.42 , p=0.0001) 
cortical BMD = 107.3% - 37.2% χ a (R2=0.44 , p<0.0001) 
where a = 1 if treated with prednisone, a = 0 if not treated with prednisone; 
b = logarithm of number of postmenopausal years 
Thus the estimated influence of prednisone was - 31.2% on trabecular BMD (95% 
confidence interval from - 50.3% to - 12.1% , p=0.001) and - 37.2% on cortical 
BMD (95% confidence interval from - 53.6% to - 20.8% , p<0.0001). 
We also performed a second procedure to correct for possibly confounding 
variables. For this purpose we formed two subgroups with comparable disease 
characteristics by matching prednisone treated with untreated female patients for 
their Larsen scores and functional indexes. A reasonable match was possible for 
10 pairs of women. The results of this analysis are presented in table 4. Again the 
prednisone treated patients had a significantly lower BMD than the patients in the 
Ρ group. 
Table 4: Female patients with and without prednisone treatment, matched for Larsen score 
and functional index Clinical characteristics and bone mineral density 
Number of patients 
Clinical characlenslics ' 
Age (years) 
Duration RA (years) 
Larsen score 
Functional index 
Bone mineral density t 
Trabecular bone (%) 
Cortical bone (%) 
Ρ group 
10 
58 4 
(57 0,47 2-76 1) 
114 
(10 8,5 2-15.6) 
56 1 
(55, 29-68) 
0 98 
(0 96,0 57-2 01) 
66 1 ± 19.7 φ 
(52 0-80 2) 
760 ± 12 5 φ 
(67 1-84 9) 
NP group 
10 
63 5 
(62 8,53 1-79 0) 
132 
(14 7.7 3-219) 
518 
(53. 31-64) 
0 82 
(0 83,0 59-1 85) 
96 0 ± 24 7 
(78 4-113 6) 
106 5 ±27 9 
(86 6-126 4) 
* Data are presented as mean (median, range). 
t Data are presented as mean ± SD percentage of expected density after correction for age 
(95% confidence interval) 
φ Significantly different from NP group (P< 0 01 ). by one-sided unpaired t-lest 
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Within the Ρ group the daily prednisone dose, the duration of therapy and the 
cumulative prednisone dose were not significantly correlated with either cortical 
or trabecular BMD. 
Vertebral deformities 
The VDS was significantly correlated with age (r
s
 = + 0.28 , p=0.02), and also 
with the age and sex corrected trabecular (г,= - 0.31 , p=0.01) but not cortical 
(r
s
 = - 0.18 ,p>0.1) density. 
In postmenopausal prednisone treated patients the mean VDS was 0.423 (median 
0.346 and range from 0 to 1.077). In the NP group the mean VDS in postmeno­
pausal patients was 0.187 (median 0.154 and range from 0 to 0.846). The 
difference between the two treatment groups is statistically significant (p=0.03 , 
one-sided Mann-Whitney test). The number of premenopausal patients is too small 
to permit separate analysis. In men the differences in VDS (data not shown) are 
small and not statistically significant. 
Discussion 
The purpose of our study was to evaluate the influence of long-term low dose 
prednisone therapy on lumbar bone mineral densily of RA patients. In postmeno­
pausal females we found a significantly lower spinal trabecular and cortical bone 
mineral density in the prednisone treated versus the untreated patients. 
Bone mineral density of RA patients will be influenced, however, by many other 
factors, some of which are related to the disease itself. The most important factor 
may be the reduced level of physical activity caused by the functional impairment 
of the RA patients (7). In addition, it has been suggested that the activity of the 
RA itself may also influence bone mineral density. This factor is difficult to 
evaluate in a cross-sectional study. It may be assumed however that the radiologi­
cal destruction, as measured by the Larsen score, is related to the cumulative 
disease activity over the years (17). 
It may be argued that the control and treatment groups in our study have imbalan­
ces with respect to these parameters. The prednisone treated patients had a longer 
duration of RA, more radiological destruction and greater functional impairment. 
We have corrected for the influence of these factors by two different procedures. 
First we have performed a multiple linear regression analysis to correct for the 
influence of the possibly confounding variables. In postmenopausal patients low 
dose prednisone therapy is associated with a loss of approximately 30% of ex­
pected cortical and trabecular densily. This negative influence of prednisone 
therapy was confirmed in the second procedure we used to correct for possibly 
confounding variables: in the two subgroups of postmenopausal patients with 
comparable disease characteristics the prednisone treated patients again had a 
significantly lower spinal bone density than the patients who had never been 
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treated with systemic corticosteroids. 
If low dose prednisone therapy contributes to vertebral bone loss, significant 
correlations between treatment characteristics and bone mineral densities might be 
expected. The absence of such correlations in our study could be explained if 
most of the negative effect of prednisone occurs early in the course of treatment, 
as has been previously suggested (18). 
The clinical importance of lumbar mineral density as a risk factor for vertebral 
fractures is generally recognized (19). In our study the higher VDS in prednisone 
treated versus untreated postmenopausal patients indicated that the differences in 
bone mineral densities in our study have clinical reference. 
The role of low dose corticosteroids in causing bone loss in patients with RA is 
controversial. 
Previous studies used either insensitive standard radiographic estimations of bone 
mass or peripheral measurements of bone mineral density (single photon absorp-
tiometry of the forearm ) or methods that evaluate total body calcium. The results 
of these studies (20-27) have been contradictory. 
The influence of low dose prednisone therapy on lumbar bone mineral density has 
been studied before in several cross-sectional studies. In all of them DPA or 
DEXA were used to measure bone mass. Three studies did not find a negative 
effect of low dose prednisone therapy on the spine (3-5). In one study (7) such an 
effect could only be demonstrated in male patients. Our study, that used QCT, de-
monstrates for the first time a deleterious effect of long-term low dose prednisone 
therapy on lumbar bone mineral density in postmenopausal RA patients. 
The discrepancies between the different studies that evaluate vertebral bone loss 
are not easily explained. Study design, and patient and treatment characteristics 
are similar in all of them. The different methods used to evaluate bone mineral 
density may partly explain the discrepancy in the results. QCT has been said to be 
a factor twice as sensitive as either DPA or DEXA for the detection of spinal 
bone loss (28). 
DPA and DEXA are influenced more by secondary degenerative ostcophytic 
lesions than is QCT. In contrast to DPA and DEXA, QCT measurements are not 
influenced by aortic calcifications. If prednisone therapy is associated with an 
increase of aortic calcifications a negative effect on BMD may be masked when 
measured by DPA or DEXA. In our study aortic calcifications were indeed 
significantly more extensive in the prednisone treated patients (p<0.05, data not 
shown), although this could also be an age related phenomenon. 
Our results show a deleterious effect of low dose prednisone therapy in postmeno-
pausal women. The small number of prednisone treated premenopausal women 
precluded statistical analysis in this subgroup. In men no influence of low dose 
prednisone could be demonstrated. Such an effect has been demonstrated, 
however, before on other parts of the skeleton (25,27), and on the spine in men 
treated with a somewhat higher mean prednisone dose (10.4 mg/day) (7). 
Suppression of adrenal androgens is one of the factors that contributes to gluco-
corticoid induced osteopenia (29). This effect may be additive to the effect of 
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estrogen deficiency, as has been shown in rats (30). Our finding that postmeno-
pausal women are most likely to develop prednisone induced osteoporosis is 
consistent with these data. Other investigators, however, found conflicting results 
(25,27). 
Our study was not designed to evaluate bone mass in non-steroid treated RA 
patients versus normal controls. To correct for differences in age, however, the 
bone mineral densities were compared with normal reference data in the literature. 
The age-corrected trabecular and cortical BMD of the patients in the NP group 
were not significantly different from the values in the normal reference populati-
on. No firm statements can be made because no age-matched normal control 
group was included in the study, but these data seem to contradict a previous 
report by Compston el al (31)(*). 
It is estimated that about 25% of nil RA patients, who are treated by rheumatolo-
gists, use systemic corticosteroids (32). Previous reports have emphasized the 
safety of low dose steroid therapy with respect to the spine. We conclude that 
postmenopausal RA patients on chronic prednisone therapy are at increased risk to 
develop axial osteopenia and vertebral fractures, even when low doses are used. 
Controlled longitudinal studies from the start of prednisone therapy onwards are 
needed to confirm the deleterious effects of low dose prednisone therapy and to 
identify the factors that determine the individual susceptibility to steroid induced 
osteoporosis. 
(*) See also chapter IV of this thesis 
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Increased susceptibility of lumbar cortical bone to glucocorticoids 
Summary 
The susceptibility to glucocorticoid-induced bone loss may vary in different parts 
of the skeleton We studied 62 patients with rheumatoid arthritis. 26 of whom 
were on low-dose glucocorticoid treatment Bone mineral content in the forearm 
was measured by single photon absorptiometry at a coi tu al, diaphyseal, and at a 
mixed cortical and trabecular, metaphyseal site Lumbar bone mineral content 
was measured by dual energy computed tomography m a trabecular and a 
cortical region of interest The presence of vertebi al deformities was evaluated on 
lateral spine radiographs After correction for possibly confounding variables, 
prednisone therapy significantly influeiued bone mineral content at both the 
trabecular (-22 0%, 95% confideme interval -36 0% to -8 1%) and cortical 
(-24 8, 95% confidence interval -39 3% to -10 3%) lumbar site A significant 
effect was also seen at the metaphyseal (-15 7%, 95% confidence interval -271% 
to -4 2%>), but not the diaphyseal (-3 9%, 95% confidence interval -14 6% to 
6 4%) site in the forearm Correlations between peripheral and vertebral bone 
mineral content were moderate at best The diaphyseal to metaphyseal bone 
mineral content ratio did not identify patients with gluiocorticotd associated 
vertebral osteoporosis It is conduded that the anterior cortical nm of the 
vertebral body is more susceptible to the effects of glucocorticoids than the 
cortical bone in the forearm, and that measurements of tiabecular and cortical 
vertebral bone mineral content ai e essential in the management of patients with 
possible glucocorticoid associated osteoporosis 
Introduction 
In patients with glucocorticoid excess, fractures occur more frequently m the axial 
than in the peripheral skeleton, thus suggesting that glucocorticoid induced bone 
loss is greater in trabecular than in cortical bone (1-4) This hypothesis of prefe-
rential trabecular loss is supported by the findings of Hahn et al, who used single 
photon absorptiometry (SPA) to measure bone mineral content (BMC) in the 
radius at a proximal, predominantly cortical, diaphyseal (D), and a distal, mixed 
trabecular and cortical, metaphyseal (M) site. In patients on prednisone, bone loss 
was more severe at the distal than at the proximal site, resulting in an elevated 
D/M ratio (5). Furthermore, glucocorticoid induced losses reported in the literature 
have been most pronounced in skeletal areas with the highest proportion of 
trabecular bone (6). Other studies comparing BMC measurements at different sites 
of the body have also suggested a preferential loss of trabecular bone in a number 
of conditions other than glucocorticoid treatment (7-15). 
Recently, attention has been given to the hypothesis that the differences observed 
between trabecular and cortical bone in fact represent differences between axial 
and appendicular bone. It was shown that in the antenor cortical nm of the 
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vertebral body the rate of aging associated bone loss, as assessed by quantitative 
computed tomography (QCT), is greater than for appendicular cortical bone 
(16,17). 
These data suggest that the anterior cortical rim of the vertebral body may also be 
more responsive to glucocorticoid excess than cortical bone in the appendicular 
skeleton. We studied the pattern of glucocorticoid therapy associated bone loss by 
comparing lumbar BMC measured by QCT, in both a trabecular and cortical 
region of interest, with BMC in the radius assessed by SPA at a diaphyseal and a 
metaphyseal site. 
Subjects and methods 
Subjects were primarily selected for a previously published study, designed to 
evaluate the influence of low dose prednisone therapy on lumbar BMC in patients 
with rheumatoid arthritis (RA). Patient selection and methods used are shortly 
described below. Further details may be obtained in the previous report (18). 
Patient selection 
During a four month period the records of all classical or definite RA patients 
attending the outpatient clinic of a university rheumatology department were 
reviewed. Patients treated with low dose (< 10 mg/day) prednisone therapy for at 
least 6 months were selected for participation in a first group (P group). Patients 
who had never been treated with systemic corticosteroids, but who had been trea-
ted with at least two different disease modifying anti rheumatic drugs (DMARD) 
were selected for participation in a second group (NP group). Al l patients in both 
treatment groups used non-steroidal anti-inflammatory drugs. Al l patients were 
allowed to use disease modifying anti rheumatic drugs (DMARD). Hydroxychlo-
roquine, sulfasalazine, gold salts, penicillamine, azathioprine and methotrexate 
were considered as DMARD. To exclude patients with mild RA, patients in the 
NP group were required to have been treated with at least two different 
DMARDs. Patients with other conditions or medication that might affect BMC, 
were excluded from the study. 
Informed consent was obtained from all participants. The study was approved by 
the institutional human research committee. 
Clinical data 
Weight (kg) and height (m) were measured in all patients, and a body mass index 
(weight/height2) was calculated. Data were recorded on the duration and severity 
of the disease. The severity of the RA was assessed by the following parameters. 
The radiological destruction of hands and wrists was evaluated independently by 
two observers using the Larscn method (19). In case of disagreement consensus 
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was reached after re-evaluation of the radiographs. A total of 20 joints was 
examined in each patient (range 0-100; a zero score indicates no radiological 
destruction). Functional capacity was evaluated by a Dutch equivalent of the 
Stanford health assessment questionnaire (range 0.00-3.00; a zero score indicates 
no functional impairment) (20). 
Measurement of peripheral BMC 
Single photon absorptiometry was performed with a sodium-iodide-125 (lî5I) 
source at a diaphyseal (2/3 of ulnar length) and a metaphyseal (85% of ulnar 
length) site in the non-dominant radius. The results were corrected for bone width. 
Each patient had three measurements at each site. Results were averaged. Similar 
measurements were done in 187 healthy controls living in the same region (84 
females and 103 males aged from 20 to 80 years). Based on these reference 
values, the results of the diaphyseal and metaphyseal measurements are expressed 
as percentages of expected BMC. The coefficient of variation of these measure-
ments in our hospital is 1.6% for the diaphyseal and 2.3% for the metaphyseal 
site. 
A diaphyseal over metaphyseal ratio was calculated in each patient using the raw 
dala, corrected for bone width, but uncorrected for the influence of age and sex. 
In the reference group the characlcrislics of the D/M ratio were quite similar to 
previously published data (5). The mean ± standard deviation was 1.32 ± 0.13 
versus 1.37 ± 0.12 in the literature (5). In the reference group, diaphyseal and 
metaphyseal BMC was lower in women than in men, and decreased with increa-
sing age. As reported before (5) the D/M ratio, however, was identical in both 
sexes and did not change with age. An elevated D/M ratio was defined as a ratio 
greater than 1.58 (mean plus 2 standard deviations). 
Measurement of axial BMC 
Dual energy QCT was performed at 125 and 85 kilovolt with a Siemens Somatom 
DR3. Scans were made through the middle of the third and fourth lumbar 
vertebra. Slice thickness was 8 mm. Collapsed vertebrae were excluded from the 
analysis. We used the procedure described by Kalender et al (21). This method 
includes the use of a reference phantom consisting of a water and a bone equiva-
lent plastic, and an automated region of interest (ROI) definition. ROIs ¿re 
generated for both the anterior cortical and the trabecular bone. To correct for the 
influence of sex and age the results are expressed as percentages of expected 
BMC. For this purpose we used linear regression equations derived from a normal 
reference population that has been measured with the same protocol on the same 
type of apparatus in several Western European countries (16). A cortical over 
trabecular (C/T) ratio was calculated using the age and sex uncorrected data in 
each patient. 
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Vertebral deformities 
Lateral radiographs of the thoracic and lumbar spine were obtained of all patients. 
The images were digitized and measuring points were interactively marked. The 
anterior (A), midvertebral (M) and posterior (P) height of 13 vertebrae (T4-L4) 
were determined automatically. Crush fractures were considered present if obvious 
on visual inspection. Wedge fractures were defined as an A/P ratio < 0.75 in the 
thoracic or an A/P ratio < 0.85 in the lumbar spine. A mild end plate deformity 
was defined as a M/P ratio < 0.85. A severe end plate deformity was defined as a 
M/P ratio < 0.75. The criteria for defining vertebral deformities were chosen with 
respect to normal (mean ± 2SD) A/P ratios in the thoracic and lumbar spine (22). 
All vertebrae were graded as follows: 0 if normal, 1 for mild end plate deformity, 
2 for severe end plate deformity, 3 for wedge fracture, and 4 for crush fracture. A 
Vertebral Deformity Score ( VDS ) was calculated for each patient by dividing 
the total score by the number of vertebra included in the analysis. 
Statistical methods 
The level of significance was chosen at ρ < 0.05. Differences between groups of 
patients were analyzed with the l-tesl. Since VDS were not normally distributed, 
the Mann Whitney lest was used for this parameter. Analysis of variance was 
used to evaluate possible interactions between prednisone therapy, age, and sex. 
Stepwise multiple linear regression was used to determine the independent effects 
of various variables on the age and sex corrected BMC. Treatment with predniso­
ne (lreated=l, unireated=0), sex (fcmalc=l, male=0), age, duration of poslmeno-
pause (logarithm of number of postmenopausal years if postmenopausal and 0 if 
male or premenopausal), body mass index, duration of RA (years), Larsen score 
and functional capacity were included among the independent variables in this 
analysis. Similar analyses were also done with the D/M and C/T ratios as 
dependent variables. Variables were added to the model if they contributed to 
BMC with a ρ value < 0.15. After adding a variable, all variables already 
included in the model were re-evaluated and deleted if they did not contribute to 
BMC with a ρ value < 0.15 anymore. The difference in prevalence of normal and 
elevated D/M ratios between prednisone treated and untreated patients was 
analyzed with the Fisher exact test. Pearson and Spearman correlation coefficients 
were calculated as indicated in the text. All statistical analyses were performed 
with standard personal computer software (23). 
Results 
In the four month period 167 patients with RA met the inclusion criteria. A total 
of 42 patients had to be excluded because of co-existing diseases. Seventyseven 
out of 125 patients gave informed consent. SPA was done only in 65 patients due 
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to limited availability of the l25Iodium source. Spinal bone densities could not be 
obtained in 3 patients due to technical problems. 
The clinical data on the 62 evaluated patients are summarized in Table 1. The 
mean duration of prednisone therapy in the Ρ group was 5.3 years (median 4.7 
years, range 0.9 - 18.0 years). The mean daily dose of prednisone at the moment 
of study was 7.2 mg (median 7.5 mg, range 2.5 - 10.0 mg). The mean cumulative 
prednisone dose was 17.7 g (median 13.1 g, range 2.0 - 96.7 g). 
Table 1 : Clinical Data: Mean (Median, Range) 
P group * NP group * 
Number 26 36 
Age (years) 65.8 55.7 
(63.5. 50.0 - 87.3) (57.1. 26.1 - 79.0) 
Female:Male 12:14 26:10 
Number postmenopausal 12 19 
Years since menopause 
Duration RA (years) 
Larsen score 
Functional capacity 
15.3 
(14.7 -38) 
14.5 
(14.1, 1.9 -54.0 ) 
48.2 
(47, 10 - 87) 
0.69 
(0.68,0.04- 1.74) 
14.9 
(16.2-29) 
11.3 
(11.2. 1.9-24.8) 
30.7 
(26.5, 2 - 78) 
0.44 
(0.34,0.00- 1.85) 
φ
 Ρ group: patients treated with prednisone, NP group: patients never treated systemically with 
glucocorticoids 
Radial and lumbar BMC and VDS are summarized in Table 2 for patients in the 
Ρ and NP groups respectively. The prednisone treated patients had a significantly 
lower age and sex corrected, spinal BMC in both the trabecular and cortical ROI, 
and also at the metaphyseal site of the radius. At the diaphyseal site no difference 
between prednisone treated and untreated patients was seen. The radial D/M and 
spinal C/T ratios were higher in the prednisone treated than in the untreated 
patients. 
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Table 2: Radial and lumbar bone mineral content (BMC), and vertebral deformity score 
(VDS). prednisone treated (P group) versus untreated (NP group) patients 
Number 
Radial BMC 
Diaphyseal 
Metaphyseal 
D/M ratio 
Lumbar BMC 
Trabecular 
Cortical 
C/T Ratio 
VDS 
Ρ group 
26 
94 3 ± 2 0 3 
(85 1 1015) 
84 6 ± 22 7 
(75 5 93 8) 
144 ± 0 29 
(1 33 - 1 56) 
85 7 ± 29 9 
(73 6 97 8) 
91 2 ± 3 0 0 
(79 1 - 103 3) 
3 21 ± 0 78 
(2 93 3 49) 
0 33 
(031,000 100) 
NP group 
36 
93 6 ± 23 6 
(85 6 - 1016) 
97 2 ± 23 1 
(89 4 105 0) 
1 29 ± 0 25 
( 1 2 1 - 1 38) 
102 4 ± 32 0 
(916- 113 3) 
109 0 1 2 3 1 
(1012 1169) 
2 8 7 1 0 7 8 
(2 61 -3 13) 
0 20 
(0 15,0 0 0 - 0 85) 
Ρ 
0 48 
0 02 
002 
002 
0 01 
0 04 
0 03 
Mean ± sd (95% confidence interval) BMC and mean (median, range) VDS BMC is expressed as 
percentage of expected BMC after correction for age and sex Probability by unpaired one-sided t test 
(BMC) or Mann-Wliitney test (VDS) 
Analysis of variance showed no significant interactions between prednisone 
treatment and age and sex. The independent effects of prednisone treatment and 
other variables on radial and spinal BMC was further evaluated using stepwise 
multiple linear regression analysis. Prednisone treatment influenced the age and 
sex corrected BMC as follows: -1.9% (95% confidence interval from -14.1% lo 
6.4%, p=0.46) at the radial diaphyseal site, -15.7% (95% confidence interval from 
-27.1% to -4.2%, p=0 01) at the radial metaphyseal site, -22.0% (95% confidence 
interval from -36.0% to -8.1%, p=0.003) at the lumbar trabecular bone, and 
-24.8% (95% confidence interval from -39.3% to -10.3%, p=0.002) at the lumbar 
cortical bone. In addition, duration ol postmenopause and body mass index also 
had independent effects on BMC. Women with a longer duration of postmenopau­
se had a lower, and patients with a high body mass index a higher age and sex 
corrected BMC at all sites (data not shown). Age and sex had no significant 
effects, as would be expected since BMC was already corrected for the influence 
of age and sex. Duration of RA, Larsen score and functional capacity did not 
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affect BMC at any site. 
The D/M ratio was influenced significantly only by prednisone therapy (parameter 
estimate +0.16, 95% confidence interval from +0.02 to +0.30, p=0.02). The C/T 
ratio was positively associated with increasing age, and increasing duration of 
postmenopause (data not shown), but was not significantly influenced by predni­
sone treatment (parameter estimate +0.12, 95% confidence interval from -0.32 to 
+0.56, p=0.60). 
BMC and VDS were also compared between patients with a normal and an 
elevated D/M ratio. The results are summarized in table 3. Elevated D/M ratios 
were seen in patients without corticosteroid treatment (3/36), but occurred more 
frequently m prednisone treated patients (7/26) (p=0.05, Fisher exact test). 
Table 3 Radial and lumbar bone mineral content (BMC), and vertebral deformity score 
(VDS) pabents with normal versus elevated diaphyseal to metaphyseal BMC (D/M) ratios 
D/M Ralio < 1 58 D/M Ratio > 1 58 Ρ 
Number 52 10 
Radial BMC 
Diaphyseal 94 0 ± 2 1 4 90 5 ± 2 6 5 0 35 
(88 0 100 0) (716 109 4) 
Metaphyseal 9 7 1 ± 201 6 1 8 ± 21 0 0 0002 
(91 7 - 102 9) (48 8 - 78 8) 
Lumbar BMC 
Trabecular 97 7 ± 12 0 84 6 ± 10 8 0 1 0 
(88 8 - 1 0 6 6) (616 105 6) 
Cortical 105 9 ± 2 7 7 79 Τ ± 9 8 0 0002 
(98 2 - 1 Π 6) (72 1 861) 
C/T Ratio 3 03 ± 0 77 2 91 ± 0 69 0 65 
(2 82 125) (2 44 141) 
VDS 025 027 016 
(023,000 100) (027.000 069) 
Mean ± sd (95% confidence interval) BMC and mean (median, range) VDS, in rheumatoid animus 
patients with nomial (< 1 58) or elevated (>1 58) D/M Ratio BMC is expressed as percentage of 
expected BMC after correction for age and sex Probability by unpaired one sided t test (BMC) or 
Mann-Whitney test (VDS) 
Correlation coefficients were calculated between BMC at different sites, and the 
VDS. The results are summarized in Table 4. 
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Table 4: Correlabons (*) between bone mineral content (BMC) (t) at different sites, and 
vertebral deformity score (VDS) 
Radial BMC Lumbar BMC VDS 
D 
Radial BMC 
D 
M 
D/M 
Lurnba 
Τ 
С 
C/T 
VDS 
AU +1 00 
NP 
Ρ 
All 
NP 
Ρ 
All 
NP 
Ρ 
г ВМС 
ЛИ 
NP 
Ρ 
AU 
NP 
Ρ 
All 
NP 
Ρ 
AU 
NP 
Ρ 
M 
+0 73$ 
+0 77$ 
+0 74$ 
+ 100 
D/M 
+0 12 
+0 31 
-Oil 
-0 49$ 
-0 30 
-0 64$ 
+ 100 
Τ 
+0 47$ 
+051 $ 
+0 43 φ 
+0 42$ 
+0 53$ 
+0 15 
-0 12 
-0 09 
-0 02 
+ 100 
С 
+0 23 
+0 21 
+0 30 
+0 36# 
+0 35 φ 
+0 27 
0 32 t 
0 24 
-0 28 
+0 61 $ 
+0 53$ 
+0 64$ 
+ 100 
СД 
-0 35# 
-0 4 4 # 
-0 23 
-0 29 t 
0 37# 
006 
004 
-0 01 
0 26 
0 54$ 
-0 6 6 $ 
-0 29 
+016 
+0 14 
+0 38# 
+ 100 
-0 19 
-0 21 
-0 21 
-028 * 
-0 31 
0 14 
+0 07 
+0 09 
-0 09 
-0 37# 
-0 22 
-0 38 
-0 12 
-0 01 
0 07 
+0 52$ 
+0 38 t 
+0 62$ 
+ 100 
* Pearson correlation coefficienls (BMC χ BMC) or S|icamiaii correlation coefficients (BMC χ 
VDS) in all patients (n=62). in prednisone treated (P group, n=26) and untreated (NP group, 
n=36) patient's 
t BMC is defined in percentage of expeUed density after correction for age and sex D/M and 
C/T ratios are calculated using ПМс uncorrected for age and sex 
$,#.$ Significant at 0 05 (φ). 0 01 (#). and 0 001 ($) level 
Discussion 
Glucocorticoid excess is thought to cause bone loss predominantly in trabecular, 
and not cortical bone. In this study we evaluated cortical and trabecular compart-
120 
Increased susceptibility of lumbar cortical bone to glucocorticoids 
ments simultaneously in both the axial and appendicular skeleton, in patients with 
RA on long term low dose prednisone therapy. Patienls with RA who had never 
been treated with glucocorticoids served as a control group. 
The main finding of our study is the discrepancy between the cortical bone in the 
anterior nm of the vertebral body and the cortical bone in the peripheral skeleton. 
We observed a significantly lower BMC in prednisone treated patients, in both the 
trabecular and cortical ROI within the lumbar spine, and at the metaphyseal site in 
the radius. In contrast, no significant difference was seen at the diaphyseal site of 
the radius. The results of the multivariate analyses showed that the differences in 
BMC were probably due to glucocorticoid therapy, and not to imbalances between 
the Ρ and NP groups. It may be argued that the concomitant use of NSAIDs may 
have influenced our results. NSAIDs have been found to influence bone metabo­
lism (24,25), and have recently been suggested to have an effect on bone mass 
(26). However, effects of NSAIDs on bone are unlikely to explain the differences 
between the Ρ and NP groups, since all patients, in both groups, used these 
compounds. The present data also showed a relation of the anterior cortical bone 
with the trabecular compartment in the spine, but not Willi the corliuil bone in the 
forearm Finally, the mean D/M ratio in the forearm was signiticanlly raised in 
the Ρ group, while the C/T ratio in the spine is not sigmficanlly atfected by 
glucocorticoid treatment after correclion for the influence ol age 
Taken together, these data indicale that the spinal anterior cortical bone reacts 
differently to glucocorticoid excess than the cortical bone ol the forearm. This 
may well reflect differences in metabolic activity between these two sites. A 
similar difference in responsiveness between cortical bone in (he anterior spine 
and at peripheral sites has been suggested before with regard to aging related 
bone loss (16,17). In those earlier reports however, spinal cortical bone losses 
were compared to appendicular losses reported in (he literature, and not to data 
obtained in the same patients The degree of correlation between the trabccul.ir 
and cortical ROI in our study is almost identical to the one reported by Pacifici et 
al (17). 
Since cortical bone losses will decrease vertebral slrcnght, and may increase 
fracture risk (27), the observed susceptibihly of the spinal anterior cortical bone to 
the effects of long term prednisone treatment could have clinical impact. It should 
be mentioned however that in our patients a significant positive correlation was 
present between the VDS and the spinal CU ratio, implying that vertebral 
deformities were most severe in those with a disproportionate trabecular loss in 
the spine. 
A preferential bone loss at the metaphyseal site in the fore-arm in glucocorticoid 
treated patients, resulting in an elevated D/M ratio, was originally reported by 
Hahn et al (5). In their study, the effect of intermediate to high doses of predniso­
ne (10 - 35 mg/day) was evalualed in patients with RA and other pnmary 
diseases. The effect of low dose (< 10 mg/day) prednisone treatment on forearm 
BMC in patients with RA has also been studied before. A significant decrease in 
metaphyseal BMC in low dose glucocorticoids irealcd versus untreated patients 
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has been reported by several authors (28,29), but has also been denied by others 
(30). Butler el al found a significant negative effect of prednisone therapy in 
males and in postmenopausal females only, and no significant effect was seen in 
premenopausal patients. Data on diaphyseal BMC are not available from their 
study (29). Nagant de Deuxchaisncs et al reported a negative effect on both the 
diahyseal and metaphyseal BMC. As a consequence the D/M ratio in this study 
was not different between prednisone treated and untreated patients, with the 
exception of a subgroup of male patients aged 50 or older (28). Verstraelen and 
Dequeker found no significant effect of prednisone therapy on cither metaphyseal 
or diaphyseal BMC, although lumbar BMC as measured by dual photon absorptio-
metry was significantly lower in the glucocorticoid treated patients. No D/M ratios 
were reported in this study (30). Our data show that elevated D/M ratios are more 
frequent in patients with RA on long term low dose prednisone therapy, than in 
those never treated with glucocorticoids, although elevated ratios do occur in 
untreated patients. One might suggest that the elevation of the D/M ratio could 
also be due to the influence of the adjacent chronic inflammatory process. This 
possibility can not be completely excluded. However, the absence of a significant 
influence of the degree of radiological wrist destruction (28,29), argues against 
this hypothesis. Our data show that RA patients with an elevated D/M ratio have 
a lower cortical lumbar BMC than those with a normal ratio. For the trabecular 
ROI the difference did not reach statistical significance. The VDS was similar in 
both groups. Finally the correlations between fore-arm and spinal BMC are 
moderate at best, as has also been reported previously (10,31,32). We conclude 
that the D/M ratio should not be used to identify patients with glucocorticoid 
associated vertebral osteoporosis. 
Knowledge of patterns of bone loss in different disease states could have impor-
tant consequences for patient care and clinical research. We demonstrated an 
increased susceptibility to glucocorticoid effects of vertebral anterior cortical bone 
as compared to appendicular cortical bone, and a poor association between axial 
and appendicular measurements. We suggest that an evaluation of the trabecular 
and anterior cortical spinal BMC should be included in the diagnostic work up of 
patients with suspected glucocorticoid therapy associated osteopenia. Similar 
measurements could also be useful in therapeutic trials in patients with this 
disorder. 
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Summary and conclusions 

Summary and conclusions 
Rheumatoid arthritis (RA) is a chronic inflammatory disorder, characterized by 
articular, juxta-articular and extra-articular manifestations. Local osteoporosis, in 
the vicinity of inflamed joints, is a common phenomenon, and various mecha-
nisms may be responsible for its development. Generalized osteoporosis is also 
frequently found in patients with RA, and increased bone loss has been suggested 
as one of the extra-articular manifestations of the disease. The studies described in 
this thesis have evaluated some possible determinants of bone mass and bone loss 
in patients with RA. 
Changes in bone mass are mediated through the cells of bone. Osteoblasts are 
responsible for bone formation, and osteoclasts for bone resorption. Several 
methods have been used to study bone metabolism in patients with RA. The 
results of these investigations are discussed in chapter II. Patients with active RA 
probably have increased rates of bone turnover. In general, parameters of bone 
resorption have been increased in most studies. Markers of bone formation may 
be increased, normal, or decreased. Glucorticoids suppress osteoblastic activity, 
and may also increase bone resorption. 
Different techniques have been used to measure bone mass in patients with RA. 
The available data are summarized in chapter III. RA is probably associated with 
small decrease in mean bone mass, and a consequent small increase in fracture 
risk. Impaired mobility is suggested in the literature as an important determinant 
of bone mass in patients with RA. Several studies have evaluated the influence of 
glucocorticoid treatment on bone mass in patients with RA. Most studies that have 
been published sofar, support the hypothesis that long-term prednisone therapy is 
associated with an increased risk of osteoporosis, even when low doses are used. 
However, all studies showing deleterious effects of glucocorticoid treatment, are 
difficult to interpret because a selection-bias may have been present in these non-
randomized investigations. 
Summary of the data presented in this thesis 
One of the methods available to measure vertebral bone mineral density is 
quantitative computed tomography (QCT), which may be performed with a single 
or a dual energy technique. Measurements with single energy QCT are subjected 
to a considerable error due to varying amounts of fat in the vertebral body. This 
may limit the usefulness of single energy QCT, especially in patients with 
diseases that may affect bone marrow composition. The results of a study 
comparing single and dual energy QCT in patients with RA are presented in 
chapter ¡V. The results show that the percentages of expected densities are 
approximately 10 percent lower in the single than in the dual energy mode. The 
difference between single and dual energy QCT was positively correlated with 
disease duration and severity. These data suggest that the vertebral fat content 
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may be increased in patients with RA, and it is suggested that dual in stead of 
single energy QCT should be used in research situations requiring accurate bone 
mineral densitometry. 
If patients with RA are at increased risk for generalized bone loss, one may 
expect that disease dependent factors operate a.s determinants of bone mineral 
density in patients with this disease In the literature, disease duration, disease 
seventy and its concomitant reduced mobility, have been suggested as important 
factors. However, most studies have examined only a limited number of these 
possible determinants at the same time. Obviously, conclusions derived from such 
data are of limited value since confounding can not be excluded m such studies. 
For instance, activity of the inflammatory process may cause both increased bone 
loss and reduced mobility. Consequently, an association between the latter and a 
decreased bone mineral density, does not imply that reduced mobility is a 
determinant of bone mass in patients with RA Furthermore, it may be expected 
that the effects of for instance disease seventy and reduced mobility, will become 
apparent only after a sufficiently long period of lime. 
In the rheumatology department of the University Hospital Nijmegen (the 
Netherlands), all patients with recent onset RA are a.skcd to participate in a 
prospective follow-up study Disease activity and functional capacity are measured 
at regular intervals For the purpose of the present investigation, bone mineral 
density was measured in 97 of these patients by dual energy X-ray absorptiometry 
in the lumbar spine and the proximal lemur Femoral measurements were done in 
a combined region of interest, including the femoral neck, the trochanteric and the 
intertrochanteric areas, and also separately in Ward's Inangle, a region with a 
high proportion of trabecular bone that may be specially important for femoral 
bone strength. The results of this study are presented in chaptei V. Using multiple 
linear regression analysis, we found duration of RA to be negatively associated 
with bone mineral density in all regions. The mean level of the erythrocyte 
sedimentation rate (a parameter of disease activity) in the six months before bone 
mass measurement, was negatively associated with bone mineral density in the 
femoral combined region of interest, and in Ward's triangle The mean degree of 
functional impairment in the 18 months before densitometry, was negatively 
associated with bone mineral density in the combined femoral region only. These 
data indicate that bone mineral density may be affected independently by several 
disease dependent mechanisms, in patients with recent onset RA 
The effects of low-dose (< 10 mg/day) prednisone on bone mineral density, in 
patients with RA, are controversial Therefore, the short-term and long-term 
effects of glucocorticoid treatment have been studied in more detail 
The interpretation of most studies that have documented dclctenous effects of 
glucocorticoids in patients with RA is difticult, because the patients treated with 
prednisone are mostly those with (previous) high disease activity and impaired 
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mobility. Since these factors may affect bone mineral density in patients with RA, 
this may have introduced a selection bias in non-randomized studies. Therefore, a 
randomized controlled trial was performed to evaluate the short-term effects of 
low-dose glucocorticoid treatment on bone mineral density and biochemical 
markers of bone metabolism (chapter Vf). Forty patients with active RA, who 
started treatment with intramuscular gold salts were randomized to either predni-
sone (initial dose 10 mg/day, cumulative dose 1050 mg in 20 weeks), or placebo. 
Treatment with prednisone resulted in a rapid and marked improvement of disease 
activity and functionalcapacity. Nevertheless, the mean trabecular bone mineral 
density decreased with 8.2 percent (95% confidence interval of change -12.7 to 
-3.7 percent) after the first 20 weeks. No change was found in the placebo treated 
patients and the difference between the two groups was statistically highly 
significant (P=0.O03). After discontinuation of prednisone a significant increase 
was found between weeks 20 and 44 (mean change 5.1 percent, 95% confidence 
interval 0.4 to 9.8 percent). The difference with the originally placebo treated 
patients was almost significant (P=0.06). No significant changes were observed in 
the anterior cortical rim of the vertebral body. Parallel to the changes in trabecular 
bone mineral density, biochemical markers of bone formation decreased, and 
parameters of bone resorption increased, in the prednisone treated patients. The 
levels of calcium regulating hormones did not differ between the two treatment 
groups. These data clearly indicate, that glucocorticoids cause a marked decrease 
in trabecular bone mineral density in the initial months of therapy, despite obvious 
and rapid improvements in disease activity and functional capacity, even when 
low doses are used. This decrease in trabecular bone mineral density is probably 
mediated by a decrease in bone formation, and possibly also an increase in bone 
resorption. After discontinuation of glucocorticoid treatment, these effects may be 
reversible, at least when duration of therapy is limited to a short period of time. 
The long-term effects of low-dose glucocorticoid treatment on vertebral bone 
mineral density have previously been studied with dual photon absorptiometry and 
dual energy X-ray absorptiometry, and the results have been controversial. QCT 
offers the possibility of separate evaluation of the trabecular compartment of the 
vertebral body. The anterior cortical rim can also be measured separately from the 
posterior cortical bone, which is probably less responsive to metabolic stimuli. 
Since glucocorticoids are thought to affect primarily trabecular bone mineral 
density, QCT may be a more senitive method for the evaluation of the effects of 
prednisone on bone. Therefore, dual energy QCT was used to investigate the 
influence of long-term low-dose prednisone therapy on lumbar bone mineral 
density (chapter Vii). Patients who had never been treated with corticosteroids 
(n=44) were compared with patients on long-term low-dose prednisone (mean 
daily dose approximately 7 mg) therapy (n=30). After correcting for various 
possibly confounding variables, lumbar bone mineral density was found to be 
significantly influenced by prednisone therapy both in the central trabecular bone 
(estimated influence -31.2 percent, 95% confidence interval -50.3 to -12.1 percent) 
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and in the anterior cortical rim (estimated influence -37.2 percent, 95% confidence 
interval -53.6 to -20.8 percent) in postmenopausal patients. Vertebral deformities 
were also significantly more frequent in the prednisone group. No signifiacnt 
differences were present between the two treatment groups in the male patients. 
The degree of bone loss in the cortical bone of the vertebral body due to long-
term low-dose prednisone treatment was somewhat surprising, since it is assumed 
that glucocorticoids mainly affect the trabecular bone. However, it has been 
previously suggested that the differences observed between trabecular and cortical 
bone, arc in fact differences between the axial and appendicular skeleton. Therefo­
re, bone mineral density in the anterior cortical rim of the vertebral body was 
compared to measurements at the radial midshaft, which consists predominantly of 
cortical bone (chapter Vili). Again, patients who had never been treated with 
glucocorticoids (n=36) were compared to patients on long-term, low-dose predni­
sone therapy. Bone mineral density was significanlly lower in the prednisone 
treated versus untreated patients at the anterior cortical rim of the vertebral body 
(/^O.Ol), but not at the radial diaphyseal site (P=0.48). These data indicate that 
the anterior cortical rim of the vertebral body is more susceptible to the effects of 
glucocorticoid treatment than the cortical bone in the fore-arm. 
Directions for future research 
Many issues related to the subject of this thesis remain to be addressed. 
Firstly, the studies presently described have focusscd mainly on bone mineral 
density, which has been shown as ал important determinant of future fracture. 
However, quantity and quality of bone may both be important factors. Therefore, 
future research should also be directed at the investigation of qualitative aspects. 
Methods for the in vivo examination of bone architecture (for instance by texture 
analysis) may facilitate these studies. 
Secondly, further prospective studies involving greater number of patients are 
needed to estimate the incidence of glucocorticoid-induced osteoporosis, and to 
evaluate the factors that determine the individual susceptibility to the deleterious 
effects on bone of these compounds. 
Finally, the management of osteoporosis associated with RA and with glucocorti­
coid use should be further examined. These studies should not be limited to the 
efficacy of medications. For example, future investigations should also evaluate 
the feasibility, efficacy and safety of exercise intervention programs in patients 
with RA. 
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Concluding remarks 
The available data in the literature suggest that generalized osteoporosis may be 
an extra-articular manifestation in some patients with RA. In this thesis it was 
shown that bone mineral density may be influenced by disease dependent mecha-
nisms in patients with recent onset RA. Further studies are required to document 
the influence of disease activity and reduced mobility on bone mineral density in 
patients with longstanding RA. 
Data on the effects of low-dose prednsione on bone mineral density have been 
controversial in patients with RA, mainly because selection bias could not be 
ruled out in previous investigations. The data presented in this thesis clearly show, 
that low-dose glucocorticoid treatment causes a decrease in mean spinal trabecular 
bone mineral density, in the initial months of therapy. This decrease is probably 
mediated through a decrease in osteoblastic activity and possibly also through an 
increase in bone resorption. The data further support a deleterious effect of long-
term low-dose glucocorticoid treatment on spinal (trabecular and anterior cortical) 
bone mineral density. Therefore, the burden of proof rests now with those who 
assume the safety of low-dose prednisone trcalment with respect lo the bone. 
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Samenvatting 
Dit proefschrift richt zich op de relatie tussen chronisch gewrichtsreuma (in de 
volksmond kortweg 'reuma', en in vaktermen 'reumaloïde artritis') en botontkal-
king ('osteoporose'). De ziekte reumatoïde artritis kenmerkt zich vooral door een 
chronische ontsteking van de gewrichten. Soms komen ook op andere plaatsen in 
het lichaam (dus buiten de gewrichten of 'extra-articulair') afwijkingen voor. 
Osteoporose komt vaak voor bij patiënten met reumatoïde artritis, en wordt soms 
beschouwd als een cxtra-articulaire manifestatie van deze ziekte. 
In de literatuur (hoofdstukken 2 en 3) worden verschillende factoren genoemd die 
bij patiënten met reumatoïde artritis aan het ontstaan van osteoporose zouden 
kunnen bijdragen. Op de eerste plaats worden als onderdeel van een chronisch 
ontstckingsproecs in het lichaam verschillende stoffen geproduceerd, die ook 
invloed hebben op de botstofwisseling. Deze ontstekingsmediatorcn zouden zo een 
rol kunnen spelen bij versneld botverlics. Op de tweede plaats is duidelijk dat 
lichamelijke activiteit noodzakelijk is voor behoud van botmassa. Patienten met 
reumatoïde artritis hebben door hun gewrichtsziekte vaak minder mogelijkheden 
om lichamelijk actief te zijn. De mate waarin in dit opzicht beperkingen aanwezig 
zijn zou voor een belangrijk deel de kans op botontkalking kunnen bepalen. Ten-
slotte kan ook behandeling met prednison botverlies veroorzaken. Geschat wordt 
dat ongeveer 25 procent van de door reumatologen behandelde patiënten met 
reumatoïde artritis prednison gebruikt. Meestal wordt een lage dosis (10 milligram 
per dag of minder) voorgeschreven. Over het effect van dergelijke lage doseringen 
op het bot is nog onvoldoende bekend. 
De botmineraaldichtheid van de wervels kan op verschillende manieren worden 
gemeten. Een veel toegepaste methode is die welke gebruik maakt van computer 
tomografie. Dit is een vorm van rontgendiagnostiek waarbij een driedimensionaal 
beeld van bijvoorbeeld de wervelkolom verkregen kan worden. Met de nodige 
aanpassingen kan deze methode ook worden gebruikt om informatie over hel 
kalkgehalte van de wervels te verzamelen. Men spreekt dan over kwantitatieve 
computer tomografie. Wanneer daarbij ròntgenslralen van één encrgicnivcau 
('single-energy') worden aangewend, kunnen aanzienlijke fouten in de resultaten 
optreden ten gevolge van variaties in de hoeveelheid vet in de wervels. Van 
verschillende ziekten is bekend dat zij gepaard gaan met een toename van de 
hoeveelheid vet in de wervels, waardoor de botmineraaldichtheid wordt onder-
schat. Deze mectfout kan voor een belangrijk deel worden voorkomen wanneer de 
melingen bij twee verschillende energieniveau's ('dual-energy') worden uitge-
voerd. Om na te gaan in hoeverre dit probleem een rol speelt, werd de botmine-
raaldichtheid bij 109 patiënten met reumatoïde artritis gemeten met zowel 'single-
energy' als 'dual-energy' kwantitatieve computer tomografie. De resultaten staan 
beschreven in hoofdstuk 4. Na correctie voor leeftijd en geslacht was de botmine-
raaldichtheid (uitgedrukt als percentage van normaal) bij 'single-energy' metingen 
ongeveer 10 procent lager dan bij 'dual-energy' metingen. Het verschil in 
uitkomst tussen beide methodieken was groter naarmate de reumatoïde artritis 
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langer bestond en meer röntgenologisch waarneembare gewrichtsdestructies had 
veroorzaakt. De/e gegevens suggereren dat de hoeveelheid vet in de wervels bij 
patiënten met reumatoide artritis, als gevolg van met de ziekte samenhangende 
factoren, kan zijn toegenomen, en dat de botmineraaldichtheid met 'single-energy' 
kwantitatieve computer tomografie bij deze patiënten wordt onderschat. 
In de 3 volgende hoofdstukken worden een aantal onderzoeken beschreven waann 
mogelijke oorzaken van botontkalking bij patiënten met rcumatoide artritis nader 
worden bestudeerd. 
In hoofdstuk 5 wordt de aandacht gencht op de mogelijke rol van het chronische 
ontstekingsproces, en op de gevolgen van verminderde mogelijkheden tot lichame-
lijke activiteit. Bij 97 patiënten met reumatoide artritis, die vanaf het begin van 
hun ziekte volgens een vast schema werden gevolgd, werd de botmineriuldicht-
heid gemeten in wervelkolom en heupen. Vervolgens werd nagegaan in hoeverre 
de aldus bepaalde botmassa samenhing met de duur van de ziekte, de emst van 
het ontstekingsproces en de mate van invalidileit. Na correctie voor andere 
factoren bleek de botmineraaldichtheid in wervelkolom en heupen lager te zijn 
naarmate de rcumaloide artritis langer bestond. De botmassa m de heupen was 
verder lager bij patiënten met cen hoge blocdbezinkingssnelheid - en dus een 
actieve ziekte -, en bij patiënten met meer handicaps. Deze gegevens wijzen erop 
dat bij reumatoide artritis botontkalking op kan treden als gevolg van met de 
ziekte samenhangende factoren. 
Het is omstreden of behandeling mei lage doseringen predmson bij patiënten met 
rcumatoide artritis osteoporose veroorzaakt. Daarom is aan deze problematiek in 
twee onder/oeken opnieuw aandacht besteed. 
In hoofdstuk 6 worden de effecten beschreven die optraden nadat patiënten met 
een actieve reumatoide artritis gedurende 20 weken behandeld werden met een 
lage dosis predmson. De botmineraaldichtheid van de wervelkolom nam daardoor, 
zelfs in die korte penode, met ruim 8 procenl af. Nadat de behandeling met 
Prednison gestaakt werd, trad in het daarop volgende halve jaar weer een gedeel-
telijk herstel op. Botweefsel wordt steeds vernieuwd door een continue botafbraak 
enerzijds, en een daarmee m evenwicht zijnde bolaanmaak anderzijds. Door 
onderzoek van bloed en urine kan beoordeeld worden hoe actief deze processen 
verlopen, en of het evenwicht tussen bolafbraak en aanmaak verstoord dreigt te 
raken. Bij de in hoofdstuk 6 beschreven patiënten bleek dat aJ snel na de start van 
een lage dosis predmson de bolaanmaak afnam, terwijl de totafbraak minimaal op 
hetzelfde niveau actief bleef. 
In hoofdstuk 7 worden de resultaten van cen studie naar de effecten van een 
langdurige behandeling met predmson beschreven. Na een zo goed mogelijke 
correctie voor mogelijk verstorende factoren, bleek de botmineraaldichtheid in de 
wervelkolom bij met predmson behandelde paticnlen aanzienlijk lager te zijn dan 
bij patiënten die nooit met dergelijke medicijnen behandeld waren. Ook hadden de 
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met prednison behandelde patiënten meer wervelmisvormingen, hetgeen be-
schouwd kan worden als uiting van een verhoogde kans op botbreuken. De 
botontkalking was vooral overtuigend aanwezig bij met prednison behandelde 
vrouwen na de overgang. 
Op grond van de hierboven weergegeven resultalen kan worden geconcludeerd dat 
prednison bij patiënten met reumatoide artritis botontkalking kan veroorzaken, 
zelfs als de dosis laag is. Een belangrijk deel van dit negatieve effect komt 
waarschijnlijk reeds in de eerste maanden van de behandeling tot stand 
In hoofdstuk 8 wordt tenslotte nader ingegaan op verschillen in reactie op 
prednison tussen verschillende delen van het skelet Globaal kan een onderscheid 
worden gemaakt tussen het compacte, massieve, of corticale bot enerzijds, en het 
in een driedimensionaal netwerk van bolbalkjes gerangschikte, trabeculaire bot 
anderzijds. Trabeculair bot wordt vooral aangetroffen in de wervelkolom, en is het 
meest gevoelig voor de invloed van prednison Het skelet van armen en benen 
wordt voornamelijk door corticaal bot gevormd, maar dit type botweefsel wordt 
ook in de wervelkolom gevonden, als omhulsel van hel trabeculaire bot De 
botmineraaldichtheid van de verschillende skeleldclen werd bij 62 patiënten met 
reumatoide arlnlis, met verschillende technieken, atzonderlijk gemeten Uit de 
resultaten bleek dat zowel het trabeculaire als hel corticale bot v.m de wervelko-
lom gevoelig was voor de negatieve effecten van prednison In de onderarm trad 
onder invloed van prednison ook trabeculair bolverhcs op, maar hel corticale bot 
daar was veel minder gevoelig voor schadelijke invloeden van lage doseringen 
prednison. 
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Dankwoord 
Bij de totstandkoming van dit proefschrift zijn velen direct of indirect betrokken 
geweest. Graag maak ik van deze gelegenheid gebruik om iedereen daarvoor 
hartelijk te bedanken. 
Op de eerste plaats gaat mijn dank natuurlijk uit naar de patiënten die ten behoeve 
van de verschillende onderzoeken tijd en moeite hebben geïnvesteerd. Zonder hun 
medewerking was deze "patient gebonden" research niet mogelijk geweest. 
Personeel van verschillende afdelingen in het ziekenhuis heeft veel van de 
noodzakelijke onderzoeken uitgevoerd, soms buiten de normale werktijden. De 
deskundigheid en grote inzet van de medewerkers van vcrpleegpost A op de 
polikliniek inwendige ziekten, van de orthopedische röntgen, van de afdelingen 
digitale radiodiagnostiek en nucleaire geneeskunde, en van het laboratorium voor 
experimentele en chemische endocrinologie, zijn een grote steun geweest bij de 
realisatie van dit proefschrift. Ook de medewerkers van het rönlgenarchief, die 
steeds opnieuw de verschillende röntgenfoto's wisten op te sporen, ben ik zeer 
erkentelijk. 
Erik Brummelkamp was behulpzaam bij het schrijven van computerprogramma's, 
en assisteerde bij de statistische analyses. Erik, steeds opnieuw was je bereid om, 
met de jou kenmerkende bescheidenheid en rust, aan weer een nieuw idee handen 
en voeten te geven. Hartelijk bedankt daarvoor! 
Martin van 't Hof wil ik graag bedanken voor zijn adviezen op statistisch gebied. 
Jouw vermogen om op een plezierige manier met statistisch weinig geschoolde 
klinici te communiceren, heb ik als zeer stimulerend ervaren. 
Alle medewerkers van de afdeling reumatologie wil ik graag bedanken voor hun 
bereidheid om patiënten aan te melden voor de verschillende onderzoeken, en 
daarnaast ook voor de uitermate plezierige werksfeer, wa;irdoor personen met heel 
verschillende karakters goed kunnen samenwerken. 
Uileraard wil ik ook mijn promotor (Leo van de Putte) en beide co-promotoren 
(Piet van Riel en Leon van Erning), alsmede allen die bij de verschillende hoofd-
stukken ids co-auteurs vermeld slaan, in dit dankwoord betrekken. Leo, bedankt 
voor de mogelijkheid die je me bood om op dit voor de afdeling nog onbekende 
onderzoeksgebied actief te zijn. Leon was mijn coach vanuit de afdeling radio-
diagnostiek. Vele avonden hebben we samen doorgebracht om gegevens te 
verzamelen en om van gedachten ie wisselen. Hartelijk dank voor je kritische en 
stimulerende inbreng. Piet van Riel was de stuwende kracht achter het project. 
Beste Piet, tijdens mijn eerste contact met de afdeling in 1985 zette jij mij op het 
spoor van de in dit proefschrift beschreven problcmaliek. Sindsdien ben je steeds 
nauw bij de voortgang van het onderzoek belrokken geweest, en heb ik veel steun 
aan je gehad bij het oplossen van de onvermijdelijke problemen. Veel waardering 
heb ik ook voor je stijl van begeleiden: open en steeds toegankelijk voor overleg, 
zonder dat afbreuk werd gedaan aan de mogelijkheid om in relatieve zelfstandig-
heid aan het onderzoek te werken. 
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De verdediging van een proefschrift kan beschouwd worden als de afsluiting van 
een leerpcriodc. Op zo'n moment wil ik niet vergeten dat de basis hiervoor werd 
gelegd door mijn ouders, die het levende bewijs zijn dat creativiteit met rechtlij-
nigheid en logisch denken gecombineerd kan worden, en die nog steeds een 
belangrijke plaats bij mij innemen. 
Tenslotte Christien. Bedankt voor alles wat vanzelfsprekend was. 
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Curriculum vitae 
De schrijver van dit proefschrift werd op 15 september 1958 te Ubbergen 
geboren. In 1976 behaalde hij het diploma Gymnasium В aan het Sint Dominicus 
College te Nijmegen. Vervolgens studeerde hij geneeskunde aan de Katholieke 
Universiteit Nijmegen, waar hij in 1983 het artsexamen aflegde. 
Op 1 augustus 1983 startte hij de opleiding tot internist in het Canisius Wilhclmi-
na Ziekenhuis te Nijmegen (opleider wijlen H.B. Benraad). Vanaf 1 september 
1985 werd de opleiding voortgezet in het Academisch Ziekenhuis Nijmegen 
(opleider prof. dr. A. van 't Laar). Op 1 september 1988 volgde inschrijving als 
internist. 
Vanaf 1 september 1987 is hij werkzaam op de afdeling reumatologie van het 
Academisch Ziekenhuis Nijmegen, waar werkzaamheden voor het in dit proef­
schrift beschreven onderzoek werden afgewisseld met de, op 1 juli 1992 voltooi­
de, opleiding tot reumatoloog (opleider prof. dr. L.B.A. van de Pulte). 
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Stellingen 
behorende bij het proefschrift 
BONE MASS IN PATIENTS WITH RHEUMATOID ARTHRITIS 
Roland F.J.M. Laan 
1. Gegeneraliseerde osteoporose kan voorkomen als extra-articulaire mani-
festatie van rcumatoide artritis 
2. Bij patiënten met reumatoide artritis wordt de botmassa waarschijnlijk 
negatief beïnvloed door activiteit van het chronisch ontstekingsproccs en 
door verminderde functionele capaciteit (dit proefschrift). 
3. Op grond van de thans beschikbare gegevens kan van géén dosering 
Prednison, hoe laag ook, worden gesteld dat geen negatieve effecten op 
het bot zullen optreden. 
4. Prednison veroorzaakt een snel optredend Irabcculair botverlies in de 
lumbale wervelkolom, zelfs wanneer de dosis niet hoger is dan 10 
milligram per dag (dit proefschrift) 
5. Het corticale bot dat de voorste begrenzing vormt van het wervellichaam 
is gevoeliger voor de effecten van glucocorlicoidcn dan het corticale bot 
in de schacht van de radius (dit proefschrift) 
6. De negatieve effecten van een lage dosis prednison op het trabcculaire 
bot zijn (gedeeltelijk) reversibel wanneer de behandeling met glucocorti-
coiden na drie tot zes maanden wordt gestaakt (dit proefschrift). 
7. Bij patiënten die met glucocorticoiden behandeld worden dient de 
betekenis van een lage bolmassa als risicofactor voor toekomstige 
fracturen nader onderzocht te worden. 
8. De afwijkende relatie tussen "single energy" en "dual energy" kwantita-
tieve computer tomografie bij patiënten met reumatoide artritis suggereert 
een toename van de hoeveelheid vet in de wervellichamen bij deze 
aandoening (dit proefschrift) 
9. De bij "single photon absorptiometry", "dual photon absorptiometry", en 
"dual energy X-ray absorptiometry" verkregen resultaten worden vaak ten 
onrechte als botmineraaldichlheid aangeduid. 
10. Thyroxine en triiodothyronine zijn waarschijnlijk beide van belang bij de 
regulatie van de afgifte van schildklicrstimulerend hormoon door de 
hypofyse (Larscn P.R. N Engl J Med 1982;306:23-32, en Laan R.FJ.M., 
Pictcrs G.F.F.M., Smals A.G.H., Kloppcnborg P.W.C. N Engl J Med 
1987:317:770). 
11. Behandeling met een lage dosis methotrexaat (7,5-15 mg/week) kan 
gunstige effecten hebben op de huidverschijnsclcn van patiënten met een 
lupus erythematosus (Laan R.F.J.M., Boerbooms A.M.Th., van Riel 
P.L.C.M., van de Putte LBA. Clin Rheumatol 1990;9:563-4). 
12. Aurothioglucosc dient pas te worden voorgeschreven aan patiënten met 
reumatoïde artritis wanneer eerdere behandelingspogingen met zowel 
sulfasalazine als methotrexaat mislukt zijn. 
13. Binnen de 6-jarige opleiding tot reumatoloog moet de mogelijkheid 
worden geboden 4 jaar te besteden aan scholing in de interne geneeskun-
de. 
14. Isolatieband blijkt eigenschappen te bezitten waardoor hel bij uitstek 
geschikt is voor het anonimiseren van röntgenfoto's. 
15. Als aan het afvalprobleem evenveel aandacht zou worden besteed als aan 
afvallen, dan zou de milicuproblemaliek aanzienlijk minder gewichtig 
zijn. 
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